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1 Introduction and Objectives 
1.1 Introduction 
The development of an optimal formulation approach is one of the key activities of 
formulators in the pharmaceutical industry. Next to the pharmacodynamic performance 
of the pharmaceutical product, sufficient aqueous solubility of an active pharmaceutical 
ingredient (API) can be seen as an important criterion in the galenic development of 
pharmaceutical dosage forms. Especially for poorly water soluble drugs an appropriate 
formulation is necessary to establish the product in the market [Fahr and Liu, 2007]. 
Beneath low aqueous solubility, a low dissolution rate and permeability of the drug can 
lead to poor bioavailability, which can hinder a potentially effective drug entering the 
market as well. For an improvement of bioavailability, the drug itself can be altered like 
creating a pro-drug or a salt of the drug. However, this change is very complex from a 
regulator’s perspective. When changing the dosage form of a poorly water soluble drug 
an improvement in drug uptake can be achieved without the need for creating new 
drug substances. 
Poorly water soluble drugs pose a challenge not only in formulation technology but 
also more and more in preclinical studies, as 90 % of the drugs in the drug development 
pipelines are poorly water soluble [Loftsson and Brewsterb, 2010]. There is a high 
chance for an optimal formulation approach if the physico-chemical properties of the 
drugs, regarding solubility in biorelevant media and permeability through cellular 
barriers, are understood, leading to minimised risk of late failure in human clinical trials 
[Möschwitzer, 2013]. The biopharmaceutical classification system (BCS) is one way to 
characterise drugs regarding their solubility and permeability. Currently, all new drugs 
approved by the U. S. Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) need to have information relating BCS classification. Four 
different classes can be distinguished, with BCS IV class drugs having low solubility 
and permeability while BCS II class drugs share the low solubility with the benefit of 
being good permeable. 
The BCS classification can be used for formulation optimisation. Butler and Dressman 
summarised the conceptualisation regarding the four different classes. For application 
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purposes, permeation enhancer addition can increase bioavailability of class III and IV 
drugs [Butler and Dressman, 2010]. To overcome the solubility problem in class II and 
IV, lipid based delivery systems, polymer based nanocarriers, crystal engineering 
(nanocrystals and co-crystals), self-emulsifying solid dispersions and miscellaneous 
techniques can be used. BCS class IV drugs are furthermore often efflux protein 
substrates, meaning that an inhibition of these transporters, like Pgp, can improve 
bioavailability [Ghadi and Dand, 2017]. Nanosuspensions (a suspension of nano-
objects in a non-solvent) can be advantageous in formulating class II drugs because 
even without co-solvents, the solubility rate can increase so that pharmacokinetic 
studies can be performed.  
Researching nanomaterials in medicine is currently of high interest. Many associations 
have formed to investigate and advance activities in the area of nanotechnology. The 
financial potentials in the nanomedicine market are important as well. According to the 
Business Communications Company Research Healthcare Report 2015 the global 
nanomedicine market was valued at 248.3 billion US dollar in 2014 and should reach 
528 billion US dollar by 2019 (Report ID: HLC069C). In 2013, 247 nanomedicine 
products were in clinical trials. However, only 38 products have received FDA 
regulatory approval for patient use in 60 years of investigational research in the field of 
nanomedicines [Etheridge et al., 2013]. Until today, the number of nanotherapeutics, 
that entered clinical practice, raised approximately to 50 [Caster et al., 2017]. 
Nanocrystals held the second largest market share with 29 % of all nano-formulations 
in the United States in the years 2010 - 2015 [D’Mello et al., 2017]. 
In August 2017 Hassan et al. published a review about ‘Evolution and clinical 
translation of drug delivery nanomaterials’ and stated that even though materials in the 
field of nanomedicines have therapeutically improved, there are still problems with 
regard to bio-distribution and degradation rate that pose a challenge for the successful 
translation to clinical application [Hassan et al., 2017]. 
Better understanding of nano-object production and fate in biological environments 
could increase the amount of products succeeding in clinical trials [Wang et al., 2017b]. 
1.2 Objectives 
This thesis has two main aims:  
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One goal is to create a better understanding of the fate of nanocrystals in biological 
environments. Gao et al. stated in 2012 that no research on the evidence of direct 
uptake of drug nanocrystals has been conducted. They suggested that for drug 
nanocrystals, much work should be done to investigate the evidence of direct uptake 
pathways and some potential influencing factors, such as surface properties and 
particle size [Gao et al., 2012]. Many previous works have used labelled nanoparticles 
or artificial metal particles [Nativo et al., 2008; Awaad et al., 2012; Munger et al., 2012] 
to investigate the behaviour of nano-objects in-vitro. The challenging detection of drug 
nanocrystals could be the main obstacle, as to why former studies focused on non-
therapeutically used formulations. This explains the need for techniques in 
nanotechnology for the detection of nanocrystal formulations in tissues. Coherent anti-
Stokes Raman spectroscopic microscopy and fluorescence microscopy were therefore 
chosen to be applied in this work as tools for nanocrystal imaging and uptake in cells. 
The uptake and transport of nanocrystals in and through cells should be determined 
with regard to the influence of particle size, type of stabiliser, incubation time and type 
of drug (BCS II and IV).  
In addition to in-vitro experiments, the detailed investigation of the influence of milling 
parameters, type of stabiliser, stabiliser concentration and type of drug on the particle 
size was the second aim in this thesis. Selecting milling parameters for nanocrystal 
production is until today done by trial and error principles [Merisko-Liversidge and 
Liversidge, 2011]. The choice of stabilisers and their adequate concentration can be 
crucial for the creation of a stable nanosuspension. There is a need for fast methods, 
which are able to forecast the stabilisation efficacy of a stabiliser for a newly discovered 
API in research processes of industrial companies or in academia. Therefore, the 
feasibility of isothermal titration calorimetry and contact angle measurement was tested 
as characterisation methods for stabiliser-drug interactions. 
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2 Theoretical Background  
2.1 Types of nano-objects 
Defining the size range of nano-objects is somewhat contentious. On the one hand, an 
official definition of nanocrystals can be found in the ISO norm ISO/TS 80004. In this 
norm, a nanocrystal is a ‘’nano-object with a crystalline structure’’ whereas a 
nano-object is defined as a ‘’discrete piece of material with one, two or three external 
dimensions in the nanoscale (length range approximately from 1 nm to 100 nm)’’. 
Figure 1 plots different kinds of nano-objects. 
 
 
Figure 1: Shapes of nano-objects described and adapted from ISO/TS 800041:2010,2.2.  
On the other hand, the FDA was involved in the publication of a ’draft’ guidance, which 
defines engineered nano-products or products that employ nanotechnology as objects 
that: 
(i) Have at least one dimension in the 1 nm - 100 nm range or 
(ii) Are of a size range up to 1000 nm, providing the unique properties (including 
physical/chemical properties or biological effects) attributable to the 
dimensions up to 100 nm [McCarty, 2011]. 
Nevertheless, a typical size range that can be found in various literature is between 
200 nm and 600 nm [Rabinow, 2006; Keck and Müller, 2006; Chin et al., 2014]. It is for 
this specific reason that in this thesis, the term ‘nanocrystal’ refers to all particles with 
a size below 600 nm.  
In the majority of cases, the term ‘nanocrystal’ in publications refers to a nano-object 
composed of 100 % drug (with stabilisers adhered), mostly produced by crushing or 
precipitation. In contrast, a ‘nanoparticle’ is created from different substances which 
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form the particle by some kind of reaction. This reaction can be exemplary an ionic 
gelation or coacervation which lead to assembly of polymers, proteins or lipid-based 
structures with a particle size mostly between 1 nm and 200 nm [Uchegbu et al., 2013]. 
Advantages of these nanoparticles are a controlled creation and thereby a variety of 
surface modifications for drug targeting or inclusion of toxic drugs for minimisation of 
side effects. Disadvantages are often a low drug load and complicated manufacturing 
steps, including several reactions that have to be controlled. Another form of a 
nano-object can be liposomal formulations. AmBisome® is one of the popular 
representatives of this group which is an amphotericin B formulation against 
generalised fungi infections. The liposomal formulation leads to less nephrotoxicity but 
the treatment costs are approximately 1000 US dollars per day, while the costs for a 
treatment with amphotericin B solution are in the range of about 10 US dollars per day 
[Müller and Keck, 2012]. Müller et al. state that the production of nanocrystals may 
lower costs and reduce physical stability problems compared to liposomal formulations 
[Müller and Keck, 2012].  
2.2 Production of nanocrystals 
2.2.1 Production methods 
One way to produce nanocrystals is the comminution of coarse powders. In most of 
the cases, the drug has to be suspended in a non-solvent which can be water for BCS 
class II and IV drugs.  
Almost all nanocrystal products on the market are produced by bead/pearl milling 
[Hafner et al., 2014] whereby small beads (often 0.2 mm - 0.6 mm) out of steel, glass, 
ceramics, special polymers or zirconium oxide are transferred into a milling chamber 
together with a drug suspension comprising a stabiliser. The milling chamber can have 
various geometries and sizes. By applying energy to the system, mostly by some kind 
of stirring, larger particles are broken down to smaller structures. The power 
consumption, that is responsible for grinding, is made up of the stress energy and the 
number of bead-bead, bead-wall and bead-rotor contacts [Beinert et al., 2015]. Many 
different contact principles between the milling beads can be differentiated. Some 
examples are: impact, torsion, shearing and rolling (Figure 2), which comminute the 
particles between the milling beads.  
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Figure 2: Scheme of contact principles of milling beads during milling. 
Newly formed surfaces have to be stabilised to avoid agglomeration or aggregation 
and therefore insufficient milling which will be explained in more detail in section 2.2.2. 
Many parameters can potentially influence the particle size outcome. Some of the most 
important are milling time, bead size, amount of beads, stirring speed and the type and 
amount of stabiliser(s) [Peltonen and Hirvonen, 2010].  
Media milling is a ‘top-down’ production method, as larger particles are the point of 
origin. Another well known ‘top-down’ production method for nanocrystal creation is 
high pressure homogenisation [Verma et al., 2009b]. High pressure homogenisation 
can be categorised into two principles: the jet stream and the piston-gap principle. For 
the jet stream principle, two fluid streams collide in an Y-type or Z-type chamber under 
pressure up to 1700 bar whereby the fluids carry the particles which should be grinded. 
The comminution principle is based on shear and cavitation forces. The piston gap 
principle usually works with pressures from 1500 to 2000 bar whereby a drug 
suspension is forced through a small gap (e.g. 5 µm - 20 µm). The particles are 
reduced in size due to the high power of the shockwaves caused by cavitation. 
With ‘bottom-up’ methods, the initial starting point is a solution of the drug. 
Nano-objects are formed from this drug solution which is mixed with a non-solvent. 
This can be done by, for example, using supercritical fluid technology, evaporative 
precipitation into aqueous solution or controlled crystallisation during freeze drying [de 
Waard et al., 2008]. Precipitation often leads to small, uniform particles with a narrow 
particle size distribution [Li et al., 2007] but the process needs to be strictly monitored 
to avoid uncontrolled particle growth. With this technique, nanocrystals or 
nanoparticles can be produced. The drawbacks of productions with bottom-up 
techniques are that the drug, to be formulated, needs to fulfil certain prerequisites, like 
sufficient ability to dissolve in one of the solvents which can be exemplary ethanol, 
methanol or dimethyl sulfoxide. In addition, the process needs to be evaluated 
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regarding miscibility of the solvent in a non-solvent and proper elimination of the 
solvent after precipitation [Gao and Chen, 2008]. ‘Top-down’ methods, like media 
milling, have other challenges to face than ‘bottom-up’ techniques such as erosion of 
the milling material during the milling process [Flach et al., 2016], high energy costs, 
and it is more time consuming compared to precipitation methods. Furthermore, the 
high energy input can lead to partially amorphisation of the drug. The knowledge of the 
solid state is important for the prediction of the drugs’ behaviour after administration 
and in storage. A crystalline drug has to overcome the energy of the crystal lattice 
before dissolving, whereas the amorphous form is unordered and therefore, in most of 
the cases, easier to dissolve. One disadvantage of the amorphous state, however, is 
its instability which mostly results in recrystallisation over time. Especially for drugs 
with polymorphic forms, this recrystallisation can lead to the formation of an 
undesirable polymorph. Polymorphs of one drug can cause significant differences in 
the bioavailability, solubility and dissolution rate of the drug. Nevertheless, the majority 
of the nano-object products on the US and EU market for oral administration are 
nanocrystalline formulations like Rapamune® (sirolimus), Tricor® (fenofibrate) or 
Emend® (aprepitant) produced by media milling [Hafner et al., 2014] as the large scale 
production with media milling is well understood and controllable. 
2.2.2 Importance of stabilisation in nanocrystal production 
Stabilisation is fundamental to avoid particle growth over time: not only for nanocrystals 
created by bead milling but nano-suspensions in general. Because of the high specific 
surface area, particles are more likely to agglomerate or even aggregate to achieve a 
lower energy level compared to micronised suspensions. In order to avoid aggregation, 
stabilisers from different categories can be used. Steric stabilisers can be polymers or 
non-ionic surfactants, which attach to the particle surfaces and hinder the approach of 
the particles with their long chains. Another principle is the use of ionic surfactants 
which can diffuse to the surface of a particle and impart charge on it. This prevents 
aggregation by similar charging which leads to an electrostatic potential barrier. A new 
approach for better stabilisation is to protect stabilisers on nano-crystalline surfaces 
from desorption. This can be performed by, for example, cross-linking of the adsorbed 
stabilisers resulting in immobilised stabiliser layer(s) [Kim and Lee, 2011]. 
Interactions between particles can be described by the DLVO theory, named after the 
scientists Derjaguin, Landau, Verwey and Overbeek. Both principles for stabilisation of 
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nanoparticles, physical and ionic, lead to hindrance of aggregation because they 
increase the energy barrier, the particles have to overcome for aggregation and 
therefore minimise the risk of potential well which can be seen in Figure 3. 
 
 
Figure 3: DLVO-theory energy diagram adapted from Lyklema et al. (1999). 
For steric stabilisation, the adsorbed molecules have a loss of free movement. The 
reduction of conformational freedom causes negative entropy change and therefore, 
the free energy system increases, leading to repulsion. Efficient steric stabilisation 
depends on the chain-solvent interactions, the chain number and the chain length of 
the adsorbed molecules [Costas, 2016]. Furthermore, the attachment ability of the 
stabilisers to the newly formed surfaces is of importance [Verma et al., 2009a]. 
Investigating the interaction of API and stabiliser in nanosuspensions is highly 
important to understand milling processes, storage stability of the suspension and the 
behaviour of the crystals in biological environments, especially regarding solubility, 
surface interactions and toxicity. An understanding of the interaction can be used to 
estimate the required type and amount of stabiliser for new APIs in pharmaceutical 
industry or academic research so that costs can be reduced as well as the time for the 
preparation of nanosuspensions. Wu et al. concluded that the formulation of 
nanosuspension is challenging because of two major aspects: 
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i) A lack of fundamental understanding of interactions within nanosuspensions 
and  
ii) A lack of an efficient and high throughput stabiliser screening techniques 
[Wu et al., 2011] 
Many stabilisers have proven to have a high efficacy in stabilising nanosuspensions, 
regardless of drug specification. Indeed, every company has its own gold standard but 
this does not change the fact that the trial and error principle increases costs and is 
time consuming. Furthermore, this lack in an efficient screening method for suitable 
stabilisers may result in drugs, not reaching the market despite their proven therapeutic 
benefit.  
Concentration of stabiliser solutions should be chosen wisely. Too low concentrations 
can lead to insufficient stabilisation while too high concentrations can cause toxicity or 
Ostwald ripening. In literature, the mass ratio of stabiliser and drug, which is mostly 
used, ranges from 1:20 to 1:1 [Merisko-Liversidge and Liversidge, 2011]. 
2.3 Effects of nanoisation 
Orally administered poorly water-soluble drugs often show problems in bioavailability, 
like varying bioavailability in the fed or fasted state, a retarded onset of action and/or 
low bioavailability due to low dissolution rates [Junyaprasert and Morakul 2015]. All 
these problems can be addressed with the choice of a nano-particulate containing 
formulation. A minimisation of bioavailability fluctuation in the fasted or fed state as 
well as the increase in dissolution rate is based on the understanding that the total 
surface area for nano-formulations is further increased than for micronised powders, 
which are often used when formulating poor aqueous soluble drugs to tablets in the 
pharmaceutical industry nowadays. The dissolution rate is directly proportional to the 
surface area of a particle, so that an increase in surface area leads to an increase in 
dissolution rate. This relationship is illustrated in the extended 
Noyes-Whitney-equation (Equation 1). 
dC
dt
= k1S(Cs − C) 
Equation 1: Extended Noyes-Whitney-equation. C standing for the concentration at time point t, 
CS for saturation solubility, S for surface area and k1 as a constant. 
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It shows that the rate of dissolution is proportional to the difference between the 
concentration C at time t, the saturation solubility Cs and the surface area S. k1 is a 
constant which includes the diffusion coefficient and the thickness of the concentration 
layer [Bruner and Tolloczko, 1900]. 
By comparing nanocrystals and micro-particles, not only the dissolution rate can be 
increased but also the saturation solubility, dissolution velocity and adhesiveness to 
surfaces/cell membranes [Müller et al., 2001; Rabinow, 2005; Gao et al., 2012]. All 
these effects can lead to a better bioavailability, especially when a drug from BCS 
class II is utilised, as the solubility is the most influencing factor here [Loebenberga 
and Amidon, 2000]. Below particle sizes of 1,000 nm, also the saturation solubility of 
the formulated drug can be increased [Junyaprasert and Morakul 2015; Müller, R. H. 
and Peters, K. 1998]. The adhesion to cell membranes can lead to an increased 
concentration gradient at the surface of the cell and therefore allow faster permeation. 
Also the retention time can be increased so that the nano-objects have more time to 
dissolve. 
Nanoisation also has an influence on the distribution of an API in-vitro and in-vivo. 
Nano-objects are more likely to cross membranes and be taken up by cells compared 
to micro-objects. Hence, a higher concentration of drug can be maintained inside cells, 
so that even the bioavailability can be enhanced in comparison to a solution of the 
drug [Junghanns and Müller, 2008]. Furthermore, the stability of nanosuspensions can 
be enhanced compared to solutions [Möschwitzer et al., 2004]. 
All in all, drug nanocrystals can dramatically improve the bioavailability of orally 
administered poorly soluble drugs as shown by changes in pharmacokinetic 
parameters of blood profiles like rising area under the blood concentration–time curve 
(AUC) and an increase in maximum plasma concentration (Cmax). This can exemplary 
be shown with the study of Jinno et al. as they detected an increase in Cmax from 
582 ng/mL (hammer-milled; 13 µm) to 5,371 ng/mL (nano-milled; 0.22 µm) for orally 
administered cilostazol suspensions to dogs (under fasted conditions). Both 
suspensions were administered with the same concentration (100 mg/body). 
Furthermore, the AUC increased 6.6 fold, from 2,722 ng/h/mL to 17,832 ng/h/mL 
[Jinno et al., 2006]. 
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2.4 Fate of (nano)objects in biological environments  
Oral uptake of particles from the gastrointestinal tract is generally, with less than 5 %, 
low [Florence and Attwood, 2016]. The uptake can involve transcellular and 
paracellular permeation as transport routes (Figure 4), as well as lymphatic transport. 
 
Figure 4: Scheme of enterocytes (light purple) with their glycocalyx (brown) and mucus 
(patterned red) and nano-object (dark purple) transport. 
Transcellular transport of particles requires some kind of endocytosis. Endocytosis is 
an energy dependent process which can be categorised in caveolae- and 
clathrin-mediated endocytosis, phagocytosis, pinocytosis and micropinocytosis. 
Caveolae- and clathrin-mediated endocytosis are receptor-mediated and two of the 
most important pathways for nano-objects between 10 nm and 500 nm. Below 10 nm, 
pinocytosis (uptake of fluids) is the most prominent uptake pathway, while above 
500 nm actin-dependent phagocytosis of macrophages, dendritic cells and neutrophils 
is known to be the dominant process [Nuri and Park, 2014]. Nevertheless, it has to be 
said that in biological environments a strict separation and categorisation of interaction 
pathways, in general, is not possible as all processes happen next to each other and 
often also in relation to one another. 
Recently it was found that the human body produces nanoparticles itself. Calcium is 
excreted in the intestinal lumen and forms amorphous magnesium-substituted calcium 
phosphate nanoparticles, which trap soluble macromolecules, such as bacterial 
peptidoglycan and orally fed protein antigens, in the lumen and transport them via 
Peyer’s patches to immune cells of the intestinal tissue [Powell et al., 2015]. Peyer’s 
Patches are accumulations of lymphoid follicles containing, amongst others 
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lymphocytes, macrophages and connective tissue cells. The surface of Peyer’s 
Patches is covered with M cells. Compared to other parts of the gastrointestinal tract, 
where enterocytes and goblet cells are present, which produce mucus and a thicker 
glycocalyx, the structure of the M cells facilitates the approach of microorganisms and 
particles (Figure 5). 
Compared to enterocytes, M cells are small in number. In the human gastrointestinal 
tract the ratio of enterocytes to M cells is 1,000,000 to 1 [Tyrer et al., 2007]. The 
mechanisms that control the transport route within M cells remain largely unknown 
[Söderholm, 2015]. Also, mechanisms of how nanoparticles penetrate the intestinal 
barrier are poorly characterised. 
 
Figure 5: Scheme of a Peyer’s Patch surrounded by enterocytes. 
Even tough already in the 1980s and 1990s different pathways of particles in and 
through tissues were discussed, like Peyer’s Patches lympho-epithelial M cells uptake 
[Eldridge et al., 1990], paracellular transport [Aprahamian et al., 1987] and endocytosis 
by intestinal enterocytes [Kreuter et al., 1989; Mathiowitz et al., 1997], the detailed 
pathways are not characterised to a full extent. In 1990, O’Hagan related size ranges 
of nano-objects to their site uptake and fate in the intestine (Table 1). 
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Table 1: Influence of the size of nano-objects and the fate in various tissues adapted from 
O’Hagan (1990). 
Site/mechanism Size range Fate after uptake 
Enterocyte/endocytosis < 220 nm Reticuloendothelial system uptake 
Paracellular transport 100 - 200 nm Unknown 
Intestinal macrophages 1 µm Mesenteric lymph nodes (MLN) 
‘Persorption’ 5 - 150 µm Blood and excretory fluids 
Peyer’s patches 20 nm - 10 µm Peyer’s Patches and MLN 
 
Later on, it became clear that this strict size ranges do not display reality but give a 
rough estimation of where the nano-objects might end up. 
The importance of stabilisers, surrounding the nano-object, on the uptake in cells, has 
also been studied. Hillery et al. found that an adsorption of poloxamers on polystyrene 
particles appeared to inhibit particle uptake in the small intestine of rats [Hillery. and 
Florence, 1996]. Contrariwise, Nadai et al. showed that poloxamers can enhance oral 
uptake of particles due to gastric mucosa damage [Nadai et al., 1972]. This contrary 
information indicates that a definitive answer cannot be given yet. All parameters must 
be investigated, such as stabiliser concentration, cell type, type of stabiliser, type of 
drug, surrounding conditions and many more. Ionic stabilisers, for example, do 
response differently when pH and ionic strength in gastrointestinal fluids changes 
[Peltonen and Hirvonen, 2010]. 
Uptake data in literature show that different cell types take up nano-objects of different 
sizes and to a different extent. Rejman et al. explored that a murine melanoma cell line 
took up particles of up to 500 nm [Rejman et al., 2004]. Depending on the role of the 
cell type, the uptake in cells is variable. Caco-2 cells, which mimic the intestinal 
epithelial cells, have a barrier function, while macrophages should take up foreign 
particles to present them to the immune system [Des Rieux et al., 2006; Cartiera et al., 
2009]. Apart from the oral route, intravenous administration of nano-objects is also 
possible. Gustafson et al. state that macrophages tend to be a problem when 
nano-objects are administered intravenously, due to their ability to rapidly clear the 
nano-objects from circulation and therefore, hinder their potent medicinal effects 
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[Gustafson et al., 2015]. They summarised various publications, showing the influence 
of particle geometry, surface charge and functionalisation on macrophage uptake and 
in-vivo fate as well as toxicity. Depending on their shape, whether short rods or longer 
rods, the nano-objects accumulated in the liver or spleen. Spherical particles were 
taken up more rapidly than rods. The influence of the size and surface charge is plotted 
in Table 2. 
Table 2: Influence of size and surface charge on the elimination of insoluble nano-objects, 
adapted from Gustafson et al. (2015). 
Size 
< 15 nm 
Removed quickly (under 24 hours) 
Renal elimination 
15 nm - 40 nm 
Removed less quickly (2 weeks) 
Biliary clearance 
> 40 nm 
May reside in the body indefinitely 
Reside in liver and spleen 
Surface charge 
Neutral and zwitter-ionic 
Longer circulation time than charged 
counterparts 
Different adsorption of proteins on 
more hydrophobic surfaces (more 
albumin, IgG) than hydrophilic 
Positively charged 
Generally taken up to a greater extent 
than neutral or negative counterparts 
 
The extent of nano-object absorption reported in the literature, is dependent on the 
intestinal model, selected material, type of species and time. The absorption of 
nano-objects ranges from 0.5 % - 10 % in just three of the many examples available 
[Kukan et al., 1989; Le Ray et al., 1994; McClean et al., 1998]. 
Hofmann-Amtenbrink et al. blamed the non-easy detection in the biological milieu or 
tissue as one reason for the poor knowledge and inconsistent results in the field of 
short- and long-term toxicities, bio-distributions and clearance of nano-objects in 
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humans. Especially magnetic iron oxide particles were investigated, regarding the 
influence of particle size, surface charge and morphology on the interactions with 
tissues but yet, no consent has been reached regarding the impact of these parameters 
[Hofmann-Amtenbrink et al., 2015]. 
As soon as nano-objects circulate in-vivo, they adapt a protein corona which has an 
influence on the fate of the objects [Tenzer et al., 2013; Lesniak et al., 2012; Ruge et 
al., 2012]. Depending on the type of stabiliser, which is situated on the surface of 
nanoparticles, the adsorption pattern of proteins can be different [Blunk et al., 1993]. 
To conclude, it can be said that uptake of nano-objects via the oral or intra-venous 
route is proven but the details of the uptake mechanisms remain controversial. One 
main challenge is that many studies investigate artificial particles which are easy to 
detect but do not display the properties of marketed products. 
2.5 Tools for the assessment of transport of substances in and through 
cells 
One of the simplest ways to study transport of substances across a barrier is the usage 
of an artificial membrane test, the so called Parallel Artificial Membrane Permeability 
Assay. A liquid membrane, consisting of an inert organic solvent like dodecane or 
hexadecane on a filter is used as a barrier between an apical and basolateral 
compartment. Two advantages of this method are the possibilities for high-throughput 
and cost effective experiments. One disadvantage can be the non-detection of drug 
interactions with transporters in the intestinal barrier. Therefore, pharmaceutical 
industry nowadays often uses the Caco-2 model [Shah et al., 2006]. Investigations of 
oral drug uptake can be done by this simplified model of the barrier of epithelial cells. 
Caco-2 cells are a colon carcinoma cell line from human colon cells. Even though they 
are derived from the colon, their enzymatic behaviour and barrier function are 
comparable to healthy small intestine epithelial cells. Still, there is a difference between 
Caco-2 cells and intestinal enterocytes, such as less brush border peptidase and 
mucins [Lundquist and Artursson, 2016]. Furthermore, an under-prediction of 
paracellular absorption more often occurs with this cell line compared to in-vivo studies. 
In addition, an overexpression of efflux transporters like Pgp has been described for 
Caco-2 cells compared to intestinal enterocytes [DiMarco et al., 2017]. As the Caco-2 
model is a well distributed model, the permeation of nano-objects was already tested 
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for several drugs and nano-object formulations. Again, a large number of publications 
deal with artificial particles [Imai et al., 2017; He et al., 2013].  
The transport of particles in comparison to solutions is interesting to investigate. Most 
approaches of nano-object formulations intend to use the advantage of faster 
dissolution rates because the nano-objects dissolve faster than their micro- or macro 
pendants, so that the concentration gradient between the intestinal lumen and the 
blood vessels is higher which also leads to an increase in permeation. Some 
publications show that the permeation of nano-objects can be even higher than their 
solution formulation, so that there has to be an additional effect of nano-objects apart 
from their dissolution rate enhancement. The EMA stated in their scientific discussion 
about Rapamune®, which is a sirolimus nanocrystal containing tablet, that the tablet 
and a solution of sirolimus were not bioequivalent after a single dose of 1 mg 
administered to healthy volunteers. The AUC was increased by 82 % for the tablet 
compared to the solution. The bioavailability of the tablet and the solution were 
approximately 17 % and 14 %, respectively [Procedure No. EMEA/H/273/X/21]. 
Lamprecht et al. investigated, whether tacrolimus containing polymeric nanoparticles 
were favourable regarding penetration of ulcerated tissues over dissolved drug. Due 
to the accumulation of nanoparticles in the inflamed tissue, and therefore, high local 
drug concentration, the Pgp capacity was saturated at this local site and the 
metabolism and transport of the drug were minimised [Lamprecht et al., 2005]. 
Next to the transport of particles through cellular barriers also the particulate uptake in 
cells can be of interest. As mentioned in section 2.4, the uptake of nano-objects in 
macrophages can lead to limited bioavailability due to fast clearance of the 
nano-objects. When administered systemically, approximately 95 % of the 
nanomaterial never reaches its target, because it is sequestered by filtration organs 
[Florence, 2012]. Nevertheless, there are some areas where an uptake in immune 
competent cells is desirable. The complexity of signals regulating the immune system 
leads to major challenges for therapies in the field of immunisation based on traditional 
single-agent bolus drug treatment. Vaccination over mucosae like the intestinal, nasal 
or lung mucosa often benefit from particulate formulations. These particles can 
stimulate immune cells directly through their physical and chemical properties and lead 
also to a local immune response [Trows and Scherließ, 2016]. Furthermore, the 
research on particle-laden immune cells as living targeting carriers for drugs continues 
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to progress, leading to new approaches for immunotherapy [Moon et al., 2012]. 
Macrophages play an important role in physiological mechanisms like inflammation, 
homeostasis and immune response but also in pathophysiological processes such as 
chronic inflammation in diseases like rheumatoid arthritis or diabetes [Wynn et al., 
2013]. Their primary role is to create an early response to foreign material 
contamination and its clearance. The uptake of nano-objects in macrophages could be 
useful in certain diseases as a targeted therapeutic approach, for example, in virus 
infections [Dou et al., 2006; Dutta et al., 2008], bacterial infections [Clemens et al., 
2012] or as tumour-associated macrophages in cancer [Zhu et al., 2013]. In these 
cases, macrophages can be used as cell based delivery systems, loaded with drugs 
or other therapeutics. They can be loaded ex-vivo and then be administered to the 
host. Loading the drug into carrier cells can increase the circulation time from several 
hours for the free drug to 10 days for the nanocrystalline drug, loaded into cells 
[Staedtke et al., 2010; Dou et al., 2006]. Loading of the nano-objects in these living 
platforms is a crucial step. Methods need to be explored that can exactly determine 
the amount of particles which are taken up, to increase efficacy of the formulation and 
reduce side effects. Particles, taken up, need to be separated from particles that have 
merely been adsorbed on the surface of the cells which could be washed away. 
Imaging methods can be used to quantify the uptake but they often require labelling of 
the particles which can alter the in-vitro or in-vivo behaviour of the nano-object. 
Therefore, techniques are favoured that can localise unlabelled organic particles. 
Fluorescent probes are the most common way to study cell uptake. Live cell imaging, 
nanoparticle tracking, enzyme degradation of endocytic load and many more analyses 
are possible with fluorescence microscopy [Duncan and Richardson, 2012]. Another, 
quite new, imaging technique is coherent anti-Stokes Raman microscopy. The rising 
interest in this technique, which can be seen in an increase in publications, led to the 
first commercial available microscope in the year 2011 (from Leica). It is a fast and 
label-free imaging technique. Therefore, the influencing factor of labelling on 
distribution and uptake can be excluded, so that the characteristics of the formulation 
as is are in focus. Brandenberger et al. titled in a paper from 2010: ‘’Intracellular 
imaging of nanoparticles: Is it an elemental mistake to believe what you see?’’ They 
investigated the uptake of quantum dots (sulphur and cadmium containing) in 
macrophages by choosing six different areas which visually seemed to show quantum 
dots taken up by macrophages. Interestingly after electron spectroscopic imaging 
Theoretical Background 
 
18 
 
analysis, just one area was confirmed having quantum dots in macrophages 
[Brandenberger et al., 2010]. Also Xu et al. saw an uptake of Nile red dye which was 
loaded in polylactic-co-glycolic acid (PLGA)-nanoparticles by fluorescent imaging but 
with coherent anti-Stokes Raman microscopy, they detected the non-fluorescent PLGA 
which revealed that the nanoparticles did not enter the cells but just stayed at the 
surface of the cell. Nile red must have been dissociated into the cell from there [Xu et 
al., 2009]. These are just two out of many examples that show, why there is a need in 
chemically specific microscopic techniques for organic structures like coherent anti-
Stokes Raman microscopy. 
In conclusion, the knowledge of in-vitro permeation through the Caco-2 model can give 
hints to bioavailability; not only of the drug but also of the drug formulation, but 
differences to in-vivo environments should not be neglected. Furthermore, the interest 
in techniques that can quantify the uptake of nano-objects in cells is rising due to 
relatively new approaches like cell based delivery systems. 
Materials and Methods 
 
19 
 
3 Materials and Methods 
3.1 Materials 
This chapter gives details on the used drugs, stabilisers and cell lines, while chapter 
9.2 in the appendix holds details on quality and supplier origin of the used materials. 
3.1.1 Model drugs 
Curcumin (CUR) and glibenclamide (GLI) were investigated as model substances in 
this project. In this part, the two drugs will be explained in more detail, regarding their 
physico-chemical parameters and their therapeutic use.  
3.1.1.1 Curcumin 
CUR is a well investigated, natural compound that is commonly known as an ingredient 
of turmeric (Curcuma longa). The phenolic, π - electron rich structure of the CUR 
molecule, which is shown in Figure 6, causes its yellow colour as well as fluorescent 
behaviour which emits light at 500 nm when excited at 420 nm. 
 
 
Figure 6: Chemical structure of CUR. 
The molecule can exist in its enolate or bis-keto form. When present in the enolate 
form, the anti-oxidative effect of CUR is pronounced [Metz, 2000]. The bis-keto form is 
more likely to form in acidic and neutral aqueous solutions as well as in the cell 
membranes, than the enolate form [Wang et al., 1997]. At pH 3-7, CUR acts as a potent 
H-atom donor [Jovanovic et al., 1999]. 
The Raman activity of CUR is based on the functional groups listed in Table 3. 
Table 3: Example for Raman activity of the functional groups of CUR from Lestari and Indrayanto 
(2014). 
Raman wavenumber in cm-1 Functional group 
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1626.2 C=O 
1600.4 Aromatic C=C 
1430.2 Phenol C-O 
1249.3 Enol C-O 
 
CUR can have different polymorphic forms which differ in conformation of the molecule 
and interaction between the neighbouring CUR molecules. Sanphui et al. findings in 
2011 show three types of polymorphs, with one polymorph (polymorph 2) having a 
higher dissolution rate and solubility than the others (Table 4) [Sanphui et al., 2011]. 
Table 4: Melting temperatures of CUR polymorphs from Sanphui et al. (2011). 
Polymorph Onset temperature in ºC Peak temperature in ºC 
1 177.54 181.42 
2 171.95 175.12 
3 168.29 172.85 
 
The log P value for CUR was found in the database chemspider with 3.29. CUR is 
poorly soluble in water and weakly permeable as well and therefore belongs to BCS 
class IV. Hence, CUR belongs to the group of APIs that are most challenging in 
formulation. Many formulation strategies are employed in research, which are 
nowadays just realised in the food supplement market. Amongst other products, 
cyclodextrin (CAVACURMIN® by Wacker Chemie AG, Curcumin Extrakt 45 by Dr. Wolz 
Zell GmbH) and liposomal formulations (Optimal Liposomal Curcumin by Seeking 
Health) are commercially available. Especially in India, turmeric has a long tradition in 
treating numerous discomforts of diseases like arthritis, menstrual difficulties, ulcers, 
hepatic disorders, cold and bruises [Ramawat, 2009]. 
Many molecular targets for CUR have been investigated, such as transcription factors, 
inflammatory cytokines, kinases, growth factors and antiapoptotic proteins. This 
variability of targets could enable a broad range of application but nowadays it is only 
used in food supplement products. The FDA has approved CUR as “Generally 
Recognised As Safe” (GRAS), showing that CUR can be used safely as a food additive 
[Chainani-Wu, 2004]. Also in pharmaceutical application, no toxicity could be seen in 
a phase I study, for 8 g of CUR per day being administered for 3 months [Sharma, 
2005]. 
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Lately, the anticancer effect of CUR has been studied more intensively. CUR is known 
to inhibit ABC transporter function like Pgp [Limtrakul et al., 2007; Anuchapreeda et 
al., 2002] which shows that CUR could be a beneficial co-medication against 
multi-drug-resistant tumours. Nevertheless, it is discussed controversially if CUR is 
also a Pgp substrate [Chearwae et al., 2004; Wang et al., 2017a]. Wu et al. state that 
‘‘it is not surprising that CUR has become one of the most exciting natural product 
modulators in recent years’’ [Wu et al., 2011]. CUR, in its free form and as nano-
formulations, has been under investigation in human clinical trials for many years in 
the field of colorectal cancer, pancreatic cancer, breast cancer and multiple myeloma 
and has shown beneficial results [Ornchuma et al., 2014]. The EMA has stated 7 
clinical trials with CUR by the year 2010. However, because they were performed with 
either a very high dose or with combination products, they are of limited value to the 
EMA [EMEA/HMPC/456848/2008]. With improved formulation strategies this could be 
changed, as lower doses could be applicable.  
In summary, it can be said that CUR has been used over decades for various kinds of 
diseases and therefore, its safety is proven but because of poor solubility and 
bioavailability its efficacy is limited, so that adequate formulation strategies are needed 
to fulfil the potential of this drug for pharmaceutical applications. 
3.1.1.2 Glibenclamide 
GLI is a poorly water soluble drug (solubility < 8 μg/mL in pH 7.4 phosphate buffer 
[Seedher and Kanojia, 2009]) but has a relatively high permeability through intestinal 
barriers, which warrants it to be classified under BCS Class II [Lindenberg et al., 2004]. 
The solubility of GLI increases with higher pH because it serves as a weak acid with a 
pKa of about 6.5, so that the adsorption of GLI can differ in the gastro-intestinal tract 
[Brockmeier et al., 1985]. The deprotonation of GLI takes place at the sulphonylurea 
structure of the molecule which can be seen in Figure 7. 
Materials and Methods 
 
22 
 
 
Figure 7: Chemical structure of GLI. 
Due to two aromatic ring systems and two carbonyl groups, GLI shows fluorescence 
at 354 nm after excitation at 302 nm [Khalaf and Perween, 2012]. 
Log P of GLI was found in chemspider database with 3.754. GLI can show 
polymorphism (Table 5). This table indicates that the stability and solubility of GLI is 
dependent on its polymorphic form. 
Table 5: Polymorphs of GLI with their melting point. 
Literature 
source 
Named 
polymorphs 
Melting 
conditions 
Melting 
point in ºC 
comments 
Suleiman. 
et al. 
(1989)  
 
I (more stable) The samples 
were 
placed on the 
hot-stage at 
room 
temperature 
and 
heated at a 
rate of 5 °C per 
min. 
173.1 At 37 ºC 
0.66 mg/100 mL 
solubility in distilled 
water 
No significant 
difference in 
dissolution to form II 
II (less stable) 148.7  At 37 ºC 
1.06 mg/100 mL 
solubility 
 
The Raman activity of GLI is based on the functional groups listed in Table 6. 
Table 6: Example for Raman wavenumbers of functional groups of GLI from Mah et al. (2013). 
Raman wavenumber in cm-1 Functional group 
1714 C=O 
1593 Aromatic C=C 
Doublet at 1345 and 1156 SO2 
1442 Enol C-O 
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GLI is used as an antidiabetic drug which is applied in the treatment of non-insulin 
dependent diabetes. It is known to block ATP-dependent potassium channels, which 
leads to a depolarisation of the beta-cells in the pancreas, therefore, activates calcium 
channels and leads to secretion of insulin. GLI is a known Pgp inhibitor [Golstein et al., 
1999]. Recently, GLI had been identified to minimise posttraumatic secondary injuries 
by interacting with a non-selective cation channel (transient receptor potential 
melastatin 4) [Hersh et al., 2017]. Doses administered can be 1.25 mg every 12 hours 
over one week. The usual starting dose in diabetes treatment is 5 mg for adults. The 
standard dosage form on the market is the tablet but in neonatal diabetes there is also 
a need for suspensions with starting doses of 0.2 mg/kg/d, which are commonly 
produced from tablets. This preparation can easily lead to dosage inconformity [Di 
Folco et al., 2012]. Nanosuspensions as formulation strategy, which could be dried and 
re-dispersed before administration, could make the production and application easier. 
3.1.2 Stabilisers 
It was described earlier that for the creation of nanocrystal suspensions via milling, 
stabilisers are essential. In this study, five different types of stabiliser were tested for 
their ability to stabilise CUR and GLI nanosuspensions. 
3.1.2.1 Polysorbates 
Polysorbates are surface active agents (surfactants). They are formed by the 
ethoxylation of sorbitan before addition of fatty acids. Depending on fatty acid and 
ethoxylation type, polysorbates are named differently. In this work, Polysorbate 80 
(PS80) was selected, which is mostly created out of 8 = oleic acid and 0 = monoester 
with 20 polyoxy ethylene units (Figure 8). 
 
 
Figure 8: Chemical structure of PS80 (W + X + Y + Z= 16). 
Polysorbates are a mixture of components. PS80 has, like mentioned above, high 
percentages of oleic acid ester content (67.8 ± 0.7 % to 96.6 ± 1.3 %) [Braun et al., 
2015] along with myristic, palmitic, palmitoleic, stearic, linoleic, and a-linolenic acid 
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esters. The calculated molecular weight is 1,310 daltons, assuming 20 ethylene oxide 
units, 1 sorbitan, and 1 oleic acid as the primary fatty acid [Sigma-Aldrich 
ProductInformation Tween® 80 Sigma Ultra].  
Braun et al. tested sixteen batches of PS80, which they selected from different 
suppliers and demonstrated a had high variability in physical characteristics such as 
critical micellar concentration (CMC), cloud point, hydrophilic-lipophilic-balance (HLB) 
and micelle molecular weight [Braun et al., 2015]. Therefore, in this work, just one 
production batch was used. 
PS80 molecules aggregate in solution to different structures, depending on the 
concentration. The CMC in water ranges from 13.4 ± 0.6 mg/L to 24.7 ± 1.4 mg/L 
[Braun et al., 2015]. Below these concentrations, the polysorbate molecules are 
dissolved as monomers. By increasing the concentration above the CMC, different 
structures can be found. Siqueira et al. found a monomodal intensity distribution near 
4 nm, measured with dynamic light scattering, for PS80 [Siqueira et al., 2013]. 
Polysorbates can be used as stabilisers in nanoemulsions, [Wang, 2014] as stabilisers 
of nanostructured lipid carriers [How et al., 2011] and in nanocrystalline formulations 
[Peltonen and Hirvonen, 2010]. PS80 can be utilised as component for oral and 
parenteral administration [Liang, 2012]. When used as a stabiliser of nano-objects, 
PS80 can change the nano-bio-interaction of the drug with tissues. Leno et al. found 
that PS80 coated nanoparticles were favourable to increase organ distribution for a 
HIV therapeutic drug and therefore, enhance the efficacy of the drug [Leno et al., 2014]. 
Araujo et al. explored PS80 to be the most effective surfactant for the direction of 
particles to non-reticuloendothelial system organs with a concentration above 0.5 % 
[Araujo et al., 1999].  
All these literature data suggest that PS80 can have a positive effect on 
nanosuspension formation and application and therefore, it was included in this work. 
3.1.2.2 Hydroxypropyl methylcellulose 
Hydroxylpropyl methylcellulose (HPMC) is a non-ionic polymer. This chemically 
changed cellulose ether can be produced with different molecular weights, depending 
on the number of subuntis (n) that can be seen in Figure 9. Parameters, like viscosity 
of an HPMC solution, are depending on their molecular weight, whereas the degree of 
substitution leads to changes in hydrophobicity. 
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Figure 9: Chemical structure of HPMC; n = number of units; R = hydroxylpropyl or methyl groups. 
The structure of HPMC in aqueous solution is still not fully explored. Proposed 
structural behaviour of HPMC in water ranges from individual chains, forming loops at 
high concentrations with the hydrophobic parts interacting, to the formation of fringed 
micelles [Müller, 2010; Klemm et al., 2005]. The properties of dissolved HPMC are 
dependent on the average-, molar- and region-specific degree of substitution, the 
solvent, temperature, concentration and molar mass [Kulicke et al., 2005]. Sarkar 
investigated the viscosity ranges and corresponding molecular weights for HPMC, 
produced by Colorcon GmbH, which is a company of The DOW chemical company 
(METHOCELTM) [Sarkar, 1979]. The results can be seen in Table 7. 
Table 7: Molecular weights and corresponding viscosities of HPMC grades [Sarkar, 1979]. 
Grade number 2 % viscosity range in mPa x s Mw range in kDa 
5 4 - 6 18 - 22 
25 20 - 30 48 - 60 
50 40 - 60 65 - 80 
100 80 - 120 85 - 100 
 
In this project, METHOCEL E5 Premium LV was used, which has following properties 
(Table 8). 
Table 8: Key figures of Methocel E5 Premium LV taken from METHOCEL Cellulose Ethers in 
Aqueous Systems for Tablet Coating. 
Product description Corresponding values 
Methoxyl 28 - 30 % 
Hydroxypropyl 7 - 12 % 
Viscosity, 2.0 % in water,  4 - 6 mPa x s 
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HPMC can be used as an excipient for hard capsules [Al-Tabakha, 2010], in retard 
matrix tablets [Timmins et al., 2014] or as coating material [Roy et al., 2009; Sangalli 
et al., 2004]. Also, as stabiliser in nanosuspensions as well as nanoemulsions it is 
widely explored [Kumar et al., 2015; Plakkot et al., 2011; Karashima et al., 2016; Chen 
et al., 2015]. The use of HPMC products is generally recognised as safe (GRAS). 
As HPMC is a widely explored and safe agent it was included in this thesis. 
3.1.2.3 Sodium dodecyl sulfate and tetra decyl trimethyl ammonium bromide 
Ionic stabilisers can also be called tensides or surfactants. They can be positively or 
negatively charged. One of the most widely known representatives of the latter group 
is sodium dodecyl sulfate (SDS), displayed in Figure 10. 
 
 
Figure 10: Chemical structure of SDS. 
It is used in soaps and washing detergents but also has many applications in 
pharmaceutical sciences. As a solubility enhancer it can be used in dissolution studies 
of poorly soluble drugs [Madelung et al., 2014], as a nucleation inhibitor in bottom-up 
production of nanocrystals [Dalvi and Yadav, 2015] and as a stabiliser for nanocrystals 
[Toziopoulou et al., 2017; Fu et al., 2017; Liu, 2013]. 
Depending on the determination method, the CMC can vary so that, amongst other 
things, CMC in literature were found between 4 mM and 10 mM [Rahman and Brown, 
1983; Khan and Shah, 2008]. Its structural behaviour in a buffer solution can differ, as 
Fuguet et al. found the CMC of SDS in 50 mM phosphate buffer being 1.99 mM [Fuguet 
et al., 2005]. 
An example for a positively charged stabiliser is tetra decyl trimethyl ammonium 
bromide (TTAB). TTAB has a long ethylene chain as well with a positively charged 
ammonium head group (Figure 11). 
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Figure 11: Chemical structure of TTAB. 
TTAB is employed in lyotropic liquid crystal formulations [Yavuz et al., 2014], as pore 
creator in porous silica nano-particles [Xu et al., 2015] and the positive charge allows 
the application of ionic interaction with negatively charged structures, for example, for 
stabilisation issues. Dhar et al. found that the stability of nanocrystalline cellulose 
(NCC) suspension was dependent on the adsorption of TTAB. The interaction was 
electrostatically driven which was followed by hydrophobically driven polymer-induced 
micellisation of TTAB on NCC particles [Dhar et al., 2012]. 
CMC values in water were found at 3.77 mM and 1.93 mM in 20 mM phosphate buffer 
for TTAB [Fuguet et al., 2005]. 
These two ionic stabilisers were added to this work, as they show potent stabilisation 
characteristics and can have a change in behaviour when being applied to biological 
surroundings, like buffered solutions which was of interest in the cell studies 
conducted. 
3.1.2.4 Poloxamers 
Poloxamers are non-ionic poly ethylene oxide-poly propylene oxide copolymers which 
general structure is given in Figure 12.  
 
 
Figure 12: Chemical structure of poloxamers. a = ethylene oxide unit b = propylene oxide unit. 
Depending on the number and arrangement of ‘a’ and ‘b’ structures, they have different 
molecular weight, solubility in water and surface activity. One of the most commonly 
used poloxamer is poloxamer 407 (a = 95 - 105, b = 54 - 60) with molecular weights 
ranging from 9840 - 14600 Da. Depending on their molecular weight, poloxamers can 
be of a liquid (poloxamere 124; molecular weight = 2090 - 2360 Da) or solid 
(poloxamere 407) state. Poloxamers are explored as thermosensitive gelling agents 
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[Yu et al., 2017], in micelle formation processes [Ćirin et al., 2017; Mendonça et al., 
2016] for solubility improvement and in nanosuspension stabilisation. Poloxamers 
adsorb on lipophilic surfaces with their middle-structure leaving the arms as steric 
barrier. The hydrodynamic thickness of the adsorbed polymers is proportional to the 
chain length ‘a’ (see Figure 12) as well as the molecular weight [Lee et al., 1989]. 
Anwar et al. utilised poloxamer 407 for the improvement of the aqueous solubility of 
their tested API and higher systemic circulation time of the created lipid nanocapsules 
[Anwar et al., 2016]. Hence, poloxamer adsorption on surfaces can have a relevant 
effect in bio-distribution of particles. Macrophages tend to take up less API particles 
when poloxamers are adsorbed to the particles, which can lead to a longer circulation 
time in the bloodstream after intravenous administration [Dunn et al., 1997; Owens and 
Peppas, 2006]. It has to be kept in mind that desorption can occur, especially in the 
surrounding of serum proteins [Neal et al., 1998]. A stable adsorption occurs when the 
proportion and the size of polyethylene oxide and polypropylene oxide segments are 
chosen wisely for the appropriate drug. Hydrogen bonds between drug and the 
polyethylene oxide ether groups, hydrophobic van-der-Waals interactions and weak 
polymer-solvent interactions can lead to quite stable interaction patterns [Moghimi and 
Hunter, 2000]. 
In this work, poloxamer 124 (Pol124) (a = 10 - 15; b = 18 - 23) and poloxamer 407 
(Pol407) were chosen, as they differ in composition and therefore, the differences in 
structure might be transferable to the ability and efficacy of producing 
nanosuspensions. 
3.1.3 Cell culture 
On the basis of in-vitro experiments, a correlation to in-vivo behaviour of the formulated 
drug can be aimed. Cell systems, as living structures, can be suitable for the prediction 
of drug transport through cells or uptake in cells in-vivo [Artursson et al., 2012].  
When a drug should be administered orally, the main absorption barrier are the 
enterocytes in the small intestine as there, most drugs have to pass the cells to appear 
in the blood stream, if they should be systemically effective. A drug should have 
sufficient permeability to achieve adequate bioavailability. In drug discovery, the 
Caco-2 cell model is a successfully used model for permeability screening [Hidalgo, 
2001]. 
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Caco-2 cells are a human colon carcinoma cell line. As explained in the theoretical 
background (chapter 2.5), the barrier functions of this colon cell line are comparable to 
healthy small intestine epithelial cells. It is an adherent cell line which forms connective 
monolayers. Hence, this ability can be used for permeability screening as the cells can 
be grown on a membrane. Under optimal culturing conditions, the monolayer is forming 
within 21 days and should look like displayed in Figure 13. 
 
Figure 13: Caco-2 cells. bright field image. cells imaged in cell culture medium. 
As the Caco-2 model is a widely explored permeation model for testing permeation of 
drugs, it was also used in this work to gain better understanding in the permeation of 
nanosuspensions. 
The second cell line, utilised in this work, was the RAW 264.7 cell line. It is an Abelson 
leukaemia virus-induced tumour cell line from mice. These adherent macrophages can 
be used for pinocytosis and phagocytosis studies. They have the morphology of 
monocytes like can be seen in Figure 14. 
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Figure 14: RAW 264.7 cells. bright field image. cells imaged in cell culture medium. 
In this work, the cell line was used to test the capability for nano-object uptake with 
regard to size, time and type of stabiliser. 
3.2 Methods 
3.2.1 Media milling 
Media milling is a standard practise for large scale production of nanocrystals in 
pharmaceutical industry, using agitated ball mills, like horizontal bead mills in 
recirculation mode [Möschwitzer, 2013]. Most nanocrystal products on the market are 
produced with the NanoCrystal® technology which is patented by the Perrigo Company 
PLC [US Patent 5145684]. The core of the patent is a horizontal bead mill with a 
circulating drug suspension. One example for the construction of an agitated ball mill 
on laboratory scale is the horizontal bead mill type Dispermat® which was utilised in 
this work (Figure 15). 
The suspension, consisting of coarse drug particles and stabiliser solution, is kept in a 
closed vessel together with the milling beads. The suspension has to be separated 
from the beads after milling. Therefore, the Dispermat® has a dynamic gap between 
milling vessel and outlet for circulation purposes. Particles in suspension are able to 
pass this gap while milling beads stay in the milling chamber. Hence, an automated 
separation of beads and product is achieved more easily when comparing the bead 
separation process to, for example, a planetary mill, where the beads have to be 
manually removed. 
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Figure 15: Scheme of a horizontal media mill in circulating mode. 
Starting material that gets in between bead–bead, bead-wall and bead-rotor contacts 
is exposed to a certain force, depending on the nature of the contact, so that depending 
on the rotor speed, milling time and bead size, different particle sizes can be produced. 
Particle size reduction to the nano-scale was accomplished, in this work, with the 
Dispermat® SL-C 5 (VMA Getzmann GmbH, Germany) in a circulation setup. Pump 
speed for all experiments was at 69 mL/min (set for double-distilled water). External 
cooling fluid was cooled down to 8 °C and circulated through the casing of the milling 
chamber while milling. As sealing liquid, the stabiliser solution for the ongoing milling 
was used. Rotor speed was set to 4,000 rpm and for every experiment 10 g of drug 
was used in 100 g of final formulation. Before milling, the drug was added to the 
stabiliser solution and directly homogenised with an Ultra Turrax® (Ultra Turrax® T25 
basic, IKA®-Werke GmbH & Co. KG, Germany, rod of 1.7 cm diameter) for 10 seconds 
at 11,000 min-1 to minimise floating of the drug on the surface. 
3.2.2 Stabiliser characterisation 
Different stabiliser characteristics can have an influence on the stability as well as on 
the production of nanosuspension. Therefore, in this work, the zeta potential of the 
produced nanosuspensions and the CMC were tested for selected stabiliser solutions. 
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3.2.2.1 Zeta potential 
With zeta potential measurements, the electrostatic or charge repulsion/attraction 
between particles can be measured. It is the calculated average potential in the surface 
of shear and can be measured by performing an electrophoresis experiment and 
simultaneously measuring the velocity of the particles by, for example, Laser Doppler 
Velocimetry, which can be done by the Zetasizer Nano ZS from Malvern Instrument 
Ltd (Malvern Instrument Ltd., UK). This was the instrument of choice for this work. 
Cuvettes from the Zetasizer Nano series (Malvern Instrument Ltd., UK) were used with 
stoppers. Samples were diluted (1:100 for GLI and 1:1000 for CUR) with 
double-distilled water before measurement. One measurement contained 3 
measurement repetitions with 10 - 100 runs (automatic mode) and a 60 second delay 
between the measurements. The temperature was set to 23.3 °C. 
3.2.2.2 Critical micelle concentration 
One of the most used methods to measure the CMC are surface tension 
measurements. In this work, the Processor Tensiometer K12 (Krüss GmbH, Germany) 
was utilised to measure the surface tension of the stabiliser solutions. A platinum 
Wilhelmy plate was used for all measurements. This plate is connected to a force 
sensor, so that after introduction of the plate to the sample, the plate is pulled out of 
the sample and this force can be measured. Based on this value, the length of the plate 
and the contact angle of the solution at the plate, the surface tension can be calculated. 
The typical pattern of increasing concentrations of surfactants is plotted in Figure 16. 
 
Figure 16: Surface tension plot of a surface active agent with increasing concentrations. 
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The CMC was taken from the graphs created with increasing concentrations of the 
stabilisers and was plotted with the same axis than shown above. The graph values 
were calculated by Microsoft Excel 2010. 
3.2.3 Particle characterisation 
3.2.3.1 Particle morphology of coarse material 
By using a scanning electron microscope, the particle shapes of the coarse powders 
of GLI and CUR were investigated. In the scanning electron microscope, a beam of 
electrons is produced by an electron gun. The electrons travel through electromagnetic 
fields and lenses, which focus the beam down toward the sample. These electrons 
lead to a removal of secondary electrons that leave the sample, are collected, amplified 
and analysed [Smith and Oatley, 1955]. Different areas of the sample produce a 
different amount of secondary energy, so that a picture can be generated by the 
analyser. 
The samples were prepared by fixing the powder on a carbon sticker and coating the 
sample with gold by a sputter coater (BAL-TEC SCP 050 Sputter Coater, Leica 
Instruments, Germany) to avoid charging of the samples. Images within this work were 
visualised with a Zeiss Ultra 55 plus (Carl Zeiss NTS GmbH, Germany) combined with 
a SE2 detector, at a working voltage of 2 kV. A magnification of 500 x was utilised. 
3.2.3.2 Particle size measurements 
Depending on the particle size, different measurement techniques are applicable. 
Laser light diffraction (LD) is suitable to measure particles from 0.01 µm to 8750 µm 
(HELOS®, Sympatec GmbH, Germany) whereas for particle size ranges from 0.3 nm 
to 10 µm (Zetasizer Nano ZS, Malvern Instruments Ltd., UK) dynamic light scattering 
(DLS) is generally the technique of choice. It has to be kept in mind that these size 
ranges are instrument dependent numbers so that they can differ to instruments from 
other brands. 
Laser diffraction  
In laser diffraction, a continuous-wave laser is directed on the sample, followed by the 
light being inflected from the surface of the particle at an angle which is dependent on 
the size of the particle. The inflected light is then focused with a lens on a detector 
array, where a diffraction pattern is collected. When observing the intensity of light 
inflected at different angles, the relative amounts of particles with different sizes can 
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be determined by a complex algorithm. The principle behind the algorithm is, that 
smaller particles inflect light at relatively larger angles compared to larger particles 
[Skoog et al., 2013]. 
There are two principles of data analysis for laser diffraction, Fraunhofer and Mie, 
whereby both describe scattering by homogenous spheres of random size. For 
particles much larger than the wavelength of the emitted light, the Fraunhofer method 
can be used. Particles are here seen as round and impervious to light. Amongst other 
things, the inflection intensity and the intensity at the maximum of the inflection pattern 
are taken to calculate the size of the particle(s). The LD method requires the particles 
to be in a dispersed state, either in liquid or in air. 
Consideration of the particles size alone is not enough to describe a population of 
particles. Equally important is the interpretation of the particle size distribution. For LD, 
the Span can be used as a particle size distribution value. It is calculated like shown 
below (Equation 2). 
𝑆𝑝𝑎𝑛 =
𝑥90 − 𝑥10
𝑥50
 
Equation 2: Particle size distribution calculation. X-values stand for a particle size. X90, for 
example, means that 90 % of the particles are smaller than the size value for X90. 
Analysis, in this project, was accomplished with the CUVETTE® (suspensions) or 
RODOS® (powder) module of a Helium-Neon Laser Optical System (HELOS®, 
Sympatec GmbH, Germany). For the CUVETTE® measurements one drop of 
suspension was dispersed in double-distilled water and measured with a R2 lens (focal 
length: 50 mm and measuring range: 0.25 μm up to 87.50 μm) directly after stirring. 
The powder was dispersed with the RODOS® module into the measuring zone by 
compressed air (3 bar) and measured with appropriate lenses. The calculation of the 
volumetric particle diameter was accomplished with Windox 5 software, based on 
Fraunhofer enhanced evaluation. From the cumulative volume-based distribution (Q3), 
the values of X10, X50 and X90 were determined in quadruplicate. Reported values are 
given as mean ± standard deviation. 
Dynamic light scattering  
Materials and Methods 
 
35 
 
In dynamic light scattering (DLS) the particles are not seen as static elements because 
they are measured in suspension and therefore, can undergo Brownian motion which 
is a random motion caused by thermal density fluctuations of the solvent.  
Again, a continuous-wave laser is used as a light source, which is shown through a 
lens on the probe, which is placed in a cuvette. The scattered light is mostly detected 
at an angle of 173° from a photomultiplier.  
When the laser light meets a particle in suspension it can be scattered as shown in 
Figure 17. 
 
Figure 17: Sketch of the change in the interference pattern of scattered intensity in DSL over 
time, caused by Brownian motion adapted from Schärtl et al. (2007). 
Hence, DLS measures the Doppler-broadening of the light that creates Rayleigh 
scattering when interacting with the particle(s). The time dependent intensity 
fluctuation is then used to obtain particle size information. Smaller particles move faster 
compared to larger particles and have therefore, faster intensity fluctuations. With the 
Stokes-Einstein-relationship (Equation 3), different intensity fluctuations can be 
analysed with respect to the velocity of the Brownian motion. Because the particle size 
is calculated during movement of the particle, the diameter that is measured equals 
the hydrodynamic diameter (dH) of a spherical particle. 
𝑑𝐻 =
𝑘𝑇
3𝜋𝜂𝐷𝑇
 
Equation 3: Stokes-Einstein-relation for the determination of the hydrodynamic diameter (dH) out 
of the Boltzmann’s constant (k), sample temperature (T), solvent viscosity ( 𝜼 ) and the 
translational diffusion coefficient (DT). 
Sample temperature, T and solvent viscosity, η must be known and the translational 
diffusion coefficient (DT) is calculated from the intensity fluctuations. k is the 
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Boltzmann's constant. Often, the hydrodynamic diameter of a sample is plotted as z-
average. The z-average is an intensity-based overall average size.  
For dynamic light scattering, the particle size distribution is characterised by the 
polydispersity index (PDI). This is a value ranging from 0 to 1 with 0 being a 100 % 
monomodal distributed sample. 
In this work, the size of the nanocrystals was determined, using DLS (Zetasizer Nano 
ZS, Malvern Instruments Ltd., Malvern, UK). Samples were diluted (1:100 for GLI and 
1:1000 for CUR) with transport buffer (for composition see chapter 9.2.4.2) or 
double-distilled water. If not mentioned otherwise, the dilution medium was transport 
buffer. The suspension was transferred to 3 mL acrylic cuvettes, mixed with a pipette 
and measured (3 x 10 runs). Particle size results are given as z-average and particle 
size distribution as PDI. 
3.2.4 Physico-chemical drug characterisation 
The physico-chemical characteristics of the drug are of major interest for the stability 
of the drug itself and the produced nanosuspension. For nanosuspensions, the 
solubility of the drug in the non-solvent is influencing particle growth while the solid 
state of the drug could also lead to stability issues. The surface area of the coarse drug 
suspension was of interest with regard to stabiliser-drug interactions and drug 
quantification was, amongst other things, necessary for dissolution and permeation 
studies. 
3.2.4.1 Drug quantification 
Drug quantification for solubility, transport and dissolution studies was performed by 
reversed phase high performance liquid chromatography (RP-HPLC). High 
performance liquid chromatography is a type of liquid chromatography where the 
solubilised drug sample (mobile phase) is directed over a stationary phase with 
pressure. The drug molecules are interacting with this highly porous solid phase, 
packed inside a cylindrical column. Depending on the distribution coefficient of the drug 
between mobile and stationary phase, the drug is leaving the column at a certain time 
point. With this technique, various chemical compounds can be separated and 
quantified in a mixture. Due to different hydrophobic and lipophilic characteristics of 
drugs, the separation is accomplished. The eluted drug can be detected with various 
detectors of which the most common one is an ultraviolet (UV) detector. 
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In this work a Waters HPLC system (Waters Materials and Methods Corporation, USA) 
was utilised, together with a LiChroCart® 125-4, LiChrospher® 100 RP18-5 column 
(Merck KGaA, Germany). For more information, details can be found in the appendix 
(chapter 9.3.1). 
Content stability was analysed with UV spectroscopy. In this widely applied method, a 
light is shown on the solubilised probe, which is situated in a cuvette of a defined width. 
The light interacts with the sample, which absorbs light, so that the transmitted light 
has different energies compared to the incoming light. 
In this thesis, the UV spectrophotometer Thermo Scientific™ Evolution 201 (Thermo 
Scientific Inc., USA) was utilised with a quartz cuvette (SUPRASIL®, Hellma GmbH & 
Co. KG, Germany) that had a light pass way of 10 mm. The solvent for both drugs was 
ethanol and the detection wavelength for CUR was set to 420 nm and 300 nm for GLI. 
A calibration was done in ethanol and the correlation coefficient had to be above 0.99. 
3.2.4.2 Saturation solubility 
The saturation solubility in different media was measured by production of a 
1 millimole (mM) suspension of drug and dispersion media in centrifugation tubes out 
of poly propylene. The tubes were shaken over 24 hours on a laboratory shaker (Model 
SM from Edmund Bühler GmbH, Germany, shaking speed of 5), centrifuged at 
7,197 relative centrifugal force (rcf) for 5 min (Centrifuge 5430 R, Eppendorf AG, 
Germany), filtered with an Omnifix® 5 mL syringe (B. Braun Melsungen AG, Germany) 
through a disposable polyethylene terephthalate filter with a pore size of 0.20 µm 
(CHROMAFIL® Xtra PET-20/25, Macherey-Nagel GmbH & Co. KG, Germany) and 
analysed with HPLC (see chapter 3.2.4.1). The saturation solubility was determined 
for the coarse drugs as well as selected nanosuspensions in dissolution buffers (see 
chapter 4.5.1 and appendix chapter 9.2.3). 
3.2.4.3 Solid state characterisation 
Two methods for solid state characterisation were utilised in this thesis: differential 
scanning calorimetry (DSC) and X-ray powder diffraction (XRPD). 
Differential scanning calorimetry 
In DSC, the difference in the heat flow between a sample and a reference cell is 
precisely controlled by a temperature program. The energy changes in the sample can 
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be endothermic or exothermic, depending on the sample absorbing (endothermic) or 
releasing (exothermic) energy during the thermal treatment. DSC can be used for 
qualitative and quantitative measurements but in the pharmaceutical science it is 
usually applied to characterise polymorphism, hydrates and amorphous systems.  
DSC analysis was performed using PyrisTM Diamond DSC (PerkinElmer Inc., USA) 
with 1 mg to 3 mg sample amount. Samples were heated in sealed aluminium pans 
with a pinhole at a rate of 10 K/min from 20 °C to 250 °C under nitrogen flow of 
20 mL/min using an empty sealed pan (with a pinhole) as a reference. Data evaluation 
was accomplished with PyrisTM Software Version 9.0.2.0193 (PerkinElmer Inc, USA). 
X-ray powder diffraction 
Every crystalline substance has its unique X-ray diffraction pattern. Therefore, 
qualitative analyses can be done with XRPD. In this thesis, XRPD was utilised to detect 
the solid state of the sample. When a sample is in a crystalline state, the X-ray beam, 
that is shown on the probe, gets diffracted in a, for the crystal typical, way. This 
diffraction angle is dependent on the distance between certain crystal levels, while the 
diffraction intensity is related to the number and nature of atomic reflection centres 
[Skoog et al., 2013]. An amorphous sample gives a low frequent halo which displays 
as a diffuse, wide background. 
The solid state of coarse GLI powder was determined with the Stadi P X-ray 
diffractometer of Stoe & Cie GmbH, Germany) in transmission mode using 
Cu-Kα1-radiation (40 kV, 30 mA). The samples were measured in the range of 2°- 35° 
at a step rate of 2Theta = 0.05° with 2 seconds measuring time per step. Due to 
technical issues, all other XRPD measurements were accomplished with the Stoe 
Stadi-Ps diffractometer (Stoe & Cie GmbH, Germany), together with the MYTHEN 1K-
detector (Dectris AG, Switzerland) with Cu-Kα1-radiation (40 kV, 30 mA) in 
transmission geometry. The measurement range was set to 2° - 80° 2Theta at a step 
rate of 2Theta = 2° with 60 seconds measuring time per step. 
For both methods, a solid sample is needed for measurements. Hence, the 
nanosuspensions had to be dried. Freeze drying was the method of choice. In freeze 
drying, a liquid sample is frozen and afterwards the water is sublimated under vacuum. 
Freeze drying was accomplished with the ALPHA 1-4 with the system control LDC1M 
(Martin Christ Gefriertrocknungsanlagen GmbH, Germany). The samples were frozen 
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with a thickness of approximately 0.5 cm at -25 °C for 2 hours. Afterwards the primary 
drying was activated with a shelf temperature of -10 °C and a negative atmosphere 
pressure of 2 mbar over 24 hours. A secondary drying was appendant with a shelf 
temperature of 10 °C and vacuum conditions over another 24 hours. 
3.2.4.4 Surface area 
Surface area measurements were done via BET gas adsorption as described in the 
European pharmacopoeia (Ph. Eur. 8, 2.9.26). By measuring the adsorption of a gas, 
usually nitrogen, on the surface of the sample compared to a reference, the 
monomolecular layer formation of the gas can be calculated. In this work, this was 
done by the volumetric method combined with a multiple point method. Sample and 
reference were cooled, so that the nitrogen is forced to adsorb on the surface of the 
sample. Different increasing relative pressures (
𝑝𝑎𝑟𝑡𝑖𝑎𝑙 𝑣𝑎𝑝𝑜𝑢𝑟 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑜𝑓 𝑎𝑑𝑠𝑜𝑟𝑏𝑒𝑑 𝑔𝑎𝑠 (𝑃)
𝑠𝑎𝑡𝑢𝑟𝑎𝑡𝑒𝑑 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑜𝑓 𝑎𝑑𝑠𝑜𝑟𝑏𝑒𝑑 𝑔𝑎𝑠 (𝑃0)
) 
were applied to the system and each time the adsorbed volume of nitrogen was 
automatically measured with a manometer. The volume of the monomolecular layer 
(Vm) of the gas can be calculated via the BET-equation that is given in Equation 4. 
1
[𝑉
𝑎(
𝑃0
𝑃 −1)
]
=
𝐶 − 1
𝑉𝑚𝐶
∗
𝑃
𝑃0
+
1
𝑉𝑚𝐶
 
Equation 4: BET-equation. Variables are defined as: P = partial vapour pressure of adsorbate gas 
in equilibrium with the surface, in pascals; P0 = saturated pressure of adsorbate gas, in pascals; 
Va = volume of gas adsorbed at standard temperature and pressure (STP) [273.15 K and 
atmospheric pressure (1.013 × 105 Pa)], in millilitres; Vm = volume of gas adsorbed at STP to 
produce an apparent monolayer on the sample surface, in millilitres; C = dimensionless constant 
that is related to the enthalpy of adsorption of the adsorbate gas on the powder sample. 
The calculation of the specific surfaces (S) from adsorption data was done by 
multiplying Vm with the area which is occupied by one adsorbate molecule (Am) and 
the Avogadro’s number (Equation 5). 
 
𝑆 =  𝑉𝑀 ∗ 𝐴𝑚 ∗ 𝑁 
Equation 5: Calculation of the specific surface (S) out of Vm (volume of a gas monolayer), Am 
(area of one adsorbated molecule) and N (Avogadro’s number). 
In this thesis, samples were kept under vacuum for above 12 hours as a conditioning 
step (VacPrep 61, Micromeritics Instrument Corporation, USA), to remove adsorbed 
molecules and to avoide unspecific binding of gas molecules on the surface. The 
surface area was measured with a Gemini 2360 System (Micromeritics Instrument 
Corporation, USA). The samples were compared to a reference sample vessel, filled 
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with the amount of glass beads, which corresponded to the dead space volume of the 
sample as measured with a helium pycnometer (Pycnomatic ATC, Porotec GmbH, 
Germany). Both tubes were cooled to 77 K during analysis. The dead space of the 
sample tube was measured with Helium prior to each measurement. Nitrogen was 
used as test gas. Information regarding the quality of the utilised gases can be found 
in the appendix (chapter 9.2.2). The specific surface area was calculated based on a 
multipoint correlation with eleven different relative pressures between 0.05 p/p0 and 
0.3 p/p0. Measurements were done in triplicate for each drug. 
3.2.5 Determination of drug-stabiliser interaction 
3.2.5.1 Isothermal titration calorimetry  
Calorimetric techniques are powerful tools for studying interactions at molecular levels. 
Isothermal titration calorimetry (ITC) is one of many techniques that measures 
calorimetric changes. It can detect small changes of heat during reactions for the 
determination of the thermodynamic parameters such as entropy (ΔS), enthalpy (ΔH), 
Gibbs free energy (ΔG), heat capacity, binding constants and effective number of 
binding sites in biological reactions [Rowe et al., 1998; Ladbury, 2001]. That is why ITC 
is used to investigate biomolecular interactions with the advantage of a label-free 
application. The enthalpy is an indication of changes in hydrogen interaction and 
van-der-Waals bonding while the entropy is indicating changes in conformational 
changes of molecules [Dutta et al., 2015]. 
Figure 18 shows the principle of an ITC experiment. The instrument has two cells, one 
holding the reference cell and one holding the sample cell. The sample cell is loaded 
with one component of the investigational interaction reactants while the reference cell 
is filled with water. Usually, a solution (or suspension) of the component in an organic 
or inorganic medium is suitable. The other part of the instrument is a syringe. It holds 
the other reaction partner at the experiment which is injected through a hole in the 
paddle into the sample cell while the paddle stirs. 
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Figure 18: Left: sketch of the used ITC setup with sample cell and syringe next to the reference 
cell. Right: titration pattern displaying heat amplitude for each titration step. 
A constant power is supplied to the reference cell heater. The sample cell has a 
feedback mechanism between power and temperature which means that if there is a 
loss/gain in heat in the sample cell, there is more/less power applied to the cell, so that 
the temperatures between reference cell and sample cell remain constant. 
The diagram in Figure 18 displays also the raw data of an ITC experiment. The change 
in heat is calculated by integrating the heater power over the time required for the 
control heater power to return to a baseline value. For each injection from the syringe 
in the sample cell, a power difference to the reference cell is measured. The created 
peaks hold, as their area/length, the information about the heat absorption or heat 
creation of one injection. Over time, multiple injections into the sample cell enable the 
detection of a heat interaction pattern. If the heat interaction stays the same across the 
time period of administered injections, there is no change in thermal interaction 
between the reactant in the cell and in the syringe.  
Adsorption of stabilisers on drugs can be characterised with ITC. The physico-chemical 
explanation of this interaction is, that prior to adsorption, the number of degrees of 
freedom is higher than for the adsorbed species. Adsorption is therefore spontaneously 
happening when the change in enthalpy (ΔH) has a sufficiently large negative value as 
the entropy change (ΔS) of the process should be negative, due to greater entropy of 
the adsorbent in liquid state than in adsorbed state. A spontaneous process is 
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happening when the Gibbs free energy (ΔG) is negative. The relationship between ΔG, 
ΔH and ΔS is displayed in Equation 6.  
 
𝛥𝐺 =  𝛥𝐻 − 𝑇𝑥𝛥𝑆 
Equation 6: Gibbs free energy (ΔG) calculation from enthalpy (ΔH), entropy (ΔS) and 
temperature (T). 
As the adsorption process of polymers on particles is in general entropically 
unfavourable, due to less variability in conformation change of the polymer, the 
hydrophobic interactions have to be high enough to destroy the organised water 
structures near the particle surface and therefore increase entropy of the system 
[Vaynberg et al., 1998].  
The general setup and concentrations of the tested solutions/suspensions as well as 
appropriate control experiments are of major importance, as are settings such as 
injection volume, injection rate, spacing between injections, filter period, reference 
power, stirring speed and temperature. Standard adjustments for the later parameters 
are dependent on the type of experiment. 
In this work, ITC was used to display the interaction of two stabilisers with two drugs 
to obtain a better understanding of how the stabilisers interact with drug surfaces. 
Isothermal titration calorimetry experiments were performed with the VP-ITC 
MicroCalorimeter (MicroCal, USA). A sample cell of 1.8 mL volume was filled with 1 mL 
coarse drug suspension (10 mg/mL), which was prepared in an Eppendorf tube by 
mixing the drug powder and Milli Q water (produced with Millipore Milli-Q Integral 15, 
Merck KGaA, Germany) with a Thermo Scientific™ Finnpipette™ F1 pipette (Thermo 
Scientific Inc., USA). Titration was accomplished with stabiliser solution in a 300 µL 
syringe with 10 µL injection volumes per injection at a reference power of 20 µCal/sec, 
a temperature of 25 ºC and a stirring speed of 1000 rpm. The concentration of the 
stabiliser suspension was calculated to simulate milling conditions, so that the relation 
of the amount of stabiliser and drug, for the minimal stabilising concentration that was 
found in media milling, was achieved in the experimental setup. 
3.2.5.2 Contact angle measurements 
The interaction potential of liquids with solid surfaces can be characterised with contact 
angle measurements. The Young equation (Equation 7) displays the correlation of 
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contact angle (cosθ), surface tension of the liquid (σli), interfacial tension between liquid 
and solid (σsl) and the surface free energy of the solid (σs). 
 
σs = σsl + σli ∗ cosθ 
Equation 7: Young equation for the determination of surface free energy of solids (σs). 
cosθ = contact angle; σli = surface tension of the liquid; σsl = interfacial tension between liquid 
and solid. 
Contact angle measurements can display the interaction of the stabiliser in solution 
and the interplay of this solution with a drug surface. As stabilisers can interact with 
surfaces, they can decrease the interfacial tension between liquid and solid and/or the 
surface tension of the liquid so that the contact angle decreases. Bad/No wetting is 
seen when the contact angle is over or equally 90º, while good wetting leads to lower 
contact angles (Ph. Eur. 8, 2.9.45). The contact angle can be measured between a 
droplet and a solid surface (Figure 19). 
 
 
Figure 19: Solid surface with a liquid droplet and applied tangent with contact angle. 
For contact angle measurements between drug and stabiliser solution, the drug is 
normally compressed to a compact so that the angle of one drop stabiliser solution on 
this compact can be measured. 
Contact angles between drug and stabiliser solution were measured with a goniometer 
(Type G1 from Krüss GmbH, Germany). The drug was processed with a hydraulic 
press (PW 10 from Paul-Otto Weber GmbH, Germany) to achieve a compressed drug 
pellet. Diameter of the die (1.3 cm), compaction force (5 kN), holding time (1 min) and 
amount of drug (0.25 g) were fixed values. A glass syringe was used for the creation 
of one drop of stabiliser suspension, while simultaneously focusing the surface of the 
drug pellet. When the drop appeared in the field of view the contact angle was 
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measured immediately by laying a tangent on the edge of the droplet. The view through 
the ocular is schematically plotted in Figure 20. 
 
 
Figure 20: Sketch of the view through the ocular of a goniometer. Lower scale displaying length 
measurement of the droplet and upper scale for contact angle measurements.  
Because of temperature differences between experiments, all values were related to 
double-distilled water contact angle that was measured at the experiment day in 
quadruplicate. Concentrations of stabiliser solutions were selected from milling data, 
to cover a concentration area around the minimal stabilisation concentration, which 
was found in milling experiments for each drug. 
3.2.6 Dissolution 
Dissolution is a standard method in pharmaceutical technology to compare different 
formulations. Dissolution can serve as a tool in drug development, in providing control 
of the manufacturing process and to assess the need for further bioequivalence 
studies. The standard method is to test solid dosage forms such as tablets and 
capsules but also transdermal therapeutic systems or nanosuspensions can be tested 
for molecular drug release from the dosage form. 
For all dissolution studies a paddle apparatus, described as apparatus 2 in the 
European Pharmacopoeia 8, 2.9.3 (Erweka DT6, Erweka GmbH, Germany), was used 
with a stirring speed of 50 rpm at 37 °C. When taking the sample, approximately 2 mL 
sample were filtered through a polyethylene terephthalate filter with a pore size of 
0.20 µm (CHROMAFIL® Xtra PET-20/25, Macherey-Nagel GmbH & Co. KG, 
Materials and Methods 
 
45 
 
Germany), while the filter was attached to a cannula with a diameter of 0.9 mm and a 
length of 70 mm (Sterican®, B. Braun Melsungen AG, Germany) which always 
remained at the same height. After taking the sample, 2 mL pre-warmed (37 °C) 
dissolution medium was filtered through the filter to push possible adsorbed drug back 
to the dissolution vessel. All used buffer compositions are described in detail in chapter 
9.2.3. 
3.2.6.1 Conditions for glibenclamide 
Conditions used were inspired by FDA recommendations for glibenclamide (glyburide) 
tablet products [U.S. Food and Drug Administration. Drug Database] as well as 
pre-tests on solubilisation. 500 mL borate buffer pH 9.4 (USP 36 under Buffer 
Solutions) was used as the first dissolution medium. The content of GLI was 
determined with UV spectroscopy (for details see chapter 3.2.4.1).  
The second dissolution medium was 900 mL phosphate buffer pH 8 (USP 36 under 
Buffer Solutions). Due to lower solubility of GLI in this medium, the concentrations 
measured were below the detection limit of UV measurements, so that the content was 
determined with HPLC and UV detection (method see chapter 9.3.1). Sampling time 
points were 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 60, 80, 100, 120, 180, 240, 1220 
and 1440 minutes. Perfect sink conditions were used. Therefore, suspensions with an 
amount of drug, corresponding to approximately 10 % of the determined saturation 
concentrations were applied to the dissolution vessels, which were 26.5 - 27 mg for 
boric acid buffer and 5.8 - 6.7 mg for phosphate buffer. 
3.2.6.2 Conditions for curcumin 
Pre-tests indicated that the solubility in acetic acid buffer was the highest (data not 
shown). Thus, 900 mL of acetic acid pH 4 were taken as dissolution medium. Sampling 
time points for CUR needed to be decreased as CUR solutions were degrading over 
time, so that HPLC analysis had to be close to sampling time point. Therefore, 
sampling time points were reduced to 1, 5, 10, 15, 30, 45, 60, 80, 120, 180, 240, 1220 
and 1440 minutes. Sink conditions could not be applied as CUR was not detectable at 
such low concentrations, so 5 times saturation concentration had to be used 
(1.3 - 1.7 mg). 
Materials and Methods 
 
46 
 
3.2.7 General cell culture and toxicity testing 
Caco-2 cells with a passage number of 62 - 69 were cultured in Dublecco’s modified 
medium (DMEM) containing 50,000 U/566 mL penicillin and 50 mg/566 mL 
streptomycin as antibiotics, sodium pyruvate (60.5 g/566 mL), non-essential amino 
acids (4.9 mg/566 mL L-alanine, 8.25 mg/566 mL L-asparagine x H20, 7.3 mg/566 mL 
L-aspartic acid, 8.1 mg/566 mL L-glutamic acid, 4.1 mg/566 mL glycine, 
6.3 mg/566 mL L-proline, 5.8 mg/566 mL L-serine) and 9 % fetal bovine serum (FBS). 
The culturing conditions were 5 % CO2 and 37 ºC, with feeding every 2 - 3 days. For 
passaging, which was done when the confluence reached 80 % - 90 %, the cells were 
rinsed with PBS buffer, incubated with trypsin/EDTA solution (0.25 %/0.02 %) for 
6 - 7 minutes, counted, and approximate 1,000,000 cells were transferred to a new 
flask (75 cm² growth area) containing pre-warmed medium. The counting was done 
with a counting chamber under a light microscope with the cells being stained with 
trypan blue (0.5 % from Biochrom GmbH, Germany) (dark blue cells were not counted 
as they are dead). Storage of the cells was accomplished in 5 % dimethyl sulfoxide 
(DMSO) - medium solutions in liquid nitrogen until used, while the DMSO was 
disposed after centrifugation when the cells were cultured. 
For toxicity tests 30,000 cells were seeded per well on a 96-well plate (TPP® 
Zellkulturplatten 96F, TPP Techno Plastic Products AG, Switzerland) three days prior 
experiment. Until experiment day, the cells were incubated at 5 % CO2 and 37 ºC. At 
the day of the experiment the medium was sucked off and was replaced by 200 µL 
sample volume. Incubation time of the sample was 4, 5, 6 or 24 hours, respectively. 
The sample volume was replaced by a 25 µL of a 5 mg/mL 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) reagent in HBSS solution and incubated 
over 2 hours. Afterwards 100 µL of a 5 % SDS in dimethyl formamide/double-distilled 
water (50:50, adjusted to pH 4.7) solution was added. Subsequently, the plate was 
placed on a shaker (IKA® Vortex 4 basic, IKA®-Werke GmbH & Co. KG, Germany) for 
1 min at 400 rpm and measured afterwards, utilising a plate reader (TECAN 
SPECTRA, Tecan Trading AG, Switzerland) at 570 nm. Data processing software was 
easy WIN fitting (32 bit). Samples were determined in quadruplicate and for each plate 
a positive control (5 mM SDS solution in water) and a negative control (DMEM or 
transport buffer) were run. The achieved absorption values were related to both 
controls (positive = 0 % cells alive; negative = 100 % cells alive). Most cell culture 
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liquids were purchased from Biochrom AG (Germany). For further compositions please 
see chapter 9.2.4. 
3.2.8 Determination of drug transport through cells 
For the so called ‘transwell model’, Caco-2 cells are grown on a filter for approximately 
21 days, to form a monolayer of tightly bound cells which serve as a barrier for 
transport of drugs. Figure 21 shows the transwell setup with the possibility of 
investigating the transport of substances from A (apical) to B (basolateral) or from B to 
A. 
 
 
Figure 21: Transwell setup for transport studies with Caco-2 cells. 
The apparent permeability coefficient (Papp) can be calculated from the initial 
concentration, the permeation time and the permeated concentration. With the Papp, 
estimations regarding bioavailability of the substance can be done (see Table 9): 
Table 9: Relation of apparent permeability coefficient and bioavailability adapted from Zhen et 
al. (2017). 
Papp (cm x sec−1) Bioavailability (%) 
> 1 × 10−6 100 
0.1 × 10−6–1 × 10−6 1 – 100 
< 1 × 10−7 < 1 
 
This general correlation is a simple model which does not reflect all drugs and 
formulations but gives a rough estimation for some drugs. Exceptions are, for example, 
drugs that permeate paracellular, as in this chase, they show lower permeation in the 
Caco-2 cell model than in humans [Artursson et al. 2012]. 
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The Papp for transport studies in this thesis was calculated as displayed in Equation 8. 
𝑃𝑎𝑝𝑝 =
𝑑𝑄
𝑑𝑡 × 𝐶0 × 𝐴
 
Equation 8: Calculation of Papp with dQ/dt as the steady-state flux in µM/sec, A as the surface 
area of the filter (cm2) and C0 as the initial concentration in the donor chamber in µM. 
The reduction in donor concentration was taken into account after every sampling so 
that the donor concentration was recalculated by subtracting the cumulative amount 
transported to the receiver chamber for each time interval. 
3.2.8.1 Transport studies 
Standardisation of cell culture is of major importance for the comparison of different 
data sets. For transport studies in transwells, the device itself and the cells should not 
vary too much from experiment to experiment. The transwell should be of the same 
material for all experiments. Pore size, pore density and growth area should be the 
same as well. As cells are not easy to standardise, a few parameters should be 
investigated and kept constant to achieve a tight monolayer with comparable 
characteristics each time, such as: 
 Reproducible transepithelial electrical resistance (TEER) values and 
permeation of a marker substance through tight junctions 
 Defined seeding density 
 Characteristic morphology 
A reproducible cell number per area in the stationary growth phase, which forms a 
connective monolayer, is the aim [Wunderli-Allenspach et al., 2000]. Similar seeding 
density and growing times with comparable feeding cycles should lead to a 
reproducible cell number in the stationary growth phase with characteristic 
morphology, while the connectivity of these cells should be controlled by TEER 
measurements and permeation studies with substances that only pass the cells via 
tight junctions [Braun et al., 2000]. The latter can be substances such as lucifer yellow 
or mannitol, while the former TEER values can be measured with voltohmmeters. 
Transport studies were performed with the transwell system from Greiner Bio-One 
International GmbH (Germany). As inserts for 12 well plates, Thincerts® with an area 
of 1.131 cm², pore sizes of 1 µm and 3 µm and pore densities of 2 x 106 cm-2 for the 
1 µm pore size and 0.6 x 106 cm-2 for the 3 µm pore size transwells were used. Prior 
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to transport experiments the transwell system with the cell monolayer was validated. 
Caco-2 cells with passage numbers ranging from 65 to 70 were seeded with a density 
of 100,000 cells per cm² culture area 16 - 23 days before the transport experiment. 
The upper compartments and the lower compartments were filled with 0.7 mL and 
1.5 mL of medium, respectively. At every feeding or rinsing, the upper compartment 
was sucked off last and fed first to avoid pressure under the cells which could lead to 
monolayer disruption. Every 2 - 3 days, the medium was replaced (the cells were fed) 
and kept in culture conditions of 37 ºC and 5 % CO2 with constant humidity. 
As transport medium either the culture DMEM medium or transport buffer was used. 
One day before the experiment the cells were fed. At the day of the experiment the 
TEER was measured with the EVOM voltohmmeter connected to the STX2 electrode 
(World Precision Instruments, Inc., USA), directly after the cells were removed from 
the incubator, to ensure that the validation parameters were achieved. When buffer 
was used as transport medium, the cells were washed twice and incubated over 30 min 
with transport buffer. The pre-experiment TEER was afterwards compared to the 
post-experiment TEER, to prove monolayer integrity during the experiment. After 
determining the TEER values, the suspension, which permeation should be tested, 
was placed in the apical compartment (0.7 mL) while cell culture medium or transport 
buffer was put in the basolateral compartment (1.5 mL) for A-B studies and 
contrariwise for B-A studies. Sampling time points were 1 hour, 3 hours, 5 hours and 
24 hours. At these time points 0.3 mL of sample for A-B studies and 0.1 mL for B-A 
studies were withdrawn from the basolateral or apical compartment, respectively and 
were replaced by fresh transport buffer or medium. In between, the cells were kept in 
the incubator at 37 ºC and 5 % CO2. 
In addition to the suspensions, a marker substance was tested on each plate. The 
permeation rate of the suspension was always calculated in relation to atenolol to 
control for day to day cell variability. After the experiment, the cells were washed twice 
with buffer or medium and incubated for 30 minutes. Afterwards the post-experiment 
TEER value was measured and a second test for monolayer integrity was done. For 
this, a 0.1 µg/µL lucifer yellow solution in PBS buffer was applied. When the transport 
medium was cell culture medium, the cells were washed three times with PBS buffer. 
When the transport medium was buffer, the cells were washed once with PBS buffer. 
Then, 0.7 mL lucifer yellow solution was pipetted in the apical compartment and 1.5 mL 
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PBS buffer were applied to the basolateral compartment. The cells were incubated for 
1 hour at 37 ºC with 5 % CO2. Finally, 0.5 mL of sample were withdrawn from the 
basolateral compartment and analysed for lucifer yellow content fluorometrically (LS 
55 Fluorescence Spectrometer, PerkinElmer Inc., USA) (measurement details can be 
seen in the chapter 9.3.2). For measurements, the cuvette module was utilised 
together with a quartz cuvette (SUPRASIL®, Hellma GmbH & Co. KG, Germany). Data 
processing was done with FL WinLab™ software. Fluorescence spectrometric 
measurements are similar to UV spectrometry (see chapter 3.2.4.1) with some 
difference like that fluorescence is measured (more details are also find in chapter 
3.2.9.3). 
3.2.8.2 Dissolution rate with regard to permeation studies 
The dissolution rate was tested to compare it to the permeation studies. To ensure this 
comparison, not a standard dissolution set–up was chosen but a setting that was 
similar to the environment in permeation studies. The aim was, to investigate how 
much of the amount of drug, that was situated in the apical compartment, did dissolve 
over time without changing concentration conditions in the actual permeation study, 
but still compare these two methods. In the permeation studies, three different kinds of 
dilution media (DMEM, transport buffer pH 7.4 and transport buffer pH 6.5) and four 
sampling time points (1 hour, 3 hours, 5 hours and 24 hours) were used. All 
suspensions used in the transport study were also tested for dissolution rate. For this, 
10 mL of 1 mM drug suspensions were created in 15 mL centrifuge tubes. These tubes 
were stored in a heating oven (Heraeus® function line, Heraeus Holding GmbH, 
Germany) at a temperature of 37 °C. At sampling time points, the samples were 
centrifuged at 7,197 relative centrifugal force (rcf) for 5 min (Centrifuge 5430 R, 
Eppendorf AG, Germany), filtered with an Omnifix® 5 mL syringe (B. Braun Melsungen 
AG, Germany) through a disposable polyethylene terephthalate filter with a pore size 
of 0.20 µm (CHROMAFIL® Xtra PET-20/25, Macherey-Nagel GmbH & Co. KG, 
Germany) and analysed with HPLC (for details see chapter 9.3.1). 
3.2.9 Visualisation of drug transport in cells 
3.2.9.1 Cell culture and general preparation methods 
CARS studies 
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Due to the use of a different cell laboratory, for CARS studies, the passaging method 
changed slightly from the description in chapter 3.2.7. The cells (Caco-2 or RAW 264.7) 
were washed with Hanks’ Salt solution buffer, which included 0.5 mM ETDA and were 
incubated at room temperature for 3 min. Then, 1.5 mL of a 0.25 %(w/v) EDTA-trypsin 
solution was added and incubated for 5 min in the incubator (37 ºC and 5 % CO2). 
Around 10 mL of media was added to the flask. A cell counting was done while the 
cells were centrifuged at 1,500 rcf for 5 min. The supernatant was removed and the 
cells were dispersed in the needed amount of media. 
Fluorescence microscopic studies 
Caco-2 cells were cultured like described in chapter 3.2.7. RAW 264.7 cells for 
fluorescence microscopy studies had similar culturing conditions, with the difference 
being that the cells were passaged by cell scraping with a cell scraper (length 16 cm, 
blade length 1.35 cm, Sarstedt, Inc. USA). Therefore, the growth medium was replaced 
by fresh medium and a cell scraper was used to detach the cells from the bottom of 
the flask. The cells were dispersed and placed into a new flask. The passage numbers 
used for experiments ranged from 4 - 10. 
3.2.9.2 Coherent anti-Stokes Raman microscopy 
Raman based microscopy is a useful tool for the chemical characterisation of many 
applications. The Raman technique is a vibrational spectroscopy method that 
essentially detects molecular vibrations. In spontaneous Raman scattering the sample 
is illuminated with a laser and light is scattered. Laser with a single wavelengths of ,for 
example, 532 nm, 785 nm and 1064 nm can be used. Scattered light is collected with 
lenses and filtered by a filter, like a notch filter. Raman scattered light is then dispersed 
onto a detector in a spectrograph, using typically a diffraction grating or a prism. In 
general, the laser light that is scattered with the exact same energy as the laser, is 
called Rayleigh scattering. However, approximately one in a million times, the light will 
be scattered at a different wavelength to the incoming light because it interacts with 
the molecule and causes vibration. The wavelengths scattered at a different 
wavelength than the incoming light are characteristic for each molecule. This scattering 
can be measured at a shorter wavelength (Stokes) or at a longer wavelength (Anti-
Stokes). Raman is a two photon scattering technique, where the first photon strikes 
the sample and a second photon is scattered. In Raman spectroscopy, the sample 
does not receive enough energy to transit the molecules into an excited electronic 
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state, but instead the molecule goes to a virtual energy state from where it quickly 
relaxes to an excited vibrational state. Raman detects change in polarisability in a 
molecule, which can be seen as the distortion of the electron cloud around the nuclei 
[Skoog et al. 2013]. 
Coherent anti-Stokes Raman scattering microscopy is a variation of Raman imaging. 
It is a four-wave mixing process, where three laser beams are coherently driven into 
the sample through high NA objective. The beams are spatially and temporally mixed 
in a small focus so that from the sample a fourth, anti-Stokes photon is created that is 
then detected [Camp et al., 2014]. The Jablonski diagram, provided below in Figure 
22, shows the energetic steps of these three laser beams that work simultaneously to 
create the CARS signals.  
 
Figure 22: Jablonski diagram in CARS microscopy adapted from Strachan et al. (2011). 
At the beginning, all molecules of the measured sample are in the ground state. When 
the pump beam is applied with the frequency ωp, some molecules move to a virtual 
state and a simultaneous addition of the Stokes beam, with the same frequency as the 
Stokes shifted light (ωs), puts the molecules into a vibrational state. At this point in time, 
the electron cloud surrounding the chemical bonds is vigorously oscillating with the 
frequency ωp - ωS. This indicates, that a certain structure in the molecule has to be 
addressed to achieve this vibrational state. By changing the wavenumbers of the laser, 
diverse differences of ωp and ωs can be produced until the desired vibration is 
achieved. Simultaneously, the probe beam with the frequency ωpr is shone onto the 
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probe. The molecules transit from the vibrational state to another virtual state, from 
which they spontaneously emit the CARS signal with a frequency of ωCARS. After 
interaction with a bond/a molecule, the incoming photon from the laser is emitted with 
a shift depending on the interplay. Consequently, a shift in wavenumber or nanometer 
of the applied laser light is used to describe CARS scattering [Krafft et al., 2009; Evans 
and Xie 2008]. 
The generated vibrational state described above is similar to that of Raman 
spectroscopy but the difference between CARS and Raman spectroscopy is important 
to understand. Raman scattering happens spontaneously when a laser beam of one 
wavelength is used. With CARS, the vibrational state can be tuned to, so that the signal 
is much faster and stronger than with Raman. The minimal sample volume that is 
measurable in confocal Raman microscopy is diffraction limited. The minimum sample 
spot diameter will change with varying illumination wavelength so that with higher 
wavenumbers the spot will decrease. In addition, the refractive index plays a role when 
looking at the depth of field. For coherent Raman mapping, no pinhole is required 
because it is inherently confocal. The spatial resolution is with 1 µm axially and 
200 - 400 nm laterally, slightly higher than in conventional Raman microscopy and 
fluorescence interference is not that high [Müllertz et al., 2016]. One of the drawbacks 
of Raman spectroscopy is the low signal intensity so that, for example, fluorescent 
impurities can easily disturb and overlap the signal. To avoid this problem excitation 
lasers in the far UV or near infrared part of the spectrum are used. Also pulsed lasers 
with gated detections can be used to ensure that the fast, femtosecond Raman signal 
is filtered from the slower picosecond fluorescent emission. Raman scattering is linear 
to concentration while CARS signals are quadratically increasing with concentration. 
Both techniques can be used for quantitative analysis [Müllertz et al., 2016] but Raman 
is easier to apply for quantitative studies as CARS signals have resonant and 
non-resonant parts and therefore the extraction of quantitative data is challenging. 
CARS is especially suitable for detecting lipid structures with their strong signal giving 
of C-H stretching, so that solid lipid extrudates, lipid based matrix tablets [Windbergs 
et al., 2009] and lipid droplets in cells [Jurna et al., 2009] were already investigated 
with CARS. Live cell and tissue imaging is another application field of CARS [Darville 
et al., 2015; Saarinen et al., 2017]. The first commercially available CARS microscope 
has been on the market since 2011 (Leica TCS SP8 CARS) and this was used in this 
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work. This CARS microscope can detect structures that have wavenumber shift from 
approximately 1,250 cm-1 - 3,400 cm-1 and has two other non-linear imaging methods 
included: second harmonic generation (SHG) and two-photon fluorescence excitation 
(TPFE). All three methods can be very useful in pharmaceutical applications [Fussel 
et al., 2013]. 
Visualisation of cell lines was performed with a TCS SP8 CARS microscope (Leica 
Microsystems, Germany). The system consists of an inverted microscope equipped 
with a laser-scanning confocal scan-head and photomultiplier tube (PMT) and GaAsP 
hybrid (HyD) photodetectors. The CARS signal was detected in forward direction using 
non-descanned PMT detectors. A water-immersion 25 × objective with an NA of 0.95 
(Leica HCX IR APO L 25 × /0.95 W) was used in all experiments. The CARS excitation 
source was a Nd:YVO4 solid-state-laser (APE GmbH, Germany) with an optical 
parametric oscillator (OPO). The Stokes beam (ωs) had a fixed wavelength of 1064.5 
nm and a pulse duration of 7 ps. The pump and probe beams (ωp and ωpr) at 781 – 827 
nm were generated from the OPO with the pulse duration of 5 – 6 ps. 325,000 cells 
were seeded one day prior the day of experiment per well (growth area: 1.9 cm²) and 
covered with 1 mL of cell culture medium. At the day of experiment the cells were 
washed. The cells were incubated with a 250 µg/mL GLI nanosuspension in 10 mM 
HBSS+HEPES buffer. The cell membrane was stained with CellMask® Orange 
(Thermo Fisher Scientific Inc., USA) and cells were fixed with 1 mL of a 2.5 % 
glutaraldehyde solution on 24-well glass-bottom plates (MatTek Corporation, USA). 
Two-photon excited fluorescence (TPEF) was used to probe the cell membranes. 
Z-stacks covering the whole height of cells were recorded using a step size of 500 nm. 
Caco-2 cell had an incubation time of 2, 6 or 24 hours while RAW cells were incubated 
for 2 or 6 hours. GLI nanocrystals used had a particle size of 300 nm ± 50 nm or 
500 nm± 80 nm. Quantitative analysis of the particle uptake in the cells was 
accomplished with Imaris 9.0 Demo that was kindly provided from Bitplane (Northern 
Ireland, UK). As no standard set-up was used, the analysation will be explained in the 
results part (chapter 4.7.1.3). 
3.2.9.3 Fluorescence microscopy 
Fluorescence happens when a molecule absorbs light at ultraviolet wavelengths and 
emits it after a time delay of 10-8 seconds or less. Depending on the number of energy 
levels for the electronic state and the energy sub-states, the absorption spectra vary 
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for different molecules. Fluorescent molecules are highly conjugated molecules, so 
that internal conversion of the absorbed light may carry the excited molecule only back 
to the lowest vibrational level of the excited state and not directly to the ground state 
by radiation-less electronic transition (Figure 23). The energy of the emitted photon is 
usually lower than the energy of the excited photon due to the mentioned internal 
conversion. This phenomenon is called the ‘Stokes shift’. The shift allows the 
separation of exciting and emitting light with just leaving the fluorescent object of 
interest to detect [Swarbrick, 2007]. 
 
 
Figure 23: Jablonski diagram in fluorescence microscopy. 
Just a few of the excited molecules in a probe will return to the ground state, emitting 
fluorescence. This fraction is called the quantum yield. Fluorescence emission spectra 
as well as the quantum yield can be dependent on many things, like type of dispersion 
medium, pH of dispersion medium, ion concentration and presence of other 
fluorophores. But under given conditions, the quantum yield is a physical constant 
[Wang and Taylor, 1990]. Fluorescence microscopy is a sensitive method because one 
fluorophore can emit many detectable photons so that often low laser powers lead to 
usable imaging while preserving the sample from degrading or biological tissue from 
being destroyed. 
Dependent on this physical background, a fluorescence microscope in its basic form 
is composed of an excitation source, often a laser, with a subsequent excitation 
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monochromator, the sample holder, an emission monochromator and a detector. For 
confocal scanning, a resonant or slit scanner can be of good use. One way to improve 
transmission of emitted light is to use a beam splitter.  
Many different kinds of special fluorescence microscopy imaging techniques have 
been developed over the years. Two-photon fluorescence excitation (TPFE) is one of 
them. It addresses the problem of spectral separation of background fluorescence and 
excitation light which is most prominent when the excitation and emission wavelength 
are near to each other. It seperates the emitted fluorescence and the excitation light 
by a large energy gap by promoting simultaneous absorption of two photons into an 
excited state [Duveneck et al., 2003]. TPFE is a nonlinear, optical imaging method 
which has been used in many fields, like tracking the fate of drugs in cells [Mouras et 
al., 2010] or visualisation of lipids in transdermal transport [Yu et al., 2003]. It is a good 
method to use, when dealing with biological tissue. There are thousands of dies on the 
market to label cell structures with fluorophores for discrimination and detection of cell 
targets. This has enabled progress over several decades in understanding the 
mechanistics of cell-cell and drug-cell interactions as well as internal cell metabolism. 
Particle tracking via fluorescent labeling has been done to a high extent but chemical 
change of surfaces can alter the behaviour of particles in biological environments 
dramatically [Gupta and Curtis, 2004]. 
In this project, a Leica TCS SP5 broadband confocal fluorescence microscope (Leica 
Microsystems, Germany) was used to image the particles and the cells. Z-stacks of 
the whole height of the cells were created with steps of 100 nm. The detection of the 
membrane stain was done with the 543 nm excitation helium-neon laser with emission 
collection at 550 - 600 nm. CUR visualisation, on the other side, was done by the cells 
excitation with a 488 nm argon laser and detection at 500 - 550 nm. A 96x immersion 
objective with immersion oil (Leica Microsystems™ Immersion Oil, Leica 
Microsystems, Germany) was utilised. 200,000 cells were seeded in one well of a 
24-well glass f-bottom sensoplates (polystyrene) from Greiner Bio-One International 
GmbH (Germany) three days prior the day of experiment per well (growth area: 1.9 
cm²) and covered with 1 mL of cell culture medium. At the day of experiment the cells 
were washed gently with PBS buffer. The cells were incubated with a 250 µg/mL CUR 
nanosuspension in PBS buffer for 2 or 6 hours. CUR nanocrystals used, had a particle 
size of 300 ± 50 nm or 500 ± 80 nm. Afterwards, the cells were washed with PBS 
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buffer. Then, the buffer was removed and replaced by the staining solution (5 µg/mL 
CellMaskTM Orange, Thermo Fisher Scientific Inc., USA). The cells were incubated in 
the dark for 6 minutes. The staining was removed and 1 mL of fixation liquid (2.5 % 
glutaraldehyde in PBS buffer) was added. The cells were incubated over 10 minutes. 
After incubation the cells were washed with PBS buffer and 1 mL of PBS buffer was 
added for the transport to the microscope and imaging. Quantitative analysis of the 
particle uptake in the cells was accomplished with Imaris 9.0 Demo that was kindly 
provided from Bitplane (Northern Ireland, UK). As no standard set-up was used, the 
analysation will be explained in the results part (chapter 4.7.1.3). 
3.2.9.4 Statistical evaluation 
Statistical evaluation was accomplished with the SigmaPlot 11.0 software (Systat 
Software GmbH, Germany). The differences of the mean values of two groups were 
compared regarding significance with a t-test. Therefore, the software utilised a 
normality test (Shapiro-Wilk), which had to be passed, followed by an equal variance 
test. When this test was also passed, the t-test was applied with a 95 % confidence 
interval. For some comparisons, the normality or equal variance test failed. Here, the 
Mann-Whitney Rank Sum Test was applied. A difference was referred to significant 
when the p-value was between 0.01 and 0.05 while it was highly significant when the 
p-value dropped below 0.01. 
Results and Discussion 
 
58 
 
4 Results and Discussion 
As described in chapter 1.2, the aims of this thesis were the investigation of stabiliser 
drug interferences with regard to an improved milling parameter selection as well as 
the research of stabiliser-drug-cell interactions, to generate a better understanding of 
nanocrystal fate in biological tissues. Accordingly, the following chapter explains and 
discusses the findings in processing of drugs and stabilisers followed by application of 
the produced nanosuspensions in biological relevant setups. 
4.1 Production of nanocrystals  
For a successful milling process, various parameters must be considered. Initial 
screening experiments with several drugs included following factors for choosing the 
best candidates for the purpose of this thesis: 
i. Grindable 
ii. Low toxicity (non-carcinogen and non-mutagen substances) 
iii. Ease of detection (fluorescent and/or Raman active) 
iv. Cost effective (less than 250 Euro per 100 g) 
Both, curcumin (CUR) and glibenclamide (GLI) did fulfil these criteria so that they were 
chosen as model drugs for this work. 
The choice of stabilisers was based on their physico-chemical variation. Therefore, two 
charged stabilisers (tetra decyl trimethyl ammonium bromide (TTAB) and sodium 
dodecyl sulfate (SDS)), a neutral surfactant (polysorbate 80 (PS80)) and three 
polymers (hydroxylpropyl methylcellulose (HPMC), poloxamer 124 (Pol124) and 
poloxamer 407 (Pol407)) were selected. 
As the influence of the size of the nanocrystals on uptake and transport in and through 
different kind of cells was of interest, milling parameters had to be found for the 
production of different nanocrystal sizes. Like described in the introduction, various 
parameters have an influence on the outcome of the nanocrystal production. For the 
mill used in this work, Scherließ already investigated optimal parameter setups for 
cholesterol as a model drug [Scherließ, 2008]. It was concluded, that a rotor speed of 
4,000 rpm and a drug content of 10 % were most suitable. These parameters were 
also used in this thesis. As every drug needs different stabilisation concentrations, 
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Scherließ’s results regarding stabiliser concentration could not be directly transferred 
to this work. Accordingly, various experiments had to be performed with CUR and GLI. 
Scherließ also found, that the longer the milling time and the smaller the milling beads, 
the smaller the nanocrystals, which is consistent with the common knowledge about 
milling processes. This tendency could also be seen for CUR and GLI. Rotor speed, 
drug content, milling time and size of milling beads seem to be transferable in a certain 
frame from one drug to another, while stabilising concentration needs to be tested for 
each drug individually. Hence, some milling parameters are more robust when 
changing type of drug than others. In this work, the influence of the bead size and type 
of stabiliser on the milling outcome was investigated in more detail. 
Concentrations of stabilisers are calculated as percentage of the used amount of drug 
for all following experiments. 
4.1.1 Influence of stabiliser 
The effect of different types of stabilisers on the grindability of CUR and GLI was 
studied. With all used stabilisers (PS80, HPMC, Pol407 and Pol124, SDS and TTAB) 
nanosuspensions with both drugs could be created. By changing the stabiliser 
concentrations stepwise, the following concentrations of stabilisers, as detailed in 
Table 10, were tested. 
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Table 10: Tested stabiliser concentrations for CUR and GLI. Underlined values are the 
concentrations that were plotted in Figure 24. 
Stabiliser Concentration in % 
for CUR 
Concentration in % 
for GLI 
HPMC 
12.5 
20 
25 
10 
5 
2.5 
Pol407 
100 
50 
20 
10 
70 
50 
20 
10 
5 
2.5 
Pol124 
200 
180 
60 
100 
70 
50 
25 
PS80 
150 
50 
25 
20 
10 
20 
7.5 
5 
SDS 
5 
3 
1 
3 
1 
TTAB 
5 
3 
1 
0.5 
6 
3 
1 
 
For the following Figure 24, the values of the lowest particle size of each tested 
stabiliser were chosen.  
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Figure 24: Particle size (bars) and particle size distribution (PDI; dots) of GLI and CUR 
nanocrystals. Production parameters: rotor speed = 4,000 rpm; drug content = 10 g; pump 
speed = 69 mL/min; milling time = 240 min. Stabiliser concentration with lowest achieved 
particle size was selected. Milling bead sizes were 1 - 1.2 mm for GLI and 0.66 - 0.91 mm for CUR. 
n = 1. Particle size measured in double-distilled water. 
With SDS, the smallest particle size, with 154 nm for CUR, could be produced. Lowest 
particle size for GLI (251 nm) was manufactured with PS80. Particle size distributions 
were similar for CUR, with the exception of TTAB stabilised nanocrystals, where an 
increase to 0.33 in PDI could be seen. The PDI values of GLI did vary between 0.18 
and 0.31 with Pol124 stabilised nanosuspensions having the highest PDI. GLI 
nanocrystals were, in average, larger than CUR nanocrystals after 240 minutes of 
milling which could be due to larger milling bead size. Interestingly, HPMC stabilised 
nanosuspensions did not show this particle size gap between CUR (299 nm) and GLI 
(281 nm). Therefore, the smallest achieved size for HPMC stabilised nanosuspensions 
for both drugs was around 300 nm with the selected conditions. 
4.1.2 Influence of bead size 
For the production of different nanocrystal sizes, diverse sizes of milling beads, varying 
milling time or rotor speed can be selected. In this thesis, the variation of milling bead 
sizes was the method of choice to produce different nanocrystal sizes. 
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It was described earlier that with all stabilisers, nanosuspensions could be produced. 
The particle size development of the first millings was monitored every hour until 
maximum milling time of 4 hours. Longer millings times did just lead to very small 
changes in particle sizes so that the maximum milling time was set to 4 hours. For the 
detection of the influence of varying bead sizes, one stabiliser/stabiliser combination 
was picked for each drug, of which milling result from preliminary test already existed. 
Therefore, also the milling time was different for CUR and GLI. Data in Figure 25 and 
Figure 26 show, that larger milling beads lead to a decrease in particle size and PDI 
reduction. 
 
Figure 25: Particle sizes (bars) and particle size distributions (PDI; dots) of CUR nanocrystals 
stabilised with 25 % PS80. Production parameters: rotor speed = 4,000 rpm; drug content = 10 g; 
pump speed = 69 mL/min; milling time = 120 min. n = 2. error bars = min/max. 
Particle sizes between 188 nm ± 4.3 nm and 594 nm ± 50.9 nm could be produced for 
CUR by varying the milling bead size. A further decrease in particle size would be 
possible with longer milling times. One experiment with smaller bead sizes 
(0.4 - 0.6 mm) (data not shown) did not lead to a further decrease in particle size 
compared to the 0.66 - 0.91 mm sized beads. 
For GLI, particle sizes between 231 nm ± 39 nm and 511 ± 42.7 nm could be 
generated. 
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Figure 26: Particle sizes (bars) and particle size distributions (PDI; dots) of GLI nanocrystals 
stabilised with 2.5 % HPMC + 2.5 % PS80. Production parameters: rotor speed = 4,000 rpm; drug 
content = 10 g; pump speed = 69 mL/min; milling time = 240 min. n = 2. error bars = min/max. 
For CUR, the size of the nanocrystals decreased by a factor of three comparing the 
smallest and the largest beads used. GLI nanocrystals just had a 2.2 times decrease 
in size. Hence, a 3.9 times increase in milling bead size at the same milling time 
(120 min for CUR and 240 min for GLI) lead to 330 % less particle size reduction for 
CUR and 220 % for GLI nanocrystals. 
Some conditions have to be considered when working with large bead sizes. With large 
beads, the filling volume had to be decreased (from 80 % to 60 %) while otherwise 
beads were destroyed by high forces in the milling chamber. Possibly, the beads could 
not roll off in cavities and therefore got crushed between the milling chamber wall and 
other beads. Due to this phenomenon, which was observed in this thesis, the filling 
volume had to be decreased when using bead sizes of 2 mm or 3 mm. Furthermore, it 
was noticed that with large milling beads and long milling times (4 hours) a degradation 
of GLI took place, which resulted in a smell of sulfonate. In the case of GLI, the stress 
produced by large milling beads is higher compared to small milling beads which could 
be due to higher weight forces of the beads. This is in agreement with the modelling of 
Beinert et al. as they found that with increasing grinding media size, the stress energy 
increased [Beinert et al., 2015]. 
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Summarised, the common knowledge about influence of milling time and bead size 
could be confirmed. In this work, nanocrystals of different average particle size and 
type of stabiliser could be produced. Still, the type of stabiliser and stabiliser 
concentration is one part of the milling that is not totally understood until today, so that 
the next chapter will focus on this stabiliser influence. 
4.2 Stabiliser influences on nanosuspension properties 
Five different stabilisers were used in this thesis. They were chosen due to their 
different properties as explained in chapter 3.1.2.  The final selection of stabilisers for 
cell studies was done by assessment of minimal stabilisation concentration and cell 
toxicity. 
4.2.1 Minimal stabilisation concentration 
Important for a stable nanosuspension is the concentration of the stabilising agents. 
Too low stabilisation can lead to agglomeration or aggregation of particles while too 
much stabiliser may cause Ostwald ripening and therefore particle growth as well. For 
each stabiliser a concentration that just allowed the production of a stable 
nanosuspension as well as a concentration that led to unstable suspensions were 
found and are displayed in Table 11 and Table 12. 
Table 11: Minimal stabilisation concentrations for GLI to form nanocrystals.  
Stabiliser Concentration that led to 
a unstable suspension 
Concentration that led to a 
stable nanosuspension  
Pol124 ≤ 25 % 50 % 
Pol407 ≤ 1.25 % 2.5 % 
HPMC ≤ 5 % 10 % 
PS80 ≤ 2.5 % 5 % 
SDS ≤ 1 %  3 % 
TTAB ≤ 3 % 6 % 
HPMC+PS80 ≤ 2.5 %+ 1.25 % 2.5 % + 2.5 % 
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Table 12: Minimal stabilisation concentrations for CUR to form nanocrystals. 
Stabiliser Concentration that lead 
to unstable suspensions 
Concentration that led to 
a stable nanosuspension 
Pol124 ≤ 180 % 200 % 
Pol407 ≤ 5 % 10 % 
HPMC ≤ 20 % 25 % 
PS80 ≤ 10 % 20 % 
SDS ≤ 1 % 3 % 
TTAB ≤ 0.5 % 1 % 
HPMC+PS80 ≤ 5 % + 5 % 12.5 % + 12.5 % 
 
The order of efficacy in stabilisation could be ranked as 
Pol124 < HPMC = HPMC + PS80 < PS80 < Pol407 < SDS < TTAB for CUR and 
Pol124 < HPMC < TTAB < PS80 = HPMC + PS80 < SDS < Pol407 for GLI. 
Similarities were seen for Pol124 and HPMC as the most ineffective stabilisers and 
Pol407 as well as SDS as most effective stabilisers for both drugs. The most prominent 
difference in stabilisation efficacy could be seen for TTAB, having the most effective 
stabilisation concentration for CUR but just medium efficacy for GLI.  
The difference between the two poloxamers can be explained by their structure. It 
seems that a higher ratio of polyethylene oxide groups and a higher molecular weight 
leads to a lower minimal stabilisation concentration, which was drug independent in 
the current study. Liu, P. et al. found that the driving force for adsorption originates 
from the hydrophobic nature of the polypropylene oxide segment, while the 
polyethylene oxide segments offer the steric hindrance that is necessary to achieve 
stable nanosuspensions. Thus, short polyethylene oxide chain length caused a poor 
physical stability of the nanosuspensions [Liu et al., 2014]. This was also the trend 
found in this work. 
The shift in efficacy for TTAB, comparing CUR und GLI, can be explained by zeta 
potential measurements. As TTAB is an ionic stabiliser, zeta potential measurements 
can give a statement about the attachment and localisation of TTAB molecules on the 
surface of the drugs. Therefore, TTAB and SDS stabilised nanosuspensions were 
investigated as well as suspensions stabilised with the non-ionic surfactant PS80. The 
results are plotted in Figure 27 and Figure 28. 
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Figure 27: Zeta potential of CUR suspensions (after 240 min of milling). Measured in 
double-distilled water. Corresponding particle sizes and conductivity can be found in the 
appendix (chapter 9.4.1). n = 1. 
 
Figure 28: Zeta potential of GLI suspensions (after milling of 240 min). Measured in 
double-distilled water. Corresponding particle sizes and conductivity can be found in the 
appendix (chapter 9.4.1). n = 1. 
Results and Discussion 
 
67 
 
A combination of SDS and PS80 resulted in a slight increase of zeta potential 
to -40.0 mV, in relation to the two stabilised CUR suspensions (-35.6 mV for PS80 
stabilised nanosuspension and -37.5 mV for SDS stabilised nanosuspension). Also for 
GLI suspensions, the zeta potential increased slightly above the highest PS80 value 
from -45 mV to -47.2 mV). The combination of TTAB and PS80 led to a similar zeta 
potential as TTAB alone for GLI suspensions but for CUR suspensions just 4 % of the 
initial TTAB value were reached with the combination. This indicated that a 
combination of stabilisers adsorbed to the surface of different drugs individually. As the 
zeta potential represents charge at the hydrodynamic shear plane, imaginably PS80 
could adsorb on GLI first and tightly, followed by TTAB so that only this component is 
crucial for the resulting zeta potential, while for CUR, TTAB could be equally bound 
together with PS80 on the surface. For SDS-PS80 combinations a different adsorption 
pattern can be interpreted. For GLI, PS80 could be more prominent in the outer layer 
while for CUR it seemed to be a mixture comparably to SDS-PS80 combinations. 
Possibly, GLI has more positive charges on the surface than CUR, so that the negative 
charged SDS could bind tightly and the positive charged TTAB was to be found in the 
shear plane. More detailed interaction measurements of stabilisers and drugs can be 
found in chapter 4.4. 
4.2.2 Stability of nanosuspensions with various stabilisers 
Suspensions are metastable systems. Instability can be caused by flocculation or 
sedimentation as well as agglomeration or even aggregation of particles. Especially in 
biological environments, stabilisation efficacy can change, as the proteins and ions 
present can lead to different stabiliser-particle or particle-particle interactions. 
Therefore, the particle size was also measured in buffer, which mimics biological 
environments. Pol124, SDS and TTAB stabilised nanosuspensions agglomerated in 
buffer, so that the particle size exceeded 1000 nm. For the other stabilisers, examples 
from the suspensions were picked randomly and stored for 6 months at 25 °C in closed 
screw cap vessels. Corresponding particle sizes can be found in Table 13 and Table 
14. Before measurement, the samples were shaken until no deposit on the bottom of 
the vessel could be seen. All nanosuspensions remained stable (did not exceed more 
than 1,000 nm). 
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Table 13: Particle sizes of CUR nanosuspensions. 
Type and concentration of 
stabilisers 
Starting particle 
size in nm 
Particle size after 
6 months in nm 
50 % PS80 172 187 
80 % Pol407 277 191 
25 % HPMC 449 380 
 
Table 14: Particle sizes of GLI nanosuspensions. 
Type and concentration of 
stabilisers 
Starting particle 
size in nm 
Particle size after 
6 months in nm 
20 % PS80 312 327 
50 % Pol407 313 328 
10 % HPMC 347 363 
 
4.2.3 Cell toxicity of stabilisers in Caco-2 cells 
The measurement of cell toxicity is crucial for the cell culture studies in chapter 4.6 and 
chapter 4.7, as toxic substances lead to biases in results and misinterpretation can 
occur. Therefore, the effect of different stabiliser concentrations on epithelial cells was 
measured and is illustrated in Figure 29. 
SDS and TTAB needed the lowest amount of stabiliser in milling experiments and were 
therefore tested in low concentrations while for HPMC, PS80 and Pol124 higher 
concentrations were needed, so that the tested amount was increased according to 
preliminary milling studies. 
It could be seen that TTAB showed very high toxicity at all tested concentrations. Also, 
incubation with SDS led to low cell viability, even though low concentrations were 
tolerated better by the cells than the same concentrations of TTAB. HPMC did not 
show a toxic potential with all tested concentrations and was therefore ranked as the 
stabiliser with the lowest toxicity of all used stabilisers. PS80 showed the most linear 
relationship between toxicity and concentration. Therefore, the choice of the 
appropriate concentration in cell studies should be uncomplicated, as concentrations 
can be titrated. Nevertheless, all tested concentrations for this experimental set-up 
were toxic. 
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Figure 29: Cell tolerability of various stabilisers and stabiliser concentrations in Caco-2 cells. 
The line at 80 % cell viability represents the limit for non-toxic solutions. Stabilisers were 
solubilised in buffer and incubated for 4 h. n = 4. error bars = SD. 
Pol124 had a high toxicity at high concentrations but at the lowest tested concentration 
it was non-toxic. Still, PS80 was ranked together with Pol124 on the second place 
regarding cell viability as less concentrations of PS80 were needed to stabilise CUR 
and GLI nanocrystals compared to Pol124.  It became obvious that the MTT toxicity 
test was not suitable for Pol407 as the absorption of light was higher than for the control 
(data not shown). Hence, it is likely that Pol407 did react during the assay or created 
high absorption by itself. Pol407 and Pol124 have similar structures so that it could not 
be excluded that also Pol124 somehow interacted with the MTT test. 
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4.2.4 Concluding remarks of stabiliser characteristics for the selection of two 
stabilisers for further studies 
One of the first selection parameters was the stability of the nanosuspension in buffer. 
SDS, TTAB and Pol124 did not form stable nanosuspensions in buffer and could 
therefore not be used for further studies. 
Cell viability measurements showed, that HPMC was not toxic for the used cell line. 
Pol407 did interfere with the toxicity test, so that no results could be created. Therefore, 
Pol407 was excluded from further studies. Consequently, the only remaining stabiliser, 
PS80, was selected for further studies as it was stable in buffer. Still, the toxicity of 
PS80 was quite high so that a combination of HPMC and PS80 was chosen together 
with HPMC alone. 
In conclusion, HPMC, with its minimal stabilising concentration for each drug and a 1:1 
combination of PS80 and HPMC were taken for all following experiments. That is why 
all following experiments were planned with regard to the stabilising concentrations for 
HPMC and HPMC + PS80 displayed in Table 15. 
The influence of the particle size on transport through and uptake in cells was of further 
interest for all following studies. Chapter 4.1.1 revealed that the lowest achievable 
particle size for HPMC stabilised particles was 300 nm with the selected conditions. 
Therefore, the small particle size was set to 300 nm (CUR and GLI small). As the PDI 
increased with increasing particle sizes, the larger particle size was set to 500 nm 
(CUR und GLI large) so that the PDI could be kept below 0.5. 
Table 15: Selected stabilisation concentrations for CUR and GLI. 
Samples Stabiliser(s) in wt% of drug 
HPMC HPMC + PS80 
CUR small 25  12.5 + 12.5 
CUR large 25  12.5 + 12.5 
GLI small 10 2.5 + 2.5 
GLI large 10 2.5 + 2.5 
 
Results and Discussion 
 
71 
 
4.3 Characterisation of selected nanosuspensions 
The influences of three different properties of the nanocrystals - namely particle size, 
type of stabiliser and type of drug - were investigated in dissolution, cell uptake and 
transport studies. As the stabiliser properties were already discussed in the previous 
chapter, this chapter will highlight the properties of the selected nanosuspensions for 
further dissolution and cell studies. 
To be able to interpret any further results, first an understanding of how and why 
nanocrystals are forming under the above mentioned conditions has to be created. 
Therefore, also the knowledge of particle size before milling and stability of the 
nanosuspension are of interest. 
As the solid state can have an influence on the solubility of the drugs and therefore on 
the rate and extent of dissolution and absorption, XRPD and DSC measurements were 
carried out. The melting point was of further interest as Li et al. found that beneath the 
log P value, also the melting point of the drugs is one important criterion influencing 
adsorption. Low melting points and log P values at approximately 5 can be favourable 
for rapid absorption [Li et al., 2014]. 
Finally, the stabilisers should not be toxic in the selected concentration range so that 
toxicity tests were repeated more detailed at longest cell experiment time. 
4.3.1 Particle size of suspension before milling 
The suspension for milling purposes was prepared with stabiliser solution, the addition 
of drug and a homogenisation step like described in chapter 3.2.1. This passage shows 
the influence of the wetting and homogenisation of the drugs before milling. Table 16 
demonstrates the change in particle size from the coarse powder to pre-processed 
suspension measured by laser diffraction. 
GLI seems to be crushable to small particles more easily. Preparation with the Ultra 
Turrax® for 10 seconds already led to 4.5 times reduction in particle size, while for 
CUR, agglomeration of coarse particles could be seen. CUR tended to agglomerate 
when surrounded by aqueous stabiliser solution. This could be one reason why CUR 
needs more than the double concentration of stabilisers to be stabilised compared to 
GLI. If the microcrystal suspension already agglomerated, the nanocrystalline 
formulation could be even more likely to agglomerate further. 
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Table 16: Particle sizes measured by laser diffraction. n = 4. ± = SD. Coarse powder was 
measured with the RODOS module (particle size distributions displayed in chapter 9.4.2) while 
for the suspension the CUVETTE module was utilised. 
Sample X10 in µm X50 in µm X90 in µm 
Coarse powder GLI 8.35 ± 0.35 52.47 ± 4.60 135.21 ± 15.33 
GLI suspension 
2.5 % HPMC + 2.5 % PS80 
1.62 ± 0.22 11.62 ± 3.01 44.16 ± 11.6 
GLI suspension 
10 % HPMC 
2.68 ± 0.79 19.21 ± 6.12 51.51 ± 14.45 
Coarse powder CUR 1.84 ± 0.04 8.70 ± 0.19 29.64 ± 0.83 
CUR suspension 
12.5 % HPMC + 12.5 % PS80 
3.64 ± 0.73 19.99 ± 2.81 48.44 ± 11.58 
CUR suspension 
25 % HPMC 
3.95 ± 0.33 13.11 ± 3.01 42.91 ± 15.01 
 
Two examples for particle size distributions of the pre-processed suspensions are 
shown below in Figure 30 and Figure 31. CUR suspensions with HPMC could be 
interpreted to have less agglomeration than with HPMC and PS80 combined but the 
high standard deviation makes interpretation challenging. Sedimentation of particles 
could be seen during measurements which also reflect the relatively high standard 
deviation. It seems that, after homogenisation, the two drugs were on a similar starting 
level in the mean of particle size and particle size distribution compared to the coarse 
powder. 
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Figure 30: Particle size distributions of CUR coarse suspension after homogenisation. n = 3. 
error bars = SD. 
 
Figure 31: Particle size distributions of GLI coarse suspension after homogenisation. n = 3. error 
bars = SD. 
Span values are ranging from 2.24 for GLI, stabilised with HPMC and PS80 to 3.66 for 
CUR, stabilised with HPMC. 
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4.3.2 Stability of nanosuspensions 
Nanosuspensions were used for dissolution, transport and uptake studies until one 
month after production to have comparable batches. This chapter will show stability 
data of the selected nanosuspensions regarding API content and particle size. 
Furthermore, the solubility can have an influence on the stability of a nanosuspension 
so that it was also investigated in this chapter. 
4.3.2.1 Solubility of drugs in stabiliser solutions 
The solubility of a drug in the (stabiliser-)non-solvent is detrimental in 
nanosuspensions, as a high solubility could induce Ostwald ripening and therefore, 
particle growth. Solubility data of the selected nanosuspensions are listed in Table 17. 
Table 17: Solubilities of CUR and GLI suspensions after 24 hours of shaking of an over-saturated 
(1 mM) suspension in double-distilled water. 
Drug suspension Stabiliser Solubility in µg/mL 
CUR coarse powder 
25 % HPMC 0.54 ± 0.02 
12.5 % HPMC + 12.5 % PS80 10.66 ± 0.51 
CUR small 
25 % HPMC 21.39 ± 6.21 
12.5 % HPMC + 12.5 % PS80 23.77 ± 8.06 
GLI coarse powder 
10 % HPMC Not detectable 
2.5 % HPMC + 2.5 % PS80 Not detectable 
GLI small 
10 % HPMC 18.76 ± 3.38 
2.5 % HPMC + 2.5 %PS80 10.71 ± 0.78 
 
CUR showed higher solubility, when a mixture of HPMC and PS80 was present, 
compared to just HPMC. For GLI the HPMC stabilised nanosuspension exhibited an 
increase in solubility compared to the HPMC + PS80 stabilised nanosuspension. 
It was not expected that the nanosuspensions did lead to this high increase in solubility 
as the saturation solubility should not be increased this much at particles sizes of 
300 nm. Hence, it could be concluded that nanoisation could have led to a 
nanosuspension composed of nanocrystal in a supersaturated drug solution. Another 
reason could be that the shaking time of 24 hours was too short to achieve saturation 
solubility. 
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4.3.2.2 Particle size and content stability 
All nanosuspensions stabilised with HPMC and HPMC + PS80 were stable in size and 
particle size distribution over one year, which can be seen in Figure 32. Stability was 
in this case defined as no increase in particle sizes above 1000 nm as well as PDI 
below 0.8. 
A slight increase could be seen for all nanosuspension but, over 12 months, the 
increase in particle size did not exceed 200 nm. Nevertheless, the nanosuspensions 
should not be used for experiments after 12 months of storage. Maximal storage over 
1 month seems more reasonable as already after 3 month the particle sizes of the 
small and large nanosuspensions did grow more similar to one another. 
 
Figure 32: Particle sizes (bars) and PDI (dots) of CUR and GLI nanosuspensions measured over 
12 month. n = 1. 
Furthermore, the content of CUR and GLI in nanosuspension was determined with UV 
spectroscopy every 1 - 4 month(s). Especially for CUR, it is known from literature that 
degradation in solution happens over time. Figure 33 shows the results of the content 
stability over 12 month for CUR. Fortunately, no degradation could be detected. At the 
beginning of the stability study, the CUR nanosuspension, stabilised with HPMC, 
showed a concentration of 6.33 g/100 mL ± 0.16 g/100 mL which decreased by 7.6 % 
to 5.85 g/100 mL ± 2.81 g/100 mL after 12 month. For the HPMC+PS80 stabilised 
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nanosuspension even an increase in content could be seen (from 
5.87 g/100 mL ± 0.10 g/100 mL to 6.24 g/100 mL ± 0.37 g/100 mL) which is possibly 
due to measurements uncertainties. 
This stability should not be confused with the (in)stability of CUR in solution. When 
conducting HPLC analysis for dissolution studies, a decrease of solubilised CUR in 
buffer was rapid. After 2 hours the concentration was reduced by half. 
 
Figure 33: Concentration of CUR in nanosuspensions measured over 12 month. Nanocrystals 
were dissolved in ethanol for measurements. n = 3. error bars = SD. 
It has to be mentioned that with UV spectroscopy no separation of CUR and CUR 
degradation products is possible. Therefore, if the degradation products also interact 
with the same wavelength, they are included in the measured values. Tønnesen et al. 
investigated the degradation of CUR in isopropanol by measuring the spectrum from 
200 nm to 600 nm. During degradation, the absorption maximum at 420 nm, which was 
also measured in this work, dropped and new signals increased around 200 – 250 nm, 
so that the degradation would be detectable in the set-up of this work [Tønnesen et al., 
1986]. 
GLI stability is plotted in Figure 34. GLI nanosuspension content showed minimal 
degradation tendencies over 12 months. The HPMC stabilised nanosuspension 
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exhibited a 10.6 % decrease from 7.43 g/100 mL ± 0.12 g/100 mL to 
6.64 g/100 mL ± 0.99 g/100 mL while the HPMC + PS80 stabilised nanosuspension 
showed a 14.2 % decrease from 7.98 g/100 mL ± 1.15 g/100 mL to 
6.85 g/100 mL ± 0.14 g/100 mL. 
 
Figure 34: Concentration of GLI in nanosuspensions measured over 12 month. Nanocrystals 
were dissolved in ethanol for measurements. n = 3; error bars = SD. 
These two figures also revealed that approximately 2 - 4 g of 10 g initial powder, which 
was applied to the mill, remained in the milling system and accordingly got lost for 
further processing. 
Summarised, stable nanosuspensions with the two selected stabilisers could be 
produced. They were relatively stable in size and content over 12 month. 
4.3.3 Solid state before and after milling 
To establish a stable and successful milling process and to receive stable 
nanosuspensions, the crystalline state is favourable. Determination of the solid state 
faces a challenge for nanocrystals. First of all, most available standard methods for the 
determination of the solid state are based on the measurement of a dry powder. Drying 
of the nanosuspensions can lead to a change in molecular order of the drug depending 
on the drying technique but to which extent is unclear. Furthermore, when nanocrystals 
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are dried, the signals in DSC and XRPD can be less defined than for macrocrystalline 
samples and a misinterpretation can be made more easily [Hao et al., 2012]. 
Physically, it is doubtful that a crystalline drug shows amorphous content after 
wet-milling because water acts as a plasticiser and therefore triggers recrystallisation, 
so that it is more likely that polymorphs are forming with an intermediate amorphous 
state than amorphous parts alone. Hao et al. stated that it is more plausible that if 
amorphous parts are detected, they come from interplay between drug and stabiliser 
after drying [Hao et al., 2012]. 
The complicated nature of the solid state determination proves that at least two 
methods should be used to try to determine the solid state of nanocrystals. Some 
researchers found that DSC did not show a sign of glass transition but X-ray 
experiments indicated an amorphous state with a total absence of Bragg peaks 
[Descamps and Willart, 2016]. Therefore, two methods were used for combinational 
interpretation in this thesis. 
Coarse powder structure of CUR (Figure 35) and GLI (Figure 36) was measured to be 
crystalline. In XRPD measurements defined Bragg peaks stand for a crystalline 
sample, while an undefined halo represents an amorphous state.  
 
Figure 35: XRPD diffractogram of CUR as received from supplier. 
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Figure 36: XRPD diffractogram of GLI as received from supplier. 
DSC curves of the coarse drugs can be observed in Figure 37 and Figure 38. An 
endothermic melting point in DSC diagrams is related to a crystalline state, while a 
glass transition and possible exothermic recrystallisation are typical for amorphous 
states. 
 
 
Figure 37: DSC curve of coarse CUR as received from supplier. Area of the peak was 94.77 J/g. 
Y-axis length corresponds to 20 mV. 
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Figure 38: DSC curve of coarse GLI as received from supplier. Area of the peak was 85.31 J/g. 
Y-axis length corresponds to 20 mV. 
The defined melting peaks for each drug show a crystalline structure of the coarse 
powders as well. For CUR, a slightly exothermic signal was found at 58.24 °C with an 
area of -0.875 mJ. XRPD diffractograms are indicating a fully crystalline sample but it 
has to be mentioned that XRPD has a detection limit of around 10 % for amorphous 
content [Saleki-Gerhardt et al.1994], so that CUR coarse powder could be partially 
amorphous as received from the supplier. 
An XRPD of a selected freeze dried CUR nanosuspension was not as defined as the 
coarse substances as can be seen in Figure 39. A high background signal that resulted 
in a shift of the baseline and low intensities could indicate a partially amorphous 
material but the difference in intensity can also be related to sample preparation. 
Furthermore, stabilisers were present in this sample so that the signal could be 
changed by them. 
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Figure 39: XRPD diffractogram of 500 nm CUR freeze dried nanosuspension. Stabilisers present: 
12.5 % HPMC and 12.5 % PS80. 
For a dried GLI nanosuspension with the same size and stabiliser combination, still 
defined Bragg peaks could be detected like plotted in Figure 40. Also in this sample 
stabilisers were present but in lower concentrations compared to the CUR 
nanosuspensions, so that no signal could be seen of them. 
 
 
Figure 40: XRPD diffractogram of 500 nm GLI freeze dried nanosuspensions. Stabilisers present: 
2.5 % HPMC and 2.5 % PS80. 
The example for CUR and GLI nanosuspensions, which were measured by XRPD, 
were also investigated by DSC and results are given in Figure 41 and Figure 42. The 
DSC curves showed a melting peak, indicating crystalline state of the drug after milling 
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and freeze drying. All other values of onset and peak temperature of the selected 
nanosuspensions can be found in the appendix at chapter 9.4.3. 
 
 
Figure 41: DSC curve of 500 nm CUR freeze dried nanosuspension. Stabilisers present: 
12.5 % HPMC and 12.5 % PS80. Peak area of 51.14 J/g. Y-axis lengths corresponds to 20 mV. 
 
 
Figure 42: DSC curve of 500 nm GLI freeze dried nanosuspensions. Stabilisers present: 
2.5 % HPMC and 2.5 % PS80. Peak area of 73.31 J/g. Y-axis lengths corresponds to 20 mV. 
For both drugs a shift in melting point and also a decrease in peak area related to 
sample amount (J/g) was detected. Both phenomena can be possibly related to the 
stabilisers present. Polymorph formation for GLI was excluded, as the value for the 
melting peak of the polymorph, in literature, was with 148.7 °C significantly lower. For 
CUR, the drop in peak area and also broadening of the peak led to difficulties in 
manually integration and setting the peak temperature. Still, the formation of 
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polymorphs could not be excluded as one known polymorph showed a melting peak at 
172 °C (polymorph 3; see chapter 3.1.1.1) and also the decrease in area compared to 
the coarse powder could be related to a change in crystalline state. 
Most results indicated that CUR and GLI were still in the crystalline state after milling. 
For CUR nanosuspensions, one XRPD measurement indicated a potential change in 
solid state but as DSC measurements did not confirm this finding, the solid state should 
be crystalline. It cannot be excluded that CUR was forming another polymorph during 
milling or drying. XRPD and DSC measurements clearly showed a crystalline state for 
GLI. Still, the freeze drying step of the nanosuspensions could have altered the solid 
state of the APIs, so that no definite answer can be given to the question if milling 
induced (partial) amorphisation of the drugs. 
4.3.4 Cell toxicity of selected stabilisers and nanosuspensions 
Incubation with small GLI nanosuspensions, stabilised with 10 % HPMC or 2.5 % 
HPMC and 2.5 % PS80, did not show a change in Caco-2 cell viability compared to 
the control when incubated over 24 hours. They were not toxic. CUR, in contrast, 
interfered with the MTT test setup used in this work, as the absorbance measured was 
extraordinary high. Hence, for CUR just the stabilisers themselves were investigated 
as it is stated in literature that CUR has a low toxicity potential for Caco-2 cells [Zhen 
et al., 2017]. CUR needed highest stabiliser concentrations and therefore the area 
around minimal stabilisation concentration of CUR (25 % HPMC and 12.5 % 
HPMC + 12.5 % PS80) was investigated.  
HPMC showed high cell viability over a wide range of concentrations. Concentrations 
from 16,279 % related to 1 mM of CUR, used in transwell studies, showed less than 
80 % of cell viability which represents 60 mg/mL as plotted in Figure 43. Below this 
value, every concentration can be used. Also the combination of HPMC and PS80 was 
not toxic in the used concentrations (data not shown). For toxicity tests, the amount of 
HPMC was fixed with approximately 400 % (1.5 mg/mL) and at a concentration of 
PS80 of 70 % (0.25 mg/mL), the cells had a viability of 82 % while an increase to 140 % 
PS80 (0.5 mg/mL) lead to a cell viability of 78 %. Nevertheless, this concentration is 
far away from the used 12.5 % HPMC + 12.5 % PS80 stabilising concentrations for 
CUR in transport and uptake studies. 
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Figure 43: Cell tolerability of HPMC. Cell viability above 80 % indicates non-toxic solutions. 
Stabilisers were solubilised in transport buffer and incubated for 24 h. n = 4. error bars = SD. 
Results for PS80 are plotted in Figure 44. A concentration of 27 % (0.1 mg/mL) was 
not toxic, while the next tested concentration of 68 % (0.25 mg/mL) showed cell viability 
below 80 %. So, the minimal stabilisation concentration of 20 % PS80 for CUR is still 
in the non-toxic range.  
 
 
Figure 44: Cell tolerability of PS80. Cell viability above 80 % indicating non-toxic solutions. 
Stabilisers were solubilised in transport buffer and incubated for 24 h. n = 4. error bars = SD. 
Results and Discussion 
 
85 
 
Cell viability was most important for transport studies as the monolayer needs be intact 
over the time of the experiment, so that the results can be comparable. In uptake 
studies, the cell viability could be seen visually. When the cells detached from the 
bottom of the plate or the cells changed morphologically the experiment was repeated.  
4.3.5 Concluding remarks of the characterisation of selected nanosuspensions 
Stable nano-objects of a most probable crystalline state could be produced. Cell 
toxicity studies showed that all selected nanosuspensions should be non-toxic for the 
transport studies. This could be directly tested for GLI nanosuspensions. CUR 
nanosuspensions showed interferences with the selected toxicity test, so that the 
probable toxicity of the nanosuspension was assessed from testing various stabiliser 
concentrations and combinations. No concentration that was used for the cell studies 
(25 % for HPMC and 12.5 % HPMC + 12.5 % PS80) demonstrated cell toxicity. The 
selected nanosuspensions proved to be predestined for further cell studies. 
4.4 Characterisation of drug-stabiliser interaction 
Until today, it is not completely understood how stabilisers hinder nanosuspensions 
from agglomeration [Wang, Y. et al. 2013]. Within this chapter, three different methods 
were tested for the predictability of minimal stabilisation concentration for CUR and GLI 
and their interaction potential with each other. The choice of methods was based on a 
literature review, which is summarised in the section below. 
4.4.1 Stabiliser - particle interaction studies in literature 
One part of the literature tested several APIs with different kind of stabilisers, regarding 
the stability of the achieved nanosuspension and milling performances but this short 
review will focus on the influence of the stabiliser characteristics. One of the main 
factors for successful stabilisation is the hydrophobicity of the stabiliser. It seems that 
the higher the hydrophobicity, the better the attachment to the hydrophobic surface of 
the drug [Lee et al., 2005]. The molecular weight of the stabiliser can have an influence, 
too. The work of Choi et al. indicated that lower molecular weight polymers are more 
suitable for nano-comminution than larger polymers [Choi et al., 2008]. 
Nakach et al. addressed the lack of methods for stabiliser screening in industry and 
academic research and measured the surface tension and zeta potential for the 
selection of the appropriate stabiliser concentration. They tested 19 stabilisers and 
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investigated the ability of the stabilisers to create a stable nanosuspension (with a 
model hydrophobic and non-ionisable highly insoluble API) in small milling setups. If 
the resulting particle size was too high (over 500 nm), the stabiliser was excluded. With 
different techniques they selected, with PVP and SDS, the best stabilisers for their drug 
and looked at the surface tension of the mixture of PVP and SDS at different ratios and 
found a minimum value at 60 % of PVP suggesting a maximum of surface activity of 
PVP/SDS mixtures. Utilising zeta potential measurements, this combination was 
suggested as well because with the increase of SDS concentration to 40 % from lower 
ratios, the zeta potential decreased down to −54 mV and remained almost constant. 
They concluded that their approach of stabiliser (concentration) selection was intended 
to support formulators to select a suitable wetting/dispersant system for any API to 
achieve an up-scalable industrial process leading to stable nanosuspensions [Nakach 
et al., 2014].  
One of the promising publications, studying the mechanistic molecular interaction of 
stabiliser molecules with a drug surface, used atomic force microscopy (AFM). The 
specific adsorption geometry for the polymers could be seen. A smooth and regularly 
branched adhesion resulted in a better stabilisation compared to clustered polymers, 
which did not stabilise the API suspension [Verma et al., 2009a]. Unfortunately, AFM 
has, until now, not proven an efficient screening technique, which would be used in 
industry, as the equipment is expensive and the analysis is time consuming. Lately, 
also Fourier transform infrared spectroscopy was used by Abhayrai et al. to get insights 
into PLGA-polysorbate 80 interaction. During adsorption of polysorbate 80 on PLGA 
nanoparticles, the acyl chain of polysorbate 80 acts as a flexible structure and changes 
conformation, while the ester group was less hydrated, which increased hydrophobic 
interactions [Abhayraj et al., 2016]. 
Regarding stabiliser interaction, there is a literature pool of critical micellisation 
concentration investigations done with isothermal titration calorimetry (ITC) [Schicke, 
2010]. Furthermore, nano-objects and their interaction with different substances have 
already been measured [Rixiang and Lau, 2016; Kolakovic et al., 2013], but there are 
just a few publications that deal with the interaction of stabilisers with nano-objects. A 
lot of publications have chosen contact angle measurements (CAM) to predict the 
feasibility of a drug-stabiliser system to form nanosuspensions. Cerdeira et al. found 
ineffective stabilisers for miconazole to have a high contact angle (CA) and therefore 
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less wetting than the other effective stabilisers [Cerdeira et al., 2010], whereas with 
ineffective stabilisers a nanosuspension could not be created. In nanosuspension 
production, usually the stabiliser with the lowest CA is chosen [Pardeike and Müller, 
2010; Pardeike et al., 2011] but this does not automatically lead to the best 
stabilisation. Pardeike et al. tested with CAM, which stabiliser they should choose prior 
to milling experiments. Liu et al. investigated the hydrophobicity and geometry of 
stabilisers [Liu et al., 2014]. However, the question, whether CAM are also able to 
display concentration dependencies and indicate the lowest stabilising concentration, 
is still left without an answer. Hence, to contribute to this question, CAM is assessed 
in this thesis to predict stabilising concentrations in nanocrystal suspensions. 
Therefore, these two techniques, ITC and CAM, were tested, in this project, with 
respect to their potential to be used as screening techniques for shortcutting the 
stabiliser selection process. 
4.4.2 Contact angle measurements 
The interaction potential of a solid and a liquid (e.g. comprising a dissolved stabiliser) 
can be predicted by CAM. High CAs show, that an interaction is less likely. If the liquid 
and solid properties are similar, the CA can be low. Surfactants are one example for 
substances that increase interaction potential between solid surfaces and dispersion 
liquid. So that it was expected, for this thesis that higher stabiliser concentrations lead 
to more wetting of the drug surface. Generally, one can say that a reduction in CA 
stands for interaction of the dissolved stabiliser with water and/or the drug compact. 
As the drugs for nanosuspension production have a hydrophobic nature and the 
stabilisers are rather hydrophilic, the CAM can display this hydrophobic-hydrophilic 
interactions as well as the influence of the stabilisers on the surface tension of the 
water droplet applied to the drug. 
For CUR, a trend of more wetting with higher stabiliser concentrations could be seen 
(Figure 45). The CAs of the stabiliser solutions on the drug compact were related to 
the CA of water on the drug compact on each experimental day. Hence, a negative 
number stands for a smaller CA related to the one of water and a positive number 
indicates a higher CA. CAs for water on GLI were mostly just below and on CUR just 
above 50°. When increasing the PS80 concentration, the wetting of CUR increased 
until 12.5 % PS80. This concentration led to an almost direct ingression of the water 
droplet in the CUR compact, so that a maximum reduction of CA was achieved. 
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Consequently, every concentration above 12.5 % could not reduce the CA any further. 
No significant change in CAs could be observed for different HPMC concentrations. 
Just a slight trend could be seen to higher CA reduction for higher concentrations. At 
higher concentrations of HPMC and PS80 mixtures, the CAs were slightly lower related 
to water than the average of the single substances. Only at the lowest concentrations, 
the combination of PS80 and HPMC seems to have a benefit on the wetting behaviour 
compared to PS80 alone. 
 
Figure 45: CAs of stabiliser solutions in double-distilled water on CUR compacts. Dotted 
columns represent minimal stabilising concentrations. n = 5. error bars = SD. 
For GLI, the CA determination with the same stabiliser solutions that were tested with 
CUR, gave a different picture (Figure 46).  PS80 addition to water at lowest 
concentrations led to comparably lower wetting of the GLI compact compared to CUR, 
e.g. at a concentration of 1.25 % PS80, the CA reduction on GLI was -3.2° ± 0° and on 
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CUR -12.95° ± 2,08°, respectively. Still, the trend of decreasing CAs for higher 
concentrations could be seen. 
 
Figure 46: CAs of stabiliser solutions in double-distilled water on GLI compacts. Dotted columns 
represent minimal stabilising concentration. n = 5. error bars = SD. 
The maximum wetting was up to -18.5° ± 1.64° for GLI and -23.2° ± 1.05° for CUR. In 
contrary, an increase in HPMC concentration led to less wetting on the GLI compact 
compared to CUR.  For GLI, the values of PS80 alone and the combination of HPMC 
and PS80 seemed to have the same impact on the CA for the two highest stabiliser 
concentrations (30 % and 25 %) as for CUR. So here, HPMC did just lightly hinder the 
wetting effect of PS80. With less concentrated combinations, there was a decrease in 
contact angle to be seen like in the lowest combinations (1.25 % + 1.25 % and 
2.5 % + 2.5 %) for CUR. Hence, the combination of the two stabilisers led, for these 
concentrations, to a better wetting than the substances alone. 
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The different behaviour of these two drugs, when exposed to the same amount of 
stabiliser, shows that stabiliser-drug interactions cannot be generalised. Each drug has 
its own optimal stabiliser and stabilising concentrations. For CUR and GLI, the 
difference was most prominent for HPMC interaction. GLI did not seem to interact with 
HPMC solutions. It is known that HPMC interacts with water while building up 
structures that lead to increased viscosity of the system. The interaction with the GLI 
compact seemed to be negligible compared to this self-interaction, as for the highest 
concentration, the CA increase compared to water was 34.03° ± 6.19° so that the total 
CA was found around 84°, which nearly indicated no wetting at all, as defined in the 
European Pharmacopoeia [8th edition monography 2.9.45]. In contrast, HPMC had an 
influence on the wetting behaviour of water on CUR. With higher concentrations, the 
wetting increased slightly from -8.04° ± 3.95° for a concentration of 1.25 % HPMC 
to -11.09° ± 1.26° for the 30 % HPMC solution. The interaction between the HPMC 
molecules in solution might have been reduced with the effect that some HPMC 
molecules could interact with the CUR surface. This indicates that CUR seems to be a 
stronger interaction partner for HPMC than GLI. Unfortunately, this does not explain 
the different stabilising concentrations of CUR and GLI for HPMC. CUR had with 25 % 
even a 2.5 higher stabilising concentration than GLI with 10 %. There must be a more 
prominent factor influencing stabilising concentration during and after milling for CUR 
than the wetting alone. PS80 had similar interaction patterns with GLI and CUR just to 
another extent. One exception was the step when there was an abrupt rise in CA 
reduction. For CUR, it happened between 5 % and 10 % PS80 and for GLI between 
10 % and 12.5 %. Again, CUR compact wetting was higher at medium stabiliser 
concentrations (10 % PS80) (-20.06° ± 2.31°) compared to GLI (-4.83° ± 1.73°). 
Unfortunately, the course of the CAM values with various stabiliser concentrations 
could not give information about minimal stabilisation concentrations. Even though it is 
an often used method in literature for the prediction of stabilising potential, it is a 
method with just a small application window. In literature, a reduced CA of hydrophilic 
stabiliser solutions on hydrophobic drugs is claimed to lead to a higher chance in 
stabilisation possibility. Results from this project however suggest that this method 
might not be useful in general application. In this work, it could be seen that even 
though HPMC creates high contact angles, it is a suitable stabiliser for GLI. HPMC 
helps to produce stable and small-sized nanosuspensions. Therefore, CAM cannot be 
the only method to choose when wanting to predict stabilisation efficacy and/or 
Results and Discussion 
 
91 
 
stabilising concentrations. Hence, in this thesis, a second method, ITC, was chosen to 
possibly display the interaction of stabiliser and drug on the molecular level in more 
detail. 
4.4.3 Isothermal titration calorimetry  
4.4.3.1 Analyses background and particle characteristics 
ITC is rarely used until today for the study of interaction potential of stabilisers and 
drugs with regard to nanocrystal production. Just a few papers studied the interaction 
of different polymers on micron-sized calcite crystals [Dimova et al., 2003], polystyrene 
beads with a hydrophobic surface [Pinholt et al., 2011] and cationic silica nanoparticles 
[McFarlane et al., 2010] with ITC. Most of the measured interactions indicated an 
adsorption, which was expressed by large exothermic signals at the beginning of the 
titration with a decline until a plateau was reached. Normally, in ITC, enthalpy can be 
calculated out of the heat signal and the concentrations in the syringe and in the cell. 
As the interaction of stabiliser and drug is not a chemical reaction but physical 
interaction, the enthalpy was not selected as the evaluation value of choice for 
comparison of drug suspension and stabiliser solution interactions. The models that 
can be fitted to the enthalpy curves do not consider particle-molecule interaction but 
molecule-molecule interaction. For a comparison of different drug-stabiliser 
interactions, the peak length of the power amplitude for each injection was subtracted 
from the length in the control experiment, so that the extent of interaction could be 
compared between different drugs and different stabilisers. Thus, every experiment 
needed to have an additional control experiment. The calculated values do not display 
information about stoichiometry or other reaction characteristics but the relation to 
each other enables comparison of the systems. Positive values were received when 
the sample had higher amplitude (more exothermic) and negative values stand for 
smaller amplitude (less exothermic) than the control. Each dot in Table 19 and Table 
20 does exhibit the amplitude of one injection of the sample with the amplitude of the 
control subtracted. Examples for more or less exothermic samples can be seen in 
Figure 47. 
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Figure 47: Raw data of injections of stabiliser solution in Milli Q water (control) and in a drug 
suspension (sample). Exemplary raw data, to show lower (top) or higher (bottom) heat 
generation of the control in relation to the sample (top: PS80 in CUR; bottom: HPMC in GLI). 
The control experiment was chosen as a titration of stabiliser solution into water as this 
gave a higher signal than the titration of water into drug suspension and therefore had 
a higher impact on the setup. These phenomena can be explained by heat of dilution 
of the stabiliser solution into water which is much higher than the dilution of drug 
suspension by water as the drugs are poorly soluble in water. The titration of water into 
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drug suspension gave such a low signal that it was not put into calculation (raw data 
can be seen in chapter 9.4.4). 
Unfortunately, it was not possible to investigate the interaction of the stabilisers with 
the nanocrystals as the nanocrystals agglomerated when the stabilisers were not 
present so that the coarse powder had to be used for interaction studies. As the coarse 
powder was used in suspension for ITC experiments, the knowledge of 
physico-chemical parameters of the coarse suspensions is of interest to interpret the 
results of the following ITC experiments. Inspection of Figure 48 indicates, that CUR 
coarse material has irregular shaped particles with a rough surface. 
 
 
Figure 48: SEM image of CUR coarse material as received from supplier. 
A broad particle size distribution could be imaged with some large and a high amount 
of small particles. 
In comparison to CUR, GLI particles appeared more plate like and with a smooth 
surface (Figure 49). Furthermore, the size is differing, with GLI having larger particles 
than CUR. Particle size distribution seemed to be wide, with small particles being 
broken off larger crystals. 
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Figure 49: SEM image of GLI coarse material as received from supplier. 
The difference in size, visualised in SEM, could also be reflected in particle size 
measurements by laser diffraction. CUR particle size distribution was slightly bimodal 
while GLI showed a broader but monomodal distribution (figures of particle size 
distribution can be seen in chapter 9.4.2). Table 18 shows that CUR had smaller 
particles and a narrower particle size distribution. 
Table 18: Particle sizes of coarse powders measured with laser diffraction. n = 4. ± = SD. 
sample x10 in µm x50 in µm x90 in µm Span value 
Coarse powder GLI 8.35 ± 0.35 52.47 ± 4.60 135.21 ± 15.33 2.42 
Coarse powder CUR 1.84 ± 0.04 8.70 ± 0.19 29.64 ± 0.83 3.20 
 
Another interesting powder parameter is the surface area. The BET surface area of 
CUR was measured to be 1.38 m²/g ± 0.17 m²/g, whereas GLI had a five times smaller 
surface area with 0.27 m²/g ± 0.02 m²/g. This trend could complete the particle size 
data. The larger, monomodal distributed GLI has less surface area than the 
polydisperse, smaller CUR. These results indicate that there could be a higher chance 
of interaction of the stabilisers with CUR as it has a five times higher surface area. 
4.4.3.2 ITC results 
As shown above, already the two control experiments of PS80 and HPMC with the 
same concentration titrated into water were different (Figure 47). The amplitude for 
HPMC was with approximately 6 µcal in average three times higher than the 2 µcal 
amplitude average for PS80. This could mean that HPMC has a higher heat of dilution 
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than PS80. The heat of dilution got slightly smaller for HPMC and PS80 with increasing 
number of injections. A demicellisation could also have happened when the stabilisers 
were titrated into water which should be a process with loss in entropy as the 
micellisation is attributed to the disruption of the structure of water [Schicke, 2010]. 
Already these control experiments indicated that titration peaks can be a result of 
overlaying thermic interactions making a straightforward interpretation of the data 
challenging. 
Usually, in ITC experiments, a concentration should be chosen at which the reaction 
is supposed to be ended, if a about half to two third of the volume to be injected is 
added to the cell. Accordingly, for the experiments within this project, the minimal 
stabilising concentration should be reached when half of the titration steps were 
performed. To highlight the trend of amplitude change, also higher concentrations were 
investigated, where the stabilising concentration was found in the beginning of titration.  
First, the lower concentrated stabiliser solutions will be compared. In Table 19, the 
thermal profiles of HPMC and PS80 titrated into CUR and GLI suspensions are 
displayed. Three different thermal interaction profiles can be seen in this table. The 
first type is a profile that does not show a change in heat exchange over the whole 
titration and therefore increasing amount of stabiliser. This means that the drug does 
not have much effect on the stabilisers’ thermometric measurable behaviour in water. 
Hence, the amplitude difference is fluctuating around 0 µcal. An explanation might be 
that no thermal interaction between the drug and the stabiliser takes place. Another 
interpretation approach could be that simultaneous thermal interactions in both 
endothermic and exothermic direction compensate each other. These thermal profiles 
were the case for HPMC - CUR and PS80 - GLI interactions. The latter had 
irregularities in the measurement at the end of the titration with the last two 
measurement points having a difference in amplitude around -6 µcal. As the titrations 
were done just once, these signals might be measurement errors. For HPMC - GLI 
interactions, even less heat was measured than for the control (negative values). With 
increasing HPMC concentrations the values of the control were approached slightly 
but not reached. An endothermic process did happen. 
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Table 19: Calculated heat interaction profiles of low HPMC (0.8 mM) and PS80 (12 mM) 
concentrations (16 mg/mL). dashed line indicates minimal stabilisation concentration. n = 1. 
 CUR GLI 
Low 
HPMC 
 
 
Low 
PS80 
  
 
A complete different interaction profile was measured for PS80 - CUR. First titration 
steps showed an increase in amplitude compared to the control which was again 
approaching the values of the control with increasing stabiliser concentration in an 
exponential trend. This trend is typical for adsorption processes as first the stabiliser 
adsorbs onto the drug surface and interaction is decreasing with increasing adsorbed 
amount until nothing more is adsorbed and the state of the control is reached. 
A second ITC setup utilising higher stabiliser concentrations was chosen to investigate 
whether the thermal interaction trends stays similar (Table 20). When increasing 
stabiliser concentrations, two thermal profiles changed. While HPMC - GLI interaction 
appeared to stay on the same level over increasing stabiliser amount, PS80 - GLI 
titration resulted in a profile that had a more exponential trend than with lower 
concentrations. 
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Table 20: Calculated heat interaction profiles of high HPMC (3.2 mM) and PS80 (49 mM) 
concentrations (64 mg/mL). dashed line indicates minimal stabilisation concentration. n = 1. 
 CUR GLI 
High 
HPMC 
  
High 
PS80 
  
 
Except for HPMC - GLI titration, every magnitude of heat creation or consumption 
changed. HPMC - GLI and HPMC - CUR interactions both did not return to zero (to the 
values of the control). This drift from zero was also measured by other researchers in 
ITC experiments with high surfactant/polymer concentrations [Chiad et al., 2009; Wang 
et al., 2015]. One explanation proposed was that the temperature of the stabiliser 
solution and the drug suspension were not exactly the same and therefore a shift of 
baseline could be seen. As the thermic interactions were generally very low in the 
experiments for this work (compared to, for example, chemical interactions), this shift 
should not be over-interpreted but just the change in trend of the titration curves should 
be discussed. 
HPMC did not show an adsorption with any drug or concentration. This could be due 
to several reasons. One reason could be a non-interaction of HPMC and CUR or GLI. 
As it is known that HPMC was able to stabilise CUR and GLI nanocrystals during and 
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after milling, non-interaction of drug and stabiliser is not likely. It is possible that the 
diffusion of HPMC in ITC experiments could be too slow to be measured while during 
hours of milling an interaction takes place. 
Typical adsorption profiles were found for all PS80 interactions, except for low 
PS80 - GLI titration. An explanation therefore could be the above mentioned surface 
area of the two drugs. CUR has a higher surface area, so interaction could be more 
prominent and therefore, only at higher concentrations of PS80, a trend to an 
adsorption profile could be seen for GLI. Other approaches could be different surface 
properties of GLI, so that PS80 is less likely to adsorb compared to CUR. When 
producing nanocrystals via milling, the surface increases remarkably. Hence, it is likely 
that PS80 will also adsorb thermodynamically measurable on the new formed GLI 
surfaces. Unfortunately, the stabilisers could not be separated to full extent from the 
nanocrystals and also nanocrystals could not be produced without stabiliser as both 
causes highly agglomerated particles, so that the nano-surface-stabiliser interaction 
could not be measured with ITC but just the micro-surface-stabiliser interaction. For 
future experiments the particle sizes of both drugs should be brought to the same level 
to exclude this factor and just concentrate on the stabiliser interaction. 
As this technique should also be investigated as a tool to predict minimal stabilising 
concentrations, the stabilising concentrations found in milling experiments were 
marked as dashed line in all figures. This experimental part showed as well that the 
determined absolute values cannot be used without the experimental frame to discuss 
interactions. As an example PS80 - CUR interaction shall be mentioned. For low 
starting concentrations of PS80 the stabilising concentration related to the difference 
of 0.4 µcal to the control while at high starting concentrations 2.0 µcal were measured. 
Depending on the starting concentrations, different values were determined but the 
thermal profile stayed similar. The plateau for the higher concentrations was achieved 
faster than for the lower concentrations, so that no direct correlation to the minimal 
stabilising concentrations could be drawn. Nevertheless, it could be shown for CUR, 
that a concentration of PS80, which is located on the exponential plateau, should 
always be sufficient enough for stabilisation. 
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4.4.4 Comparison of contact angle measurements and isothermal titration 
calorimetry 
CAM and ITC display different interaction levels. While ITC measures interactions of 
stabiliser and drug surfaces, CAM deals with interaction of compressed drug surfaces 
and stabiliser solutions or the stabiliser self-interaction in water. CAM is detecting 
wettability where hydrophilic-hydrophobic interactions are most pronounced, while ITC 
displays interactions like hydrogen bonding or hydrophobic interactions. For 
nanocrystal stabilisation, hydrophobic interactions between the stabiliser and drug are 
most common because, typically, drugs are hydrophobic. Furthermore, other kinds of 
interactions, most importantly hydrogen bonding, can be found. 
CAM and ITC results show a higher interaction potential of CUR with both stabilisers 
compared to GLI. Looking at the possibility of forming hydrogen bonds for the selected 
stabilisers and drugs, CUR and GLI were found to have similar hydrogen bond counts 
whereas HPMC has more possibilities to form hydrogen bonds than PS80. These 
counts for hydrogen bonds were found in a chemical data base (Pubchem) and are 
listed in Table 21. 
It was shown in literature that the polyhydric alcohols of PS80 are capable of forming 
hydrogen bonds with the hydroxyl groups and hydrogen atoms present in CUR 
[Sharma et al., 2005] and also HPMC is known to form hydrogen bonds with CUR 
between the OH groups of HPMC and the CO group of CUR [Li et al., 2017]. 
Table 21: Calculated hydrogen donor and acceptor count of selected stabilisers and drugs taken 
from Pubchem. 
substances Hydrogen bond donor 
count 
Hydrogen bond 
acceptor count 
PS80 3 10 
HPMC (estimated for a 
molecular weight of 
20,000 g/mol) 
126 475 
CUR 2 6 
GLI 3 5 
 
Eudeng et al. calculated, with molecular dynamics simulations, that HPMC stabilises 
indapamide better than GLI, through a higher number of hydrogen bonds formed 
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[Edueng et al., 2017]. Indapamide can be found with 2 hydrogen bond donor counts 
and 5 acceptor counts, so that it has slightly less counts than GLI. These results 
indicate that not only the number of hydrogen acceptors and donators might play a role 
but also molecular dynamics and steric issues, regarding stabilisers and drugs. No 
direct correlation could be drawn from structural comparisons. 
Both methods are fast and sample preparation is simple. Different interaction patterns 
of HPMC and PS80 with both drugs could be detected and differences between the 
two methods became obvious. Interaction patterns for HPMC with both drugs were 
similar in ITC measurements while in CAM they were different. Higher HPMC 
concentrations led to viscosity increase of the stabiliser solution and therefore, higher 
contact angles but the molecular interaction detected with ITC stayed similar over 
different HPMC concentrations because the heat of dilution, which increased at higher 
concentrations, was eliminated by subtracting the control experiment. CAM could be a 
useful method to select a certain range of stabiliser concentrations for milling 
experiments, while ITC experiments gave information about the feasibility of stabilisers 
in general.  
4.4.5 Concluding remarks of stabiliser-drug interaction studies 
CAM and ITC could not be used to forecast minimal stabilisation concentration. 
However, CAM could be utilised to imply ‘maximum’ stabiliser concentrations of PS80. 
The concentration that had CAs of approximately 0° were, in the frame of this thesis, 
mostly sufficient enough for stabilisation. Further, ITC experiments gave information 
about the feasibility of stabilisers in general and suitable stabiliser concentration, when 
a adsorption profile was detected. HPMC did not show an adsorption pattern, which 
could mean that it does not adsorb but just stabilises via viscosity change or that the 
adsorption is too slow to be measured with ITC. Also, a too low heat change, which 
could not be detected, could have been a reason. From these three theories, the 
middle one could be most likely. As the viscosity and concentrations for stabilising were 
different for GLI and CUR, only the stabilisation via viscosity seems not reasonable. 
HPMC is a comparably large molecule to PS80 and PS80 leads in most cases to an 
entropy change of the system, when adsorbing, which should also be the case for 
HPMC. That is why the theory of slow adsorbing HPMC molecules is plausible. In 
literature, it was described that the speed of adsorption also has an influence on 
stabilisation [Kumar Thakur and Kumar Thakur, 2015]. When the adsorption speed is 
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too slow, a stabilisation of nanosuspensions might not happen during milling, as the 
stabilisers cannot get fast enough to the newly formed surfaces and therefore 
aggregation can occur. Stabilisers with high molecular weight can have a decreased 
diffusion rate of the polymer chains but an increased physical adsorption. So, in the 
beginning of milling, stabilisers with low molecular weight might be favourable but most 
of the time this effect disappears upon prolonged milling [Choi et al., 2008]. For the 
millings in the Dispermat® SL-C 5, HPMC adsorption speed was fast enough but for 
other high energy millings it might not be sufficient enough. Then PS80 seems to be a 
better candidate as rapid adsorption patterns could be detected with ITC. 
4.5 In-vitro dissolution of suspensions 
A drug, which is in a solubilised state, often shows higher bioavailability than a 
non-dissolved drug. Therefore, dissolution studies can be one tool to predict 
bioavailability. Nowadays, they are more often used to compare different formulations 
than to predict bioavailability. 
As stated by Noyes-Whitney, a beneficial dissolution can be found with drugs having 
a large surface area, like nanocrystals. Furthermore, drugs with a small molecular 
weight (large diffusion coefficient) [Hörter and Dressman, 2001], the right balance 
between H donors and acceptors as well as low melting points [Lipinski et al., 2001] 
are favourable for high bioavailability. As the molecular weights and melting points 
were similar comparing CUR and GLI different attributes of the structure of GLI and 
CUR lead to different solubility and dissolution profiles as discussed in this chapter. 
4.5.1 Solubility in dissolution media 
Creating a set-up for dissolution studies includes the investigation of saturation 
solubility of the drug in dissolution medium as the selected concentration can have an 
influence on the dissolution. For BCS class I and III drugs the concentration should be 
≤ 10 % of the saturation concentration (perfect sink-conditions) to avoid an influence 
of the concentration on the dissolution rate but with poorly soluble drugs from BCS 
class II and IV the saturation concentration in bio-relevant media is already very low 
and even lower concentrations might not be detectable. As CUR and GLI face 
challenges with regard to aqueous solubility, a medium had to be found that provides 
detectability of the drugs even at short sampling time, meaning a medium in which the 
drug has sufficient saturation solubility. 
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The saturation concentration was therefore investigated for eleven different media with 
varying pH values, to find a suitable medium for each drug (data not shown). For GLI, 
boric acid buffer with pH 9.4 showed highest solubility while CUR was best soluble in 
acetic acid buffer at pH 4. Considering the bio-relevance of these media, a phosphate 
buffer (pH 8) was additionally investigated. A common practice to increase solubility in 
dissolution media is an addition of surfactants. In this study, the coarse powder of the 
respective drug was chosen as the reference for the produced nanosuspensions. As 
the nanosuspensions include stabilisers and the influence of these stabilisers should 
also be investigated throughout this thesis, an addition of external surfactants was 
avoided. Values for saturation solubility (ss) of the selected media and ‘internal’ 
stabilisers can be seen in Table 22. 
Table 22: Saturation solubility (ss) of CUR in acetic acid buffer and GLI in boric acid buffer as 
well as phosphate buffer with and without the addition of stabilisers. n = 3. ± = SD. 
Acetic 
acid 
buffer 
ss CUR in 
µg/mL 
Boric acid 
buffer 
ss GLI in 
mg/mL 
Phosphate 
buffer 
ss GLI in 
mg/mL 
Without 
stabiliser 
addition 
0.31 ± 0.00  
Without 
stabiliser 
addition 
0.54 ± 0.06  
Without 
stabiliser 
addition 
0.022 ± 0.0017 
With 
25 % 
HPMC 
0.87 ± 0.12 
With 10 % 
HPMC 
0.55 ± 0.09 
With 10 % 
HPMC 
0.024 ± 0.0015 
With 
12.5 % 
HPMC + 
12.5 % 
PS80 
7.63 ± 0.83 
With 2.5 % 
HPMC + 
2.5 % 
PS80 
0.59 ± 0.02 
With 2.5 % 
HPMC + 
2.5 % 
PS80 
0.050 ± 0.0025 
 
Depending on the drug, the solubility changes in dependency on the stabiliser. The 
increase in solubility is most pronounced for CUR with the addition of HPMC and PS80. 
A 24.6 times increase could be determined, while for GLI a rise of 2.3 in phosphate 
buffer was detected. When the solubility was already comparably high in the dissolution 
medium without the addition of stabiliser, like for GLI in boric acid buffer, the influence 
of the stabiliser was minimal. As dissolution rate is a function of saturation solubility, it 
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can be expected that the dissolution rate of the coarse drugs will be influenced by the 
stabilisers. 
4.5.2 Dissolution of coarse suspension 
CUR coarse powder dissolution was very poor as can be seen in Figure 50. Only 
8.15 % ± 1.93 % of saturation concentration did dissolve after 24 hours (1,440 min) 
even with the addition of stabilisers. After the experiment, non-dissolved powder could 
be seen floating on the dissolution medium. So, just approximate 0.023 mg of the 
roughly 1.4 mg CUR got dissolved (0.28 mg would be 100 % dissolved drug). 
 
Figure 50: Dissolution of coarse CUR powder with and without the addition of stabilisers at 
5 times saturation concentration in acetic acid buffer. n = 3. error bars = SD. 
The coarse suspension of GLI showed a dissolution extent of 79.50 % ± 2.11 % to 
95.98 % ±1.27 % in boric acid buffer within 24 hours. So, approximate 25.9 mg were 
maximal dissolved from the applied 27 mg of GLI. When comparing the dissolution 
profiles in the first 200 minutes, HPMC and HPMC + PS80 addition changed the 
velocity and magnitude of dissolved drug which is plotted in Figure 51. In boric acid 
buffer pH 9.4, the stabilisers seemed to have a decelerating effect on the dissolution 
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rate of GLI. An addition of 2.5 % HPMC + 2.5 % PS80 to the dissolution medium 
decreased dissolution rate approximately by half at 200 minutes. 10 % HPMC addition 
lead to 17 % less solubilised amount of GLI after 200 minutes. 
 
Figure 51: Dissolution of coarse GLI powder with and without the addition of stabilisers in boric 
acid buffer at perfect sink conditions. n = 3. error bars = SD. 
After 24 hours, the dissolution of powder with 10 % HPMC was with 79.50 % ± 2.11 % 
dissolved drug on a similar level as the coarse powder (81.45 % ± 3.58 %) and the 
powder with 2.5 % HPMC and 2.5 % PS80 achieved 95.98 % ± 1.27 % dissolution. 
This trend was not expected as surfactants or tensides are commonly used to increase 
solubility and wetting of drugs in dissolution media. For this purpose, usually SDS but 
also PS80 is used. Nevertheless, the phenomenon that stabilisers also lead to a 
decrease of dissolution was also found by a small number of other researchers. Chen 
et al. discovered that low PS80 concentrations slowed down the dissolution of their 
tested compound in 0.1 N HCl, while high concentrations led to an increase in 
dissolution [Chen et al., 2003]. Their proposal for the mechanism was that below CMC 
of PS80, there was an increase of the formation of insoluble chloride salt of their drug 
on the surface of their compound due to surface tension reduction, while for 
concentrations above CMC other factors played a more important role like adsorption 
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so that the dissolution was higher. These literature results raised the question of CMC 
values of the stabilisers in this thesis. Hence, the CMC of PS80 and HPMC was 
determined. Stabilisers, that form micelles, should have a long hydrophobic chain and 
a polar head group. This structure subdivision can be seen for PS80, while HPMC as 
polymer does not form typical micelles. From literature review it is expected that HPMC 
forms some kind of clusters or even fringed micelles [Müller, 2010]. In this work, the 
determined CMC of PS80 in water was 5 - 10 µg/mL and 2 - 10 µg/mL for HPMC. In 
general, the CMC of non-ionic surfactants should not be much affected by the presence 
of a buffer so that it can be assumed that HPMC and PS80 concentrations in 
dissolution studies (0.75 µg/mL for PS80 and 2.99 µg/mL for HPMC) were for PS80 
below the CMC. This could be an influencing factor on dissolution. Contrariwise Li et 
al. experienced that an addition of PS80 (87.8 µg/mL) to their dissolution medium 
(water) decreased dissolution of carbamazepine. They suggested that PS80 formed 
an interfacial barrier which hindered the drug’s dissolution and resulted in nucleation 
and growth of the applied crystals with the formation of carbamazepine dehydrate [Li 
et al., 2013]. Seedher at al. found, that PS80 lowered the dissolution rate of GLI in 
0.1 M phosphate buffered solutions (pH 7.4) compared non-buffered solutions even 
though hydrogen bonds between water and PS80 should be decreased in the 
presence of a buffer so that PS80 should have higher interaction potential with the drug 
[Seedher and Kanojia, 2008]. All in all, PS80 was found in most publications as a 
dissolution rate enhancer. In this selected paper, the dissolution rate decreased when 
certain amount of PS80 was applied, like it was seen in this thesis. The buffer salt 
concentration might play a role and/or an interfacial barrier formation and nucleation of 
the drug. 
A second dissolution medium was used to evaluate, if the influence of the stabilisers 
was the same and also to create a more bio-relevant condition than a boric acid buffer 
with a pH of 9.4. That is why a phosphate buffer with a pH of 8 was chosen for further 
investigations (see Figure 52). Phosphate buffers with even lower pH values, which 
would be more physiological, did lead to a drop in solubility so that the determination 
with HPLC was difficult. Therefore, a compromise between bio-relevant and precise 
content evaluation was chosen with the phosphate buffer of pH 8. 
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Figure 52: Dissolution of coarse GLI powder with and without the addition of stabilisers in 
phosphate buffer at perfect sink conditions. n = 3. error bars = SD. 
With this dissolution medium, two differences could be detected. First of all, as the 
solubility was lower in this medium also the dissolution was slower than in boric acid 
buffer. Secondly, an addition of HPMC lead to fastest and highest dissolution followed 
by stabiliser free medium and phosphate buffer containing HPMC as well as PS80. 
Regarding HPMC, a formation of a gel layer around the GLI particles in boric acid might 
be possible and therefore an increase in diffusion layer. The salt concentration in 
phosphate buffer is different compared to boric acid buffer as the ionic strengths were 
calculated with 150 mM/L and 640 mM/L, respectively. Until today, the ion formation in 
boric acid buffer is not totally understood, so that an interaction with HPMC cannot be 
linked to one specific ion in the solution. Assuming that the buffer system has equal 
amounts of HB4O7- and B4O72- [Thorsten, 2013] an ionic strength can be calculated 
with 640 mM/L. Similarities with literature data could be found as Kavanagh et al. 
investigated the decrease in erosion rate of HPMC with a high molecular weight and 
explored an increase of erosion rate with high ionic strengths [Kavanagh and Corrigan, 
2004]. They attributed this phenomenon to the ‘salting out’ of the polymer by the 
inorganic ions present in the dissolution media with the polymer’s molecular chains 
loosing water of hydration due to the ions competing for the available water of 
Results and Discussion 
 
107 
 
hydration. This process could also have happened in this thesis even that different 
molecular weights for HPMC were used. 
Consequently, it could be concluded that CUR has very low dissolution rate in acetic 
acid as well as low solubility in all tested media. As the dissolution rate was low, an 
addition of stabiliser did not change the dissolution pattern. For GLI, depending on the 
buffer, stabilisers had varying influences on solubility and dissolution. 
4.5.3 Dissolution of nanosuspensions 
CUR formulated as nanosuspension had an advantage in dissolution rate over the 
coarse powder as demonstrated in Figure 53.  
 
Figure 53: Dissolution of CUR nanosuspensions in acetic acid buffer at 5 times saturation 
concentration. n = 3. error bars = SD. 
Compared to coarse powder, which did not show any dissolution in the first 4 hours, 
the nanosuspensions exceeded a value of approximate 29 % dissolution (with the 
saturation concentration being 100 %) after 4 hours. A trend for the influence particle 
size could be seen as smaller nanocrystals had faster and higher dissolution than 
larger nanocrystals. Furthermore, the influence of stabilisers was comparable between 
small and large nanocrystals. Nanocrystals stabilised with HPMC, led to slightly faster 
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and higher dissolution than a combination of HPMC and PS80 which can be linked to 
the saturation solubility of the drug which is with 0.00087 mg/mL in 25 % HPMC-acetic 
acid solution lightly higher than in 12.5 % HPMC + 12.5 % PS80-acetic acid solution 
(0.000763 mg/mL). The percentage is again related to the amount of drug which was 
used in the suspension. After 24 hours still just 29.82 % ± 3.60 % to 45.66 % ± 2.85 % 
were dissolved, so that no saturated solution could be achieved. So, from the applied 
1.44 mg just 0.08 mg - 0.13 mg got dissolved (0.28 mg would be 100 % dissolved 
drug). 
GLI dissolution was expected to be faster for the nanocrystals as even the coarse 
suspension had a comparably fast dissolution in boric acid and phosphate buffer. This 
expectation was met as can be seen in Figure 54 and Figure 55. All nanosuspensions 
exhibited dissolution of 76.61 % ± 1.18 % to 80.78 % ± 12.65 % after 5 minutes in 
boric acid buffer and 82.21 % to 91.90 % ± 3.82 % in phosphate buffer. So, in boric 
acid buffer 20.7 mg - 21.8 mg from the applied 27 mg got dissolved, while in phosphate 
buffer it were 4.93 mg - 5.51 mg from 6 mg. In the first two hours no clear difference 
between different sizes or type of stabilisers could be seen. 
At the end of the dissolution study in both media a slight difference between the types 
of stabiliser was measured, with HPMC + PS80 stabilised nanosuspensions showing 
a higher percentage in dissolution. This difference was more pronounced in boric acid 
buffer. Here, also a difference in particle size can be seen as small nanocrystals led to 
higher dissolution values. 
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Figure 54: Dissolution of GLI nanosuspensions in boric acid buffer at perfect sink conditions. 
n = 3. error bars = SD. 
 
Figure 55: Dissolution of GLI nanosuspensions in phosphate buffer at perfect sink conditions. 
n = 3 for large nanocrystals stabilised with 10 % HPMC; all others n = 1. error bars = SD. 
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4.5.4 Concluding remarks of dissolution studies 
All in all, the formulated nanosuspensions could increase dissolution rate to a higher 
level. Especially when the solubility in dissolution medium was low, the increase in 
dissolution rate was eminent when comparing nanocrystals and coarse powder. After 
4 hours, the increase in dissolved amount from CUR coarse powder with HPMC and 
PS80 addition to small nanocrystals with the same amount of stabiliser was changing 
from 0 mg to 0.1 mg (of the applied approximate 1.4 mg). For GLI, these suspensions 
led to a 5 times increase in dissolved amount from 1.06 mg to 5.19 mg in phosphate 
buffer (of the applied approximate 6 mg).  
For poorly soluble substances like CUR also the type of stabiliser plays a role in 
dissolution of nanosuspensions. The influence was, in this thesis, not as high as the 
particle size but it definitely has to be kept in mind in formulation development as most 
companies have their standard set of well investigated stabilisers. If there is no 
comparison done between different stabilisers, it could be the case of a non-fulfilment 
of the maximum benefit of nanosuspensions as a dosage form. For companies, it saves 
time to run a standard program but for promising drugs, which are known to be able to 
have a high value in therapy and which fail to get to clinical trials because of low 
bioavailability, the choice of stabiliser should be reconsidered. 
Also, the stabiliser influence on the coarse powder should be explained. As CUR 
showed low dissolution rates, no influence could be detected. For GLI, different 
dissolution media had changing influence on the dissolution after stabiliser addition to 
the coarse powder. In boric acid buffer, addition of any stabiliser led to a decrease in 
dissolution rate while in phosphate buffer, HPMC addition did increase the dissolution 
rate and the extent of dissolution. Different pH values and salt concentrations could 
play a role. 
Dissolution can usually not display/predict bioavailability but show a comparison of 
different kinds of formulations. Nevertheless, especially for BCS class III (and IV) 
sufficient dissolution profiles can be measured but permeation through tissues is low, 
so that dissolution as a forecast to bioavailability is limited. Hence, the investigation of 
the permeation of the two chosen model drugs through cellular barriers was examined 
for this thesis as well and results can be found in the next chapter. 
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4.6 Transport of drugs through epithelial cells 
The assessment of transport of drugs through epithelial cells is one way to predict 
bioavailability of this drug from a formulation. In this work, the permeation of 
nanocrystals was investigated with a transwell system, in order to answer the question 
if the drug is transported in a dissolved state or even in a particulate form. 
In the first step, the used transwell system had to be validated, followed by first 
experimental approaches to, in the end, investigate the influence of particle size, type 
of stabiliser and type of drug on the permeation. 
4.6.1 Validation of the Caco-2 transwell model 
Depending on the cell culture lab, the person who is handling the cells, the used 
equipment, the environment conditions and passage numbers of the cells, the outcome 
of cell experiments can be very different. That is why a validation is of major 
importance. 
Three factors are commonly used in combination to create comparability between cell 
experiments with transwells. The transepithelial electrical resistance (TEER) displays 
integrity of the cell monolayer on the transwell membrane. When a monolayer is 
formed, the TEER should gradually increase until a plateau is reached at cell 
confluence. Two different pore sizes for the membranes were used in this work (1 µm 
and 3 µm pore sizes, respectively) which TEER values are presented in Figure 56. 
 
Figure 56: TEER value development over 23 days of cell growth on transwells; starting seeding 
density was 100,000 cells/cm² of Caco-2 cells. n = 3. error bars = SD. 
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For 3 µm transwells, all TEER values above 300 Ω*cm² indicated an intact monolayer 
while for 1 µm pore size transwells the minimum value was set to 500 Ω*cm². Below 
these values the experiment was not started. Further preliminary studies investigated 
the TEER value as a marker for integrity of the monolayer during the transport 
experiment (data not shown). The maximum specification border was set at a 
difference of 100 Ω*cm² regarding the TEER values before and after the experiment. 
Every well that showed higher negative difference was excluded from evaluation. 
As drugs and stabilisers have an influence on the TEER value and the cells could not 
be totally cleaned from suspension that got stuck to the cell surface, another marker 
was included in the validation process. Lucifer yellow (LY) permeation is a better way 
to show a tight contact of cells after experiments: the lower the LY permeation the 
tighter the contact of the cells was. LY permeation results are displayed in Figure 57. 
 
Figure 57: Paracellular permeation of lucifer yellow through Caco-2 cells during growing period 
of 21 days. starting seeding density was 100,000 cells/cm². n = 2. error bars =  min/max. initial 
amount = 0.1 mg/mL. 
As the cells grow, the connection to each other closes up. From the diagram above, 
the conclusion was drawn that if a LY permeation of 5 % or lower compared to the 
initial LY amount was determined, the monolayer could be considered as intact. All 
transwells that had a higher permeation of LY at the end of the experiment and did not 
show TEER values above the specified values were excluded from evaluation and the 
experiment was repeated. When the permeation of LY increased over 10 % the well 
was not evaluated even though the TEER value was in specification.  
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The next step for validation was the selection of a permeation marker. On every 
transwell plate one marker should be included in the experimental setup to exclude 
inter-day variability. Atenolol was selected as permeation marker. Atenolol is a poorly 
permeating substance through Caco-2 monolayers. Toxicity of atenolol (1.5 mM) was 
tested and no toxicity could be detected over 24 hours in transport buffer as well as in 
cell culture medium (data not shown). 
As suspensions were investigated for permeation, the incubation time was extended 
to 24 hours because the uptake time for particles can be much higher than for 
molecules. This created a new problem. Normally, in transport experiments, a buffer is 
used as transport medium. Unfortunately, it was seen that an incubation of Caco-2 
cells with transport buffer for 24 hours led to a complete disconnection of cells (TEER 
value on the same level than filter without cells and high LY permeation) and also a 
15 % loss in viability was measured in MTT tests, so that another transport medium 
had to be found for 24 hour studies. For this purpose, full cell culture medium was 
tested. For medium, LY permeation was in specification and also the atenolol 
permeation was on the similar level at 3 hours and 24 hours incubation (data not 
shown). Nanocrystals sizes were measured to have similar sizes in transport buffer 
and cell culture medium as plotted in Figure 58.  
 
Figure 58: Particle size (bars) and particle size distribution (PDI; dots) of the same CUR and GLI 
nanosuspensions in buffer or medium. n = 1. 
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Differences could be observed for the particle size distribution as in buffer, PDI values 
were higher than in medium with the exception of the one selected example of large 
CUR nanocrystals. 
4.6.2 Experimental approach for method set-up 
The transport of GLI and CUR through different cell lines has already been 
investigated. Due to the low solubility of CUR some authors used organic solvents, 
heat or alkali solubilisation to prepare solutions that were investigated for their transport 
ability through Caco-2 cells [Zhen et al., 2017; Wahlang et al., 2011]. These 
preparations however do not mimic the in-vivo situation, thus physiological media 
should be utilised in this thesis. 
For GLI, exemplary apparent permeability coefficients of 2.16 x 10-5 cm/sec [Zerrouk 
et al., 2006] and 2.6 x 10-5 cm/sec [Jiang et al., 2015] were found in literature. CUR has 
exemplary, with 1.13 (± 0.11) x 10−6 cm/sec [Zhen et al., 2017] or 
2.93 (± 0.94) x 10−6 cm/sec [Wahlang et al., 2011] a slower permeability rate, which is 
why it is categorised into BCS class IV. 
Data values in this and the following chapter will be plotted as permeation of the drug 
related to atenolol (
100
𝑃𝑎𝑝𝑝𝑎𝑡𝑒𝑛𝑜𝑙𝑜𝑙
𝑥𝑃𝑎𝑝𝑝𝑑𝑟𝑢𝑔).  
First transport studies were conducted to test the range of permeation and feasibility 
of used concentrations and setup. The difference in permeation of the tested 
suspensions is visible in Figure 59 and Figure 60. CUR proved to be a drug with low 
permeability through intestinal barriers. No permeation could be seen in buffer even 
for the small nanocrystal suspension after 5 hours. Likewise, the coarse suspension in 
medium did not show any permeation. Just small nanocrystal formulations were able 
to permeate but still the permeation in medium was, after 24 hours, with 
3.80 % ± 1.27 % to 4.46 % ± 0.00 % of atenolol permeation very low. As atenolol itself 
is categorised as low permeable and CUR nanocrystal formulations merely were able 
to reach 4.46 % of this permeation, the improvement from 0 % for coarse powder to 
4.46 % for nanosuspension formulation might not be relevant for the pharmaceutical 
industry. 
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Figure 59: Permeation of CUR coarse suspension and small nanosuspensions in buffer and cell 
culture medium related to permeation of atenolol under the same conditions. The Papp of atenolol 
was set to 100 %. Pore sizes of 1 µm and different incubation times (5 h and 24 h) were 
investigated. n = 2. error bars = min/max 
CUR is not a highly potent drug for which a small increase in permeation could improve 
treatment to a high extent. Furthermore, at this low value, a stabilisation with HPMC or 
HPMC + PS80 did not make a difference in permeation. 
The permeation through 3 µm pore sized transwells was measured to be even lower 
than for 1 µm (data not shown). This could be due to different monolayer formation on 
the membrane. In microscopic images it could be seen that cells were growing within 
the pores of 3 µm diameter so that they were not free for particle/substance transport 
while for the 1 µm pore sized transwells a smooth monolayer growth was observed. 
GLI was expected to have a different permeation pattern than CUR as it belongs to 
BCS class II and therefore, should be highly permeable. The values in Figure 60 
confirmed this expectation. 
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Figure 60: Permeation of GLI coarse suspension and small nanosuspensions in buffer and cell 
culture medium related to permeation of atenolol under the same conditions. The Papp of atenolol 
was set to 100 %. Pore sizes of 1 µm and different incubation times (5 h and 24 h) were 
investigated. n = 2. error bars = min/max 
Again, the coarse suspension was lower in permeation than the nanocrystal 
formulations. In comparison to CUR, GLI achieved with 60.36 % ± 6.83 % to 
291.42 % ± 24.89 % even a higher permeation than atenolol. The permeation through 
3 µm pore sized transwells was again lower than through 1 µm pores. 
As GLI is a good permeable substance, the achieved low values for coarse suspension 
permeation were taken as a hint that for GLI, the dissolution rate plays an important 
role for the amount of permeation. That is why the comparison of dissolution rate in 
buffer and medium for all tested suspensions and the corresponding permeation rate 
are described in chapter 4.6.4 in more detail. 
As outcome of the preliminary studies, shown in this chapter, detailed permeation 
studies were planned. Therefore, for CUR, medium was taken as transport fluid and 
permeation over 24 hours was of interest. For GLI, buffer and medium were taken as 
transport fluids but buffer not for 24 hour studies. 
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4.6.3 Permeation comparison of coarse drug suspensions and 
nanosuspensions 
Chapter 4.6.2 contains the findings for usable transwell setups, so that following 
experiments could be created to investigate the influence of stabiliser, drug, particle 
size and time on the permeation of drug being formulated as nanosuspension through 
Caco-2 cells.  
For CUR, all these influences are depicted in Figure 61. Up to 5 hours, no CUR 
permeation could be detected. Thus, the permeation was not calculated from several 
values as a typical permeation rate but from the permeated amount after 24 hours. 
Furthermore, the size has a high impact. Particles in the micrometer range showed 
lowest permeation in average, followed by 300 nm nanocrystals and highest 
permeation was achieved with 500 nm sized nanocrystals. 
 
 
Figure 61: Permeation of CUR coarse suspension, small and large nanosuspensions in cell 
culture medium related to permeation of atenolol under the same conditions. The Papp of atenolol 
was set to 100 %. Filter pore size was 1 µm and permeation was measured over 24 h (sampling 
time points: 1 h, 3 h, 5 h and 24 h). n = 2. error bars =  min/max. 
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The influence of the stabilisers was varying. For microcrystals and large nanocrystals 
HPMC - PS80 combination increased permeation while for small nanocrystals the 
combination was not benefiting compared to a stabilisation just with HPMC 
(6.47 % ± 0.50 % and 6.36 % ± 0.42 %, respectively). 
For GLI, permeation was also detected between 1 and 5 hours of incubation, presented 
in Figure 62. The trend of particle size influence was similar to CUR. Permeation rate 
increased from coarse powder, over small nanocrystals to large nanocrystals.  
 
Figure 62: Permeation of GLI coarse suspension, small and large nanosuspensions in cell 
culture medium related to permeation of atenolol under the same conditions. The Papp of atenolol 
was set to 100 %. Filter pore size was 1 µm and permeation was measured over 5 h and 24 h 
(sampling time points: 1 h, 3 h, 5 h and 24 h). n = 2. error bars =min/max. 
The impact of stabilisers was opposed to CUR. HPMC, as a stabiliser, led to higher 
permeation rates. The difference does not appear to be high in this figure as 
permeation is much higher in general but when comparing, for example, the small 
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nanocrystals after 5 hours, stabilisation via HPMC (291.42 % ± 24.89 %) led to 25 % 
higher permeation than stabilisation with HPMC and PS80 (232.68 %± 18.69 %). 
The amount of stabiliser was not comparable between GLI and CUR as minimal 
stabilisation concentrations, as results from milling experiments did vary. Therefore, 
also GLI nanocrystals, stabilised with HPMC and PS80, with half of the HPMC 
stabilisation concentration were produced and tested for permeability to have a better 
comparison between CUR (25 % HPMC and 12.5 % PS80 + HPMC) and GLI 
(10 % HPMC and 5 % PS80 + HPMC). Results are plotted in Figure 63. 
 
Figure 63: Permeation of GLI coarse suspension, small and large nanosuspensions in cell 
culture medium related to permeation of atenolol under the same conditions. The Papp of atenolol 
was set to 100 %. Filter pore size was 1 µm and permeation was measured over 24 h (sampling 
time points: 1 h, 3 h, 5 h and 24 h). n = 2. error bars =min/max. 
The permeation of the newly produced GLI suspensions was performed over 24 hours 
and in medium to have the same conditions as for CUR. Different trends regarding the 
influence of stabilisers could be seen comparing the coarse, small and large 
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suspensions. For the coarse suspensions, all stabiliser concentrations did increase the 
permeation rate but the influence of the stabilisers was marginal. For small 
nanocrystals stabilised with 5 % HPMC + 5 % PS80 mixture, the highest permeability 
could be detected (291.03 % ± 46.47 %) followed by the HPMC stabilised nanocrystals 
(213.51 %± 18.93 %) and the 2.5 % HPMC + 2.5 % PS80 mixture 
(177.00 % ± 7.83 %). For the large nanocrystals, HPMC stabilised nanocrystals still 
showed, with 407.91 % ± 9.22 %, highest permeation and the added 
5 % HPMC + 5 % PS80 mixture stabilised nanocrystals had similar permeation to the 
nanocrystals stabilised with the half concentrated mixture (311.23 % ± 38.80 % and 
335.78 % ± 9.29 %, respectively). The nano-formulations created in this work could 
increase the permeation of GLI through intestinal barriers up to 7.8 times. 
In comparison to CUR, the increase of the stabilising concentration mixture to half of 
the HPMC concentration led to similar permeation results regarding the small 
nanocrystals. The mixture showed highest permeation. For the large nanocrystals, 
HPMC alone stabilised nanocrystals showed highest permeation while for CUR the 
stabiliser mixture resulted in a higher permeation. 
Additionally to ‘normal’ A-B transport studies also the transport from the basolateral to 
the apical compartment was measured. The ratio between the two permeability 
coefficients could then be used as a first indicator of possible involvement of an active 
transport process. For CUR, no permeation from B to A could be detected up to 
24 hours in medium. GLI showed varying permeability coefficients. For the 
determination of the coefficient, every Papp value was again related to atenolol whereby 
the average of all conducted transport studies was chosen to calculate the average 
atenolol Papp for A-B (2.014 x 10-7 cm/sec) and B-A (1.897 x 10-7), respectively. Results 
of the permeability coefficient are plotted in Figure 64. The value of 1 displays equal 
permeation values for A-B and B-A. Formulations with values above 1 have a higher 
permeation from A-B than from B-A and vice versa. 
First of all it shall be mentioned that as for every experiment a 1 mM suspension was 
used, the solubility of GLI should be the same for A-B and B-A studies. Hence, the 
permeability coefficient should be also similar. It might be the case for the coarse 
suspension that the layer that was seen to settle on the cells at transport studies from 
A-B hindered the transport of solubilised drug. Hence, when the drug was settling on 
the bottom of the basolateral compartment at B-A studies, a higher transport could be 
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detected. 5 % HPMC + 5% PS80 stabilised nanosuspension display an exception. As 
the transport studies from B-A were just conducted once this could be a measurement 
error. 
 
Figure 64: Permeability coefficients of 1 mM GLI suspensions. Permeation was measured from 
A–B and B-A for 24 hours in medium. Papp values of GLI were related to average atenolol Papp 
values before the coefficient was calculated. Filter pore size was 1 µm.  n = 1. 
All nanosuspensions show a coefficient above 0.9 so that most nanosuspensions 
(values above 1) have a higher permeation from A-B than from B-A. The 
5 % HPMC + 5 % PS80 stabilised nanosuspension had enhanced transport from A-B 
compared to the other nanosuspensions. Larger nanosuspensions had a higher 
coefficient compared to small nanosuspensions. The differences in the coefficient can 
be explained by local changing concentration gradient around the Caco-2 monolayer. 
When particles are settling onto the membrane the concentration gradient in direct 
contact to the cell surface might be higher compared to equally distributed particles in 
the compartment. As just a small amount of large nanocrystals might be settling on the 
cells no repression of permeation could be seen like for the coarse suspensions. 
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4.6.4 Dissolution rate of drugs at transport study conditions and inclusion in 
permeation results 
One possibility to investigate, whether particles or just molecules permeated through 
Caco-2 monolayers, is to compare the solubility at sampling time points and the 
permeation of the drug. If the permeation is above 100 % of the solubility at this time 
point, the permeation of particles is likely. Hence, the dissolution rate of coarse 
suspension with the addition of stabilisers and the solubility of large and small 
nanocrystals in medium and buffer were tested. In this chapter, the focus will be on the 
dissolution rate data of the suspensions and time points used in transport studies in 
the last chapter. For CUR, permeation could be seen in medium after 24 hours, so that 
this time point will be also plotted in the next Figure 65.  
 
Figure 65: Solubilised amount of CUR suspensions in medium after 24 hours of a 1 mM 
suspension. n = 3. error bars = SD. 
Coarse powder dissolution rate was not detectable while the large nanoparticles gave 
highest dissolution rates. A combination of HPMC and PS80 gave higher dissolution 
rates than just HPMC stabilised suspensions. The dissolution rate increases over 
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5 hours while at 24 hours, it decreases for almost all formulations (data not shown). 
This indicated that CUR undergoes degradation which is reasonable as it is known 
from literature [Wahlang, B. et al. 2011]. The degradation was more prominent in buffer 
than in medium so that it could be concluded that CUR is more stable in medium than 
in buffer. There is a chance that the small nanocrystals had a higher amount of 
dissolved drug so that also the degradation was faster and therefore a lower dissolution 
rate was measured as for the large nanocrystals. GLI had a different dissolution pattern 
than CUR (Figure 66).  
 
Figure 66: Solubilised amount of GLI suspensions in medium after 24 and 5 hours of a 1 mM 
suspension. n = 3. error bars= SD. 
Similar to CUR were the low dissolution rates of the coarse powder compared to the 
nanosuspensions and the higher dissolution rate in medium compared to buffer (data 
not shown). A difference could be seen in the influence of the stabilisers. In most cases, 
a combination of HPMC and PS80 did not lead to higher dissolution rate but HPMC 
stabilised nanosuspensions showed highest dissolution rate. The results indicate that 
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larger nanosuspension formulations were not favourable compared to the small 
nanocrystal formulations which is in better agreement with the Noyes-Whitney 
equation as it was the case for CUR nanocrystals. The dissolution rate in buffer stayed 
more or less on the same level for all sampling time points (data not shown) while the 
dissolution rate in medium increased, in average, for all formulations over time. This 
indicated that no degradation was happening for GLI. 
A lot of conclusions can be drawn from this experiment. Stabilisers can influence the 
dissolution from drug suspensions differently. While for CUR, a combination of HPMC 
and PS80 was most beneficial, GLI showed higher dissolution rates with just HPMC.  
With these solubility rate results, a connection to the transport studies can be drawn. 
As the solubility studies were done at similar conditions as the transport studies (37 °C, 
no shaking), the permeated amount of drug could be related to its dissolution at 
different time points. For CUR, permeation could just be seen at 24 hours incubation 
time in medium like described above. Therefore, in the next Figure 67, just the 24 hour 
data were put into relation. 
For coarse CUR with addition of HPMC, no permeation could be seen, even though 
the solubilised amount was 0.56 µg in the apical compartment (700 µL). An addition of 
HPMC and PS80 to the coarse suspension led to an increase in permeation, even 
though the solubilised amount was with 0.89 µg just slightly higher. Of this solubilised 
amount 68.61 % ± 5.02 % permeated. For the large nanosuspension formulations, the 
permeability and the solubility were the highest but the percentage of permeation was 
on the same level as for the small nanocrystal suspensions. Just around 20 % 
(17.71 % ± 0.38 % and 20.47 % ± 1.50 %) of the solubilised amount permeated which 
indicated that probably no particles crossed the Caco-2 cells because not even the 
solubilised drug permeated completely. 
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Figure 67: Relation of dissolution rate and permeation of formulations for CUR coarse 
suspension, small and large nanosuspensions. 100 % represents the solubilised amount 
determined at 24 h. Filter pore size was 1 µm and permeation was measured over 24 hours. n = 2. 
error bars = min/max. 
For GLI, already after 3 hours permeation could be detected to that this time point and 
the following ones are plotted in Figure 68. Highest permeation, related to solubilised 
amount, could be detected for the coarse powder with HPMC addition. Of the 
9.94 µg ± 0.29 µg GLI dissolved after 24 hours, 79.76 % ± 0.16 % could permeate. 
Large nanocrystals, stabilised with HPMC, showed highest permeation rates and with 
47.34 µg/mL ± 1.53 µg/mL second highest dissolution rate after 24 hours, so that their 
permeated percentage resulted in 46.37 % ± 0.51 %. Again, permeation seems to be 
governed by dissolved drug, so particulate transport is unlikely. 
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Figure 68: Relation of dissolution rate and permeation of formulations for GLI coarse 
suspension, small and large nanosuspensions. 100 % represents the solubilised amount 
determined at 24 h. Filter pore size was 1 µm and permeation was measured over 24 hours. n =2. 
error bars = min/max. 
4.6.5 Concluding remarks of transport studies 
A validated transwell model could be generated so that the influence of particle size, 
time and type of stabiliser on the permeation of nano-crystalline formulations could be 
investigated. 
For the BCS class IV drug CUR, no permeation through epithelial cells could be seen 
within 5 hours. The solubility of this drug was very poor at all tested time points, so that 
the classification as BCS class IV drug could be confirmed. Addition of PS80 to all 
suspensions increased the solubility at all tested time points as well as the permeation 
rate for the coarse suspension. PS80 addition enhanced the permeation of large 
nanocrystals within 24 hours by approximately 100 % compared to large nanocrystals 
stabilised just with HPMC. It was mentioned in the material part (chapter 3.1.1.1) that 
CUR could possibly be a Pgp substrate and as PS80 is known to inhibit Pgp [Zhang et 
al., 2003] the increased permeation could be also due to the Pgp inhibition of PS80. 
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No influence of the type of stabiliser could be detected for the small nanocrystals. An 
explanation could again be related to Pgp. To be able to use the inhibitory effect of 
PS80, drug and stabiliser have to be at the same site at the same time. Possibly, 
smaller nanocrystals have a higher dissolution and high concentrations of PS80 are 
not at the same time with the solubilised CUR molecules in the cells. Larger particles 
could settle on the cells and be attached to the mucus layer of the cells, so that the 
local drug concentration and PS80 concentration might be higher and therefore, the 
Pgp inhibiting process can occurs. Regarding the size, large nanocrystals led to higher 
permeation than small nanocrystals.  
GLI, as a BCS II class drug, proved to show higher solubility and permeation rates than 
CUR. Addition of stabilisers changed the dissolution in dispersion media differently. In 
transport buffer, the dissolution was increased when adding HPMC compared to no 
stabiliser addition or mixtures of HPMC and PS80. For all tested suspensions, HPMC 
had a more positive effect on the permeation rate of GLI than a PS80-HPMC mixture 
(at lower concentrations) which might be due to solubility rate enhancement in the 
transport buffer. Only at higher concentrations of the mixture, a higher permeation 
could be detected for the small nanocrystals. The permeation rate within 5 hours was 
higher as within 24 hours. 
Relating the dissolution to the permeation of the drugs, the coarse powders, for which 
permeation rates could be detected, exhibited the highest percentage of dissolved drug 
being transported. The reason might be again the settling of the particles on the 
monolayer creating a higher gradient. Amongst each other, GLI and CUR nanocrystals 
had similar percentages of permeated drug related to dissolution. Comparing the 
permeation and dissolution at 24 hours, CUR showed in average 18.8 % permeation 
of the dissolved amount and GLI 48.7 %. Still, looking at these numbers, a permeation 
of particles is not presumable.  
It was mentioned above that for both, CUR and GLI, a higher permeation rate could be 
seen for the large nanocrystals compared to the small nanocrystals. This size 
dependence is inconsistent as small nanocrystals should lead to a faster dissolution 
and higher dissolved amount than the large nanocrystals (see Noyes-Whitney-
equation chapter 2.3). Hence, it is an unexpected result as all other data suggest that 
the drug has to be dissolved before being transported through the cells and the better 
the dissolution/solubilisation, the higher the permeation rate. In literature, examined 
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size dependencies on the transport through Caco-2 cells were performed with 
non-dissolvable nano-objects [Awaad et al., 2012; Munger et al., 2014] or nano-objects 
that are taken up prior to getting dissolved [McClean et al., 1998]. One very interesting 
publication showed the influence of the particle size of efavirenz solid drug 
nanoparticles on the permeation through Caco2 cells. With efavirenz solid drug 
nanoparticles, the expected trend could be seen with larger nanocrystals leading to a 
decrease in Papp [Siccardi et al., 2016]. A drawback of this study is that they produced 
the different particle sizes with different types of stabilisers, so that not only the 
influence of the particle size was tested. Therefore, this data cannot be used for just 
interpreting size dependencies. Anhalt explored in her dissertation that permeation 
was higher for 150 nm nanocrystals compared to 860 nm nanocrystals of a Merck 
Serono Compound [Anhalt, 2012]. Hence, the phenomenon, which was seen in this 
thesis, describes a poorly researched area of nanocrystals. Therefore, the following 
explanations for the large nanocrystals showing a higher permeation than the small 
nanocrystals are assumptions that need further investigations in the future. One reason 
could be that the large nanocrystals were more likely to settle on the Caco-2 cell 
monolayer and therefore increased the concentration gradient at the surface, so that 
the diffusion was more likely. Another reason for the higher permeation of large 
nanocrystals could be the supersaturation status of the nanocrystals in the apical 
compartment. Dissolution data in the last chapter suggest that a supersaturation is 
present as the solubility is tremendously higher for the nanocrystals compared to the 
coarse suspension. Literature data suggest that the saturation solubility increase is 
most pronounced with nanocrystal sizes below 200 nm [Anhalt, 2012], so that in this 
case a supersaturation, which is also caused by the stabilisers, is more likely than this 
high increase in saturation solubility. During permeation study, also stabiliser 
molecules would permeate, so that the possible higher supersaturation status of the 
small nanocrystals can lead to faster precipitation and therefore, less solubilised 
molecules would be there for transportation, so that a decrease in permeation would 
be possible. A third theory is related to the stabiliser-particle ratio. If an assumption is 
done, that all stabilisers adsorb on the surface of the nanocrystals, large nanocrystals 
have more stabiliser on the surface, as the weight percentage of stabiliser is the same 
for small and large nanocrystals but the particle number decreases when large 
nanocrystals are produced. A layer around the nanocrystals that composes of more 
stabiliser molecules can possibly interact with the Caco-2 monolayer in a way that 
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paracellular transport is more likely because it is known that stabilisers can make cells 
more penetrable [Tuomela et al. 2016]. 
Summarised, PS80 addition led to permeation and dissolution rate increase for CUR 
while for GLI just HPMC as a stabiliser was found to have a benefit. For both drugs 
larger nanocrystals lead to a higher permeation than smaller nanocrystals. Transport 
studies did indicate that a permeation of particles is not expectable. Consequently, 
further experiments would be needed to gain deeper inside into particle transport 
mechanisms with consequently smaller particle sizes. The signals expressed by cells 
or the adhesion to receptors can be different when a molecule or a particle permeates 
through the cell [Rauch et al., 2013] which is of major interest for fate and processing 
of nanocrystals in biological environments. 
4.7 Uptake of nanocrystals in cells 
The results of the uptake of nanocrystals in Caco-2 cells and RAW 264.7 cells will be 
explained in this chapter. Therefore, the cells were incubated with the selected 
nanosuspensions over different time periods and the amount of particles being taken 
up was calculated. Two microscopic methods were chosen: CARS and fluorescence 
microscopy. 
4.7.1 Uptake studies with CARS microscopy 
As CARS microscopy is not a standard technique in the field of uptake studies, some 
preliminary experiments for set-up arrangements had to be conducted. 
4.7.1.1 Evaluation of CARS microscopy set-up 
CARS microscopy is only chemically-specific when a wavenumber shift of the drug can 
be found that does not interfere to a high extent with the background. The backgrounds 
in these studies were cellular tissues. Therefore, CARS signals from the living and 
stained as well as fixed cells were collected. Both cell lines had high signals in the 
region between 2800 cm-1 and 2900 cm-1. This is known as the ’lipid region’ because 
the stretching of lipid C-H bonds can be related to this area. A CARS shift of the drugs 
had to be found aside from this ’lipid region’ to be chemically-specific. Unfortunately, 
CUR did not show a suitable pattern, possibly due to its high fluorescent activity but 
GLI showed one maximum at 3074 cm-1. Figure 69 shows the wavenumber shifts of 
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GLI, GLI nanocrystals and lipid droplets in cells. GLI could be clearly differentiated from 
the lipid droplet in the cells at 3074 cm-1. 
 
Figure 69: CARS spectra of GLI powder suspended in water, lipid droplets and GLI nanocrystals 
in RAW 264.7 cells. 
In preliminary experiments also the CARS signals of buffer, medium, staining solution 
and fixation liquid were measured. They did not show interferences with the selected 
GLI peak. Furthermore, the stabilisers were tested and were also found not to interfere 
at the wavenumber of 3074 cm-1. 
CARS is claimed as a label-free technique but still, in this thesis, staining of the cell 
membranes had to be done and was detected with two-photon fluorescence excitation 
(TPFE). The staining had to be conducted because until today there is no specific 
membrane structure found that exhibits CARS signals aside from the ‘lipid region’. 
4.7.1.2 Uptake studies of epithelial cells 
The uptake quantification of nanocrystals in cells was challenging. Caco-2 cells are 
building a connective cell structure, so that the localisation of nanocrystals was 
problematic to detect. To address this problem, the amount of stain was increased from 
5 µg/mL to 7.5 µg/mL. The connected Caco-2 cells could be visualised as can be seen 
in Figure 70. 
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Figure 70: Z-stack of CellMaskTM Orange stained Caco-2 cells at a concentration of 7.5 µg/ml. 
Unfortunately, when adding nanocrystals, the visualisation of the membranes became 
blurry. Another problem was faced with the Caco-2 cells detaching from the bottom of 
the well when they were incubated for 6 hours with 500 µg/mL of API-nanocrystals 
stabilised with HPMC and PS80. Most of the cells of a lower concentration (250 µg/mL) 
were still attached. Hence, this concentration was chosen for all further experiments. 
Still some cells detached which is observable in Figure 71. When using cell culture 
medium as dilution medium for the nanocrystals, fewer cells detached so that for all 
further 24 hour incubations, medium was used as dilution liquid. 
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Figure 71: CellMask OrangeTM stained and fixed Caco-2 cells incubated with small GLI 
nanocrystals (250 µg/mL) stabilised with HPMC + PS80 in buffer for 24 hours. Left: bright field 
image. Right: TPFE detection of stain. 
Still, at optimum experiment conditions for the cells, only a few images could be 
created, in which the uptake of nanocrystals into Caco-2 cells could be observed. An 
exemplary image can be seen in Figure 72. 
As only a few areas of possible uptake of nanocrystals could be found in all 
experiments, quantification was not conducted. Just with incubation times of 24 hours, 
an uptake could be seen. This time period however is an artificial time for nanocrystal 
uptake in-vivo because most crystals will most likely be cleared by then. The Caco-2 
cells were proven to be a barrier for particles as healthy intestinal cells should be 
in-vivo. Unfortunately, no influence of size and type of stabiliser could be measured as 
the uptake was this low. Therefore, another model was chosen: the RAW 264.7 
macrophage cell line. 
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Figure 72: Orthogonal projection of Caco-2 cells incubated with small GLI nanocrystals 
stabilised with HPMC + PS80 over 24 hours. GLI (red) with a measured CARS shift at 3074 cm-1. 
Cells were fixed and membrane was stained (green). Detection of the stain was accomplished 
with TPFE. 
Macrophages are more likely to take up particles in comparison to enterocytes, so that 
it was expected that a quantitative measurement of the uptake could be accomplished, 
showing a difference of the various nano-formulations. 
4.7.1.3 Uptake studies in macrophages 
Labelling and imaging conditions were the same as for the epithelial cells. Still, images 
were clearer for the macrophages. Furthermore, every experimental set-up showed a 
definite uptake of nanocrystals in the cells. An exemplary image is shown in Figure 73. 
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Figure 73: Orthogonal projection of RAW 264.7 cells incubated with small GLI nanocrystals 
stabilised with HPMC + PS80 over 2 hours. GLI (red) with a measured CARS shift at 3074 cm-1. 
Cells were fixed and membrane was stained (green). Detection of the stain was accomplished 
with TPFE. 
As imaging conditions were optimal and nanocrystal uptake could be imaged, the 
uptake could be quantified. The experimental setting is described in the method part 
(at the end of chapter 3.2.9.2). Here, the evaluation of the created images with the 
Imaris software should be explained. One set of images contained of one image done 
with TPFE, so that the cell membranes were plotted (green), and one image created 
with the CARS signals, were the particles are visualised (red). First, the threshold of 
the particle image was adapted manually so that the particles could still be seen but 
red in the background was minimalised. Afterwards the membrane image was loaded 
and the surface wizard was used for creating and adapting a surface on the cells. 
Furthermore, the spot wizard was utilised to mark the nanocrystals. The number of 
spots and the volume of the cells were given by the program so that just the spots 
(nanocrystals) had to be counted that were situated outside of the cells. This was done 
by manually counting the spots outside the cells and subtracting this number from the 
Results and Discussion 
 
135 
 
total spot number. An exemplary image of the images after processing is shown in the 
appendix (chapter 9.4.5). These mentioned steps were done for each data set. To keep 
conformity in evaluation, all data sets were evaluated with Imaris within one week and 
from one person because the adaption of the cell surface and the adjustment of dots 
for the nanocrystals was still done manually and therefore, could cause bias in resulting 
values when evaluated with a time shift or from different persons. The following results 
are plotted as particles taken up per cell to achieve reasonable numbers for 
comparison. For this reason, a cell was defined as a cube with lengths of 15 µm.  
The influences of particle size, time and type of stabiliser on the uptake of nanocrystals 
are manifold. For a better overview, the same data will be plotted in three different 
figures with one of the three parameters set into focus. Figure 74 shows the influence 
of the particle size on the uptake in macrophages.  
 
Figure 74: Influence of particle size, time and type of stabiliser on the uptake of GLI nanocrystals 
per cell with the focus set on the size. * = significant difference (p = 0.01 - 0.05).   n = 4. error bars 
= SD. 
Except for the HPMC stabilised nanocrystals after 6 hours of incubation, no 
stabiliser-time combination showed a significant difference in particle uptake due to its 
size. 
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Also different incubation times just led to one significant difference. Large, HPMC 
stabilised, nanocrystals are taken up in a larger number when incubated over 6 hours 
compared to 2 hours as shown in Figure 75.  
 
Figure 75: Influence of particle size, time and type of stabiliser on the uptake of GLI nanocrystals 
per cell with the focus set on the time. * = significant difference (p = 0.01 - 0.05).   n = 4. error bars 
= SD. 
Another picture is given by the influence of the stabilisers (Figure 76). Three time-size 
combinations showed a significantly higher uptake of the nanocrystals stabilised with 
HPMC and PS80 compared to HPMC alone. Just for large nanocrystals incubated over 
6 hours, the stabiliser does not seem to influence uptake in macrophages. The highest 
uptake, calculated in average, could be seen for the small GLI nanocrystals incubated 
over 6 hours and stabilised with HPMC and PS80, followed by the small nanocrystals 
incubated over 2 hours and stabilised with HPMC and PS80. 
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Figure 76: Influence of particle size, time and type of stabiliser on the uptake of GLI nanocrystals 
per cell with the focus set on the type of stabiliser. * = significant difference (p = 0.01 - 0.05). n = 
4. error bars = SD 
Comparing the lowest number of particle uptake with the highest, namely small 
nanocrystals after 2 hours of incubation stabilised with HPMC (5.1 ± 4.1) and small 
nanocrystals incubated over 6 hours and stabilised with HPMC and PS80 
(29.2 ± 11.8), 5.7 times more GLI particles could be transported in the cell. Theoretical 
calculations with the estimation that the nanocrystals are perfect spheres, result in an 
increase in up-taken dose from 1.185 x 10-4 ng for 5.1 and 6.786 x 10-4 ng for 29.2 
taken up particles, respectively for one macrophage. Detailed calculations can be 
found in the appendix (chapter 9.4.6). 
CARS microscopy was successfully used to detect the influence of particle size, 
incubation time and type of stabiliser on the uptake of nanocrystals in macrophages. 
An important factor was that the fate of the nanocrystals could be measured even 
without labelling them, which can be beneficial for enhancing in-vitro in-vivo correlation 
compared to labelled particles or artificial metal particles. PS80-HPMC combinations 
were found to increase the uptake of nanocrystals of GLI compared to nanocrystals 
stabilised with HPMC alone. The type of stabiliser was the most prominent influencing 
factor on uptake compared to time and size. 
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4.7.1.4 Outlook on ex-vivo imaging with CARS 
It was stated earlier, that in-vitro environments cannot mimic in-vivo conditions to a full 
extent. Therefore, also for this work, an intermediate state; a ex-vivo study was 
planned. The nanocrystals should be administered to the intestines of living rats and 
the intestinal cells should be visualised after incubation to either prove poor uptake as 
seen in-vitro in epithelial cells or to show that in-vivo, the uptake is enhanced. Also the 
location of the nanocrystals was of interest as different cell assemblies are present in 
the intestine like the Peyer’s patches, which would naturally be more capable for 
particle uptake than epithelial cells. Unfortunately, the rat experiments could not be 
conducted but preliminary visualisation experiments could show that CARS 
microscopy is suitable to differentiate between different cellular structures in the 
intestine. To show this, different preparation and slicing of the intestine was 
investigated for an ideal sample preparation. It was found, that the best imaging results 
were conducted by freezing parts of the intestine, gluing them to a holder of a cryotom 
(Figure 77) and cutting them as a longitudinal section with a layer thickness of 40 µm.  
 
Figure 77: Plate holder of a cryotom. Frozen intestinal samples (brown) were glued (white) to the 
holder and a plate was used to cut the intestine in slices. 
The cut samples were mounted between two object holders within a window of parafilm 
and a drop of buffer was added. These preparation methods gave the best images of 
the villi of the rat intestine as can be seen in Figure 78. 
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Figure 78: Villi of rat intestine. A was summed to be enterocytes, B goblet cells and C lipid 
droplets. 
One feature of the used CARS microscope from Leica was of further advantage for the 
visualisation of rat intestines. Next to the TPFE detection for fluorescent materials, 
which was used in uptake experiments, also the second harmonic generation (SHG) 
was of use. SHG displays ordered crystalline structures. Therefore, the collagen 
layers, present in the intestine, could be imaged without further labelling which is 
observable in Figure 79. 
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Figure 79: Parts of a rat intestine with following structures from left to right: intestinal outer wall, 
collagen layer (green) detected with SHG, Villi which were partly ripped apart. 
Successful imaging of different structures and cell types in the rat intestine showed 
that, in future, the CARS microscope from Leica could be a good choice to investigate 
nanocrystal uptake ex-vivo.  
4.7.2  Uptake studies with fluorescence microscopy 
CUR, as a naturally fluorescent drug, could be imaged by fluorescence microscopy 
without labelling of the nanocrystals. GLI nanocrystals could not be detected with the 
fluorescence microscope as no laser for the excitation of GLI (302 nm) was available. 
As the uptake studies for GLI nanocrystals in epithelial cells only showed a few 
particles being taken up in all the samples and CUR is known to even permeate less 
than GLI, uptake studies for CUR in epithelial cells were not conducted. Hence, 
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macrophage uptake studies should show the influence of time, size and type of 
stabiliser on the uptake of CUR nanocrystals in cells. This set of experiments was 
conducted to link CARS results and fluorescence microscopy results as these 
techniques could be used complementary. 
4.7.2.1 Uptake studies in macrophages 
The preparation of the cell line is explained in the method part (end of chapter 3.2.9.3). 
Evaluation of the quantitative uptake of the particles was the same than used for CARS 
images and can be found in chapter 4.7.1.3. 
Again, the first parameter regarding its influence on the uptake to be investigated was 
the size of the nanocrystals as shown in Figure 80.  
 
Figure 80: Influence of particle size, time and type of stabiliser on the uptake of CUR nanocrystals 
per cell with the focus set on the size. * = significant difference (p = 0.01-0.05).     n = 4. error 
bars= SD 
One statistical significant difference was calculated for HPMC and PS80 stabilised 
nanocrystals with an incubation time of 6 hours where the small crystals were taken 
up to higher extent than large nanocrystals. 
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More statistical differences of the influence on particle uptake were calculated for the 
time. Three significantly different stabiliser-size combinations showed a higher uptake 
for 6 hours as incubation time compared to 2 hours (Figure 81). 
 
Figure 81: Influence of particle size, time and type of stabiliser on the uptake of CUR nanocrystals 
per cell with the focus set on the time. * = significant difference (p = 0.01-0.05). ** = highly 
significant (p = <0.01). n = 4. error bars = SD 
Again, the highest influence was seen for the type of stabiliser as plotted in Figure 82. 
All size-time combinations showed a significant higher uptake for HPMC and PS80 
stabilised nanocrystals compared to HPMC stabilised particles. The particle uptake per 
cell of the small nanocrystals with the fewest amounts of particles being taken up 
(0.69 ± 0.46) is 31.7 times lower uptake than the one with the highest uptake 
(21.90 ± 5.24). Here, the theoretical calculation leads to an up-taken dose of 
1.826 x 10-5 ng and 5.794 x 10-5 ng, respectively for one macrophage. Details for the 
calculation can be again found in the appendix (chapter 9.4.6). 
 
Results and Discussion 
 
143 
 
 
Figure 82: Influence of particle size, time and type of stabiliser on the uptake of CUR nanocrystals 
per cell with the focus set on the type of stabiliser. * = significant difference (p = 0.01-0.05). 
** = highly significant (p = <0.01). n = 4. error bars = SD 
4.7.3 Concluding remarks of fluorescence microscopy and CARS microscopy 
The uptake of GLI nanocrystals in macrophages has been determined with CARS 
microscopy while CUR nanocrystals detection was done with fluorescence 
microscopy. GLI was not possible to image with standard fluorescence microscope as 
its autofluorescence is only visible at very short wavelengths, while the imaging of CUR 
causes problems in CARS microscopy possibly due to its high fluorescence. As these 
are two different techniques, the direct comparison between these two drugs is not 
without doubt. The direct comparison of GLI and CUR can be seen controversial as 
two different techniques were utilised. It might be that one method could show the 
uptake in more detail without becoming obvious to the operator and therefore, a higher 
number could have been calculated. One example can be given with the z-stack height 
difference. With the CARS microscope, every 500 nm an image could be taken, while 
the fluorescence microscope was able to go down to 100 nm. Therefore, small 
nanocrystals would have had a higher chance of being detected with the fluorescence 
microscope. Furthermore, the background-particle differentiation was more 
differentiated in the fluorescence microscope than in CARS microscopy. However, the 
trend of the influencing parts should be comparable. For both drugs, a stabiliser 
combination of HPMC and PS80 led to a higher extent in particle uptake compared to 
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just HPMC stabilised nanocrystals. This influence of the stabilisers was the most 
significant for both drugs compared to the size and incubation time. The difference of 
HPMC and HPMC + PS80 stabilised nanocrystals might be even higher for CUR as it 
has a 5 times higher concentration of PS80 in the nanosuspension than GLI, which is 
due to the different stabilisation concentrations. Nevertheless, the time had more 
influence on the uptake of CUR than GLI nanocrystals.  
The usage of DMEM medium was possible for CARS but not for fluorescence 
microscopy (at least with phenol red). Consequently, incubations over 24 hours would 
have been challenging in fluorescence microscopy. Also, the knowledge about insert 
material is important. For CARS imaging, the image quality was better when the cells 
were imaged on polytetrafluoroethylene inserts rather than the poly ethylene and poly 
carbonate [Saarinen et al., 2017], while in fluorescence microscopy also poly ethylene 
filters could be used for imaging. Still, for both methods, glass bottom plates were most 
favourable. Fluorescence microscopy could have been used without labelling the 
membrane of the cells as CUR in its solubilised form did stain the membranes naturally 
whereas the solubilised amount of GLI could not be detected in CARS microscopy due 
to the high background signals in the cells. This background mainly comes from the 
lipids in the cells as CARS is highly sensitive to lipid structures. This can also be used 
as an advantage. Sometimes, granular structures could be seen in the cells which 
could have been confused with nanocrystals. These structures did not show a signal 
when tuning the laser to the 3047 cm-1 (GLI signal) but at the ’lipid-wavenumber’(2845 
cm-1) signals could be detected as plotted in Figure 83. 
 
 
Figure 83: Caco-2 cells incubated with 330 nm GLI nanocrystals over 3 hours. Cells were fixed 
and the cell membrane was stained (green). Left: CARS signals at 3047 cm-1. Middle: bright field 
image.  Right: Lipid droplets (red) with a detected CARS shift at 2845 cm-1. 
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In fluorescence microscopy the signals of solubilised drug-filled lipid droplets might be 
confused with nanocrystals. This was not the case for CUR as the nanocrystals were 
highly fluorescent compared to the solubilised drug but for less fluorescent drugs 
confusion might be possible. Still, CARS microscopy might nowadays not be that 
chemical-specific as it is claimed to be. At least the CARS microscope used for this 
thesis only had a small region of wavenumber shift detection. Some self-built 
equipment are able to visualise in the finger print region so that higher detection 
variability can be achieved. Broadband CARS microscopes can measure from 
600 - 3,200 cm-1 while the narrowband microscopes, like the Leica microscopy, can 
just image from 1,400 - 3,300 cm-1. The fingerprint region (< 1,800 cm-1) could be used 
to differentiate between different proteins or lipids, so that visualisation of cell 
compartments would perhaps be possible in detail and without labelling. 
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5 Concluding Remarks and Overall Discussion 
This chapter will deal with the achieved results of this thesis in terms of drug-stabiliser 
interaction and their influence on cellular transport and uptake of GLI and CUR. The 
most important results from this thesis will be shortly summarised and the link to current 
research will be drawn. Furthermore, recommendations for formulation approaches 
and important factors for the pharmaceutical industry will be resumed. Therefore, three 
recently published review papers were chosen to identify challenges and opportunities 
in the field of nano-objects in pharmaceutics. Yadollahi et al. stated in 2015 that future 
research directions in the field of nano-objects should include: 
i. Creation of an increase of in-vivo bioavailability and correlation to in-vitro 
experiments 
ii. Controlled and sustained drug release by incorporation of nano-objects in 
biocompatible matrix polymers 
iii. Development of stimuli-responsive systems 
iv. Increase in understanding of the behaviour of nanosuspensions in-vivo, 
including interactions with cells and biological barriers 
v. Surface engineering of nano-objects for active and passive targeting 
[Yadollahi et al., 2015] 
Jeevanandam et al. summarised in 2016 that improvement in uptake and efficiency of 
nano-formulations can be achieved by: 
i. Stable drugs in the formulation without self-aggregation 
ii. Knowledge of drug delivery and degradation mechanisms 
iii. Complying with FDA quality and related regulations while maintaining 
inexpensive production 
[Jeevanandam et al., 2016] 
Jain et al. named in 2017 that the understanding of the relationship between 
physico-chemical properties of nanoparticles and their biological interactions is still a 
challenge in nanotechnology [Jain et al., 2017]. 
All three review papers highlight the fact that there is still some work to do in the field 
on nano-bio-interactions. For Yadollahi et al. it is the ‘’Increase in understanding of the 
behaviour of nanosuspensions in vivo, including interactions with cells and biological 
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barriers’’, for Jeevanandam et al. the ’’Knowledge in drug delivery and degradation 
mechanism’’ and for Jain et al. the fact that ‘’the relationship between physicochemical 
properties of nanoparticles and their biological interactions is still a challenge in 
nanotechnology’’. In this work, regarding nano-bio-interactions, it could be shown that 
transport and uptake studies in the Caco-2 cell model indicate that a permeation of GLI 
and CUR nanocrystals with sizes of 300 nm and 500 nm is not supposable. The 
enterocytes were proven to be a healthy barrier for nanocrystals with sizes of 300 nm 
and above. Furthermore, PS80 was found to act as a permeation enhancer for CUR 
even in small concentrations, while HPMC addition led to a higher permeation of GLI. 
Still, the size of the nanocrystals was the most influencing factor on permeation. Large 
nanocrystals led to higher permeations than small nanocrystals. This unexpected 
results and following intensive literature review revealed that the influence of the size 
of nanocrystals on the permeation through Caco-2 cells is a poorly researched field in 
nanocrystal research. Three theories were developed to try to explain these results. 
The first explanation could be the settling of the large nanocrystals on the Caco-2 cell 
monolayer and therefore, increasing concentration gradient at the surface. Another 
reason could be the supersaturation status of the nanocrystals in the apical 
compartment. Higher dissolution of the small nanocrystals and permeation of the 
stabiliser molecules could lead to faster precipitation. A third theory is stabiliser-particle 
ratio related. Large nanocrystals could have more stabilisers on the surface, which can 
possibly interact to a higher extent with the Caco-2 monolayer. Regarding the uptake 
of nanocrystals in macrophages, the stabiliser was found as the most prominent factor 
in uptake enhancement whereby PS80-HPMC mixtures did increase the total uptake 
of nanocrystals.  
Furthermore, stabilisers had different influences on dissolution rate and permeation 
rate on micro- and nanocrystals. In classical dissolution studies, HPMC stabilised CUR 
nanosuspensions led to a higher dissolution rate while in transport studies the 
stabilisation with HPMC and PS80 increased permeation rate. In dissolution studies 
that had similar conditions than the permeation studies, just large CUR nanocrystals 
that were stabilised with HPMC + PS80 showed a higher dissolution rate. As in the 
end, the permeation is necessary to achieve sufficient bioavailability, dissolution 
should, in this case, not be used to forecast the behaviour in biological environments. 
The transport through Caco-2 cells seemed to be highly dependent on the solubility of 
the drug in formulation while the influence on uptake in macrophages was dominated 
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by the stabiliser type which showed highest membrane interaction potential. The 5.7 
times increase in uptake, which could be shown for small GLI nanocrystals, when just 
changing the stabiliser, is an alarming number for therapeutic treatments. The numbers 
both belong to small nanocrystals. Hence, it is not enough to just standardise size for 
nano-medicines, which is still the most investigated value in the field of 
nano-formulations. In transport studies, the size of the nanocrystals played an 
important role, while in uptake studies the size was the least influencing factor. One 
has to decide whether a transport through epithelial cells is of interest or the uptake in 
phagocytotic cells, to pick the best stabiliser for the purpose. The uptake data in 
macrophages could increase knowledge in drug delivery and degradation mechanism 
and can be used from different point of views. Either, one has an application aim for 
nanosuspensions where the macrophages serve as a clearance system, for example, 
for intra-venously administered drugs. Here, the results indicate that the addition of 
PS80 can lead to lower bioavailability compared to nanosuspensions just stabilised 
with HPMC. On the other hand, if the macrophages are aimed to be the therapeutic 
target, the loading might be more efficient with PS80 as a stabiliser. Prabhaker et al. 
suggested that PS80 enhances low density lipoprotein-mediated endocytosis and 
inhibits Pgp transport at the blood brain barrier [Prabhakar et al., 2013]. The enhanced 
endocytosis might be due to apolipoprotein E absorption on the PS80 surface [Kreuter, 
2001]. Wang et al supported this data with gemcitabine nanoparticles [Wang et al., 
2009]. Still, it has to be said that the uptake was measured in-vitro and with just two 
specific drugs, which cannot be transferred one to one to in-vivo environments and 
other drugs but gives an impression of what can happen if a change in formulation is 
not tested properly. If the drug is poorly soluble and permeable, like CUR, also the time 
plays an important role for uptake and transport of the drug. Here, formulations should 
be created which increase the time that the nanocrystals stay on the targeted cells with 
techniques like mucus adhesion/permeation for epithelial cells or PEG circulation 
enhancement, if the phagocytotic system is the aim. For good permeable substances, 
like GLI, the increase in solubilisation should be the major aim. 
There is still a need in techniques that can measure and display nano-bio-interactions. 
In this work, CARS microscopy was shown to be a good alternative to usually used 
fluorescence microscopy (unless the material is fluorescent itself) as no labelling of the 
nano-objects has to be done. Also animal tissues could be imaged so that further 
ex-vivo studies are possible.  
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The interest in surface engineering of nano-objects for active and passive targeting 
shows that also methods are needed to evaluate the results of the surface engineering 
while even the addition of stabilisers to nanosuspensions can count as surface 
engineering. An understanding of the stabiliser-drug interaction is of major importance 
for the selection of an appropriate stabiliser. In the pharmaceutical industry, new drugs 
are developed frequently. If the formulation approach of a nanosuspension is chosen 
for a certain drug, a stabiliser has to be selected. Polymer adsorption on solid surfaces 
can be studied with several methods, such as solid-state NMR, Fourier transform 
infrared (FTIR), [Pawsey et al., 2002] Raman [Bjelopavlic et al., 2000], 
microcalorimetry [Pinholt et al., 2011], surface plasmon resonance (SPR) and atomic 
force microscopy (AFM). HPMC was shown to have high interaction potential with 
crystal surfaces [Verma et al., 2009a]. Literature review revealed following important 
facts: 
i. Surface hydrophobicity plays an important role. High hydrophobicity of the drug 
can lead to self-aggregation of the nanocrystals and therefore, lower the 
success rate of production [Eerdenbrugh et al., 2009] Furthermore, the 
hydrophobicity of the stabiliser should be high enough to increase the chance 
of interaction and the chance of a resulting stable nanosuspension [Lee. et al., 
2005]. 
ii. Non-ionic stabilisers were found to have a higher adsorption potential than 
polymers [Palla and Shah, 2002; Choi et al., 2008]. 
iii. For surfactants, the CMC of the stabiliser might play a role. Clustered polymers 
can decrease stability of nanocrystals due to of possible micellar bridging [Liu 
et al., 2014]. Deng et al. found that they could achieve stable nanosuspensions 
of paclitaxel when they used Pol407 below CMC but not above CMC [Deng et 
al., 2010]. 
 
 
In this thesis, the findings about stabiliser-drug interaction revealed that: 
i. Zeta potential measurements can give an impression about the mechanism of 
the adsorption order of charged stabilisers, like SDS and TTAB with non-ionic 
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stabilisers, like PS80. From this, stability of nanosuspensions can be forecasted 
and stabiliser selection can be optimised. 
ii. ITC can display the speed of interaction. As it is known that CUR and HPMC 
are interacting via hydrogen bonding but no signal could be detected in ITC, the 
speed of this formation process was possibly too slow. These results can 
improve the selection of stabilisers regarding the milling process as large 
polymers, like HPMC, might not be suitable for high energy millings. PS80 was 
found to be a fast adsorbing stabiliser. 
iii. All used stabilising concentrations were above CMC but still, stable 
nanosuspensions could be created. Hence, the thesis of Deng et al. and other 
researcher could not be confirmed but must be a drug dependent phenomenon. 
The above results were found for the used drugs and stabilisers but were not translated 
to other systems, so that no generalisation can be done. Further experiments with a 
higher variety of drugs and stabilisers should be conducted to gain more insight in 
interaction pathways and for the prediction of a suitable stabiliser for a certain drug. 
Regarding pharmaceutical industry, maintaining inexpensive production is of great 
interest. Minimal stabilisation concentration is important for cost effective productions 
on a large scale. Also the stability of the nanosuspension is dependent on the minimal 
stabilisation concentration. A too high concentration can lead to Ostwald ripening while 
a too low concentration can lead to particle agglomeration or aggregation. Möschwitzer 
summarised with his review: ‘’Drug nanocrystals in the commercial pharmaceutical 
development process’’ that nano-formulations are a well-established and proven 
formulation approach for poorly soluble drugs [Möschwitzer, 2013]. He concluded that 
the ongoing research should focus on the production of even smaller nanoparticles 
and that the bioavailability of oral administered nanocrystals can just be raised when 
the compounds show dissolution rate limited bioavailability. In this work, 
nano-formulation for the BCS II drug was confirmed to have a higher benefit than for 
the BCS IV drug, as CUR had an increase in permeation but the still very low values 
seem to be negligible for therapeutic issues. Still, these results could show that it 
should not be generalised that BCS IV drugs should not be formulated as 
nanosuspensions like Möschwitzer did. If a drug has a high potency, so that even a 
very small increase in permeation changes therapeutic responses, a nano-formulation 
might still be a promising approach. As described above, the aim of the industry is to 
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produce nanocrystals as small as possible. In this thesis it was found that milling 
conditions for small nanocrystals can be more or less independent of the drug. 
Following factors resulted in a decrease in size for both drugs: small milling beads, 
long milling times and high rotor speed. Even a continuous milling would be possible 
with the used mill so that large scale production could be possible. 
Consequently, this work could increase the knowledge in production and nano-bio 
interaction of nanocrystals. Even though only 2 drugs and 2 to 6 stabilisers were 
tested, some results might be transferable to BCS classes II and IV, regarding drugs 
and stabiliser classes, like surfactants or polymers.  
In the future, the already started work of ex-vivo and in-vivo studies should be 
continued as, generally, the reports on in-vivo in-vitro correlation are until today not 
consistent in the field of nanomedicines so that an increase in the knowledge of in-vivo 
in-vitro correlation would help to employ more safe and effective nano-medicines in the 
market. 
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6 Summary 
Nowadays, the pharmaceutical formulation development faces various challenges. A 
high percentage of the newly developed active pharmaceutical ingredients (APIs) show 
poor aqueous solubility but high therapeutically efficacy. However, to be efficient, the 
API must reach its target. The oral administration is the most used type of application. 
Here, the API has to permeate from the intestine to the blood stream to get to the target 
location. The gastro intestinal tract displays a barrier for permeating substances. 
Usually, a solubilised API is desirable which can easily permeate via active or passive 
transport. When an API is poorly soluble in water, the absorption is usually low and 
therefore the therapeutic effect is decreased.  
For this thesis, two poorly water soluble model APIs were selected: On the one hand, 
curcumin (CUR) which exhibits also low permeability and on the other hand, 
glibenclamide (GLI) which shows high permeability. In this work, a processing to 
nanocrystals (NCs) was performed. NCs have a large surface area due to the 
comminution to the nanometer area and therefore exhibit high solubility rates (SR). For 
the production of NCs, the API was suspended in a non-solvent (water) together with 
a stabiliser (ST) and grinded in a media mill. ST are essential as they hinder 
agglomeration of newly formed particles. Until today it is not fully explored which ST is 
most suitable for which API and how the stabilised NCs perform in-vivo. This is why in 
this work the focus was set on the influence of six different ST on the production and 
interaction with bio-relevant environments of NCs. With all stabilisers, 
nanosuspensions with particle sizes down to 300 nm could be produced. However, 
they had different efficacies. These nanosuspensions were tested for the applicability 
in bio-relevant environments. Hydroxylpropyl methylcellulose (HPMC) demonstrated 
to be stable in buffer and was also found to be non-toxic for epithelial cells even at high 
concentrations. Polysorbate 80 (PS80) exhibited relatively high toxicity, so that it was 
used in combination with HPMC for further studies. All other stabilisers were excluded 
from further cell studies as they exhibited high toxicity of instabilities in buffer. 
To investigate interactions between ST and API and to possibly forecast minimal ST 
concentration, two methods were chosen: isothermal titration calorimetry (ITC) and 
contact angle measurements (CAM). ITC proved PS80 as being a fast adsorbing ST. 
HPMC showed a slow speed of diffusion. Therefore, HPMC might not be suitable for 
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high energy millings as it might not be able to stabilise newly formed surfaces fast 
enough. CAM could be used to forecast the PS80 concentration, which is most 
definitely suitable for stabilisation for GLI.  
The influence of the ST on the permeation of CUR and GLI in bio-relevant 
environments was investigated in an epithelial cell model. Depending on the SR, 
different permeation rates were observed. GLI had higher SR for HPMC stabilised NCs 
and therefore also higher permeation compared to HPMC + PS80 stabilised NCs while 
CUR showed highest permeation rates for HPMC stabilised NCs as well as highest 
SR. Furthermore, the influence of the particle size was investigated. The larger NCs 
with 500 nm had higher permeation rates compared to 300 nm NCs. The influence of 
the particle size was even more pronounced than the influence of the stabiliser.  
Fluorescence microscopy and coherent anti-Stokes Raman microscopy were utilised 
to investigate the uptake of NCs. No uptake of NCs after 24 hours of incubation could 
be seen for both substances in an epithelial cell line. The epithelial cells were proven 
to have a barrier function for GLI and CUR NCs in the tested size ranges. To further 
investigate the influence of the ST on the uptake of NCs, a macrophage cell line was 
employed. Next to the influence of the stabiliser also the influence of the particle size 
and incubation time were examined. The type of stabiliser had the most significant 
influence on uptake of NCs with HPMC + PS80 stabilised NCs giving the highest 
uptake rates.  
In this thesis the substantial influence of the ST on every part of nanosuspension 
formulations could be highlighted. The production, absorption in enterocytes and 
elimination (through, for example, macrophages) of NCs are dependent on the type of 
ST. Therefore, the selection of ST must be of high priority in the development of 
nanosuspension systems. 
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7 Summary (German) 
Die heutige pharmazeutische Entwicklung von Arzneiformen steht vor vielfältigen 
Herausforderungen. Ein großer Teil neu entwickelter Arzneistoffe (AS) weist eine 
schlechte Wasserlöslichkeit bei gleichzeitigem hohem Wirkungspotential auf. Davon 
kann jedoch nur dann profitiert werden, wenn die AS auch an den Zielort gelangen. 
Die orale Verabreichung ist die am häufigsten genutzte Applikationsart. Damit der AS 
zu seinem Zielort gelangen kann muss er vom Magen-Darm-Trakt in die Blutbahn 
gelangen. Der Magen-Darm-Trakt stellt allerdings eine Art Barriere für die Absorption 
von Stoffen dar. Meist muss die gelöste Form des AS vorliegen, da diese am 
einfachsten durch aktiven oder passiven Transport in den Körper aufgenommen 
werden kann. Weißt der AS jedoch eine schlechte Wasserlöslichkeit auf, kann er oft 
kaum absorbiert werden und somit auch keine systemische Wirkung entfalten. Um 
dem Körper diese schwer löslichen AS besser zugänglich zu machen wurden im 
Rahmen dieser Arbeit Nanosuspensionen entwickelt. Als Modelarzneistoffe wurde 
zum einen Curcumin (CUR) ausgewählt, das zusätzlich zu seiner schlechten 
Wasserlöslichkeit auch schlechte Permeationseigenschaften aufweist, zum anderen 
Glibenclamid (GLI), das über gute Permeationseigenschaften verfügt. Um die 
Lösungsgeschwindigkeit (LG) zu erhöhen, wurden diese Stoffe über einen 
Mahlprozess zu Nanokristallen (NK) verarbeitet. Dadurch kann von der in Folge der 
Zerkleinerung stark vergrößerte Oberfläche profitiert werden. Für die Herstellung von 
NK wurden die AS zusammen mit einem Nichtlösemittel (Wasser) und Stabilisatoren 
(ST) in einer Perlmühle zerkleinert. Letztere dienen dazu, die neu entstanden Partikel 
stabil zu halten. Sie sind also bei einem Nano-Mahlprozess essentiell. Es ist jedoch 
noch nicht vollständig geklärt, welche ST für welche AS am besten geeignet sind und 
wie die stabilisierten NK sich genau im Körper verhalten. Daher wurde in dieser Arbeit 
der Fokus auf die Frage gelegt, welchen Einfluss sechs verschiedenen ST auf die 
Produktion von NK und die Interaktion mit biorelevanten Umgebungen, wie 
Zellsysteme haben. Mit allen ST konnten für CUR und GLI bis zu 300 nm kleine NK 
hergestellt werden, jedoch waren die ST unterschiedlich effektiv. Weiterhin wurden die 
Nanosuspensionen auf die Applikationsfähigkeit in biorelevanter Umgebung 
untersucht. Durch Hydroxypropylmethylcellulose (HPMC) stabilisierte NK zeigten 
Stabilität in Puffer und entwickelten auch in hohen Konzentrationen keine Zelltoxizität. 
Polysorbat 80 (PS80) dagegen ließ eine relativ hohe Zelltoxizität erkennen, weshalb 
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es in Kombination mit HPMC für weitere Studien genutzt wurde. Alle anderen ST 
wurden für die Zellstudien ausgeschlossen, da sie entweder eine zu hohe Zelltoxizität 
oder Partikelgrößenwachstum in Puffer zeigten. 
Um die Interaktion von AS und ST genauer zu untersuchen und eventuell die minimale 
Stabilisierungskonzentration vorauszusagen, wurden zwei Methoden herangezogen: 
Isothermale Titrationskalorimetrie (ITK) und Kontaktwinkelmessungen (KWM). ITK 
zeigte PS80 als schnell adsorbierenden ST. HPMC zeigte eine langsame 
Diffusionsgeschwindigkeit und könnte deswegen bei extrem schnellen Mahlprozessen 
nicht von Nutzen sein. KWM ließen eine Voraussage, der mit Sicherheit 
stabilisierenden Konzentrationen von PS80 für GLI zu.  
Die ausgewählten ST zeigten einen Einfluss auf die Permeationseigenschaften der 
Nanoformulierungen durch Epithelzellen. Hierbei erwies sich die Messung der LG von 
CUR und GLI in den jeweiligen Nanosuspensionen als gute Methode zur 
Prognostizierung der Permeationsrate. GLI war, als HPMC stabilisierte NK, am 
schnellsten löslich und zeigte eine höhere Permeation im Vergleich zu den 
HPMC + PS80 stabilisierten NK. Die Permeationrate, sowie die LG, von CUR war bei 
den HPMC + PS80 stabilisierten NK höher. Der Einfluss der Partikelgröße auf die 
Permeationsrate war im Vergleich zu dem Einfluss der Stabilisierer größer, wobei die 
500 nm NK gegenüber 300 nm NK eine höhere Permeationsrate zeigten.  
Mit Hilfe der mikroskopischen Methoden Fluoreszenzmikroskopie und koherente 
anti-Stokes Raman Mikroskopie wurde die Aufnahme der NK in Zellen untersucht. Für 
die Darmepithelzellinie ließen sich auch nach 24 Stunden Inkubation nur wenig 
Hinweise auf eine Aufnahme der NK finden. Die Enterozyten weisen also bei diesen 
Größenordnungen für die beiden Stoffe mit den ST eine Barrierefunktion auf. Um 
jedoch den Einfluss der ST auf die Aufnahme in Zellen zu untersuchen, wurde eine 
Makrophagenzelllinie herangezogen. Bei diesen Aufnahmestudien wurde auch der 
Einfluss der Inkubationszeit und der Partikelgröße untersucht. Es stellt sich heraus, 
dass der Einfluss der ST am höchsten ist, wobei bei CUR und GLI die HPMC + PS80 
stabilisierte NK im Vergleich zu den HPMC stabilisierten NK die höchste 
Aufnahmequote zeigten.  
In dieser Arbeit konnte nachgewiesen werden, dass die ST auf alle Teilschritte der 
Arzneiform Nanosuspension einen Einfluss haben. Die Produktion, die Absorption 
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durch Enterozyten und die Elimination der NK (durch z.B. Makrophagen) hängen von 
den jeweiligen ST ab. Die Auswahl der ST sollte also eine hohe Priorität bei der 
Entwicklung von Nanosuspensionen haben. 
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9 Appendix 
9.1 List of abbreviations 
A  Apical 
API  Active pharmaceutical ingredient 
B  Basolateral 
BCS  Biopharmaceutics Classification System 
CA  Contact angle 
CAM  Contact angle measurements 
CARS  Coherent anti-Stokes Raman spectroscopy 
CMC  Critical micelle concentration  
CUR  Curcumin 
DLS  Dynamic light scattering 
DMEM Dulbecco's modified medium 
DMSO Dimethyl sulfoxide 
DSC  Dynamic scanning calorimetry 
EDTA  Ethylene diamine tetra acetic acid  
EMA  European medicines agency 
FBS  Fetal bovine serum 
FDA  Food and drug administration 
GLI  Glibenclamide 
h  Hour/s 
HEPES Hydroxyethyl-piperazineethane-sulfonic acid buffer  
HPLC  High performance liquid chromatography 
Appendix 
 
182 
 
HPMC Hydroxypropyl methylcellulose  
ISO  International organisation for standardisation 
ITC  Isothermal titration calorimetry 
LD  Laser diffraction 
LY  Lucifer yellow 
min  Minut/es 
MLN  Mesenteric lymph nodes 
mM  Millimole 
PBS  Phosphate buffered saline 
PDI  Polydispersity index 
Pol124 Poloxamer 124 
Pol407 Poloxamer 407 
PP  Peyer’s patches 
PS  Polysorbates 
PS80  Polysorbate 80 
rcf  Relative centrifugal forces 
SD  Standard deviation 
SDS  Sodium dodecyl sulfate 
SEM  Scanning electron microscopy 
SHG  Second harmonic generation 
Ss  Saturation solubility 
TEER  Transepithelial electrical resistance 
TPFE  Two-photon fluorescence excitation 
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TTAB  Tetra decyl trimethyl ammonium bromide  
UV  Ultraviolet 
XRPD  X-ray powder diffraction 
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9.2 Materials 
9.2.1 APIs, stabilisers and dispersion medium 
Table 23 holds information about the utilised APIs, stabilisers and the used type of 
water. 
Table 23: Used materials. 
Substance name CAS 
number 
Supplier LOT Additional 
information 
Curcumin 458-37-7 Alpha 
Aesar 
(Germany) 
10165835 95 % total 
curcuminoid 
content 
extracted 
from 
turmeric 
rhizome 
Glibenclamide 
(glybencyclamide) 
10238-21-8 Alpha 
Aesar 
(Germany) 
10197956 
10190555 
10147611 
99 % 
Polysorbate 80 9050-57-1 Croda 
GmbH 
(Germany) 
1007PC0045 Kindly 
donated 
Hydroxy propyl methyl 
cellulose 
9004-65-3 Colorcon 
GmbH 
(Germany) 
OL02012402 Methocel E5 
Premium LV 
A 2 % 
solution at 
20 °C has 
viscosity of 
5 mPa*s  
Kindly 
donated 
Poloxamer 124 9003-11-6 BASF SE 
(Germany) 
WPNI564B Kindly 
donated 
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Substance name CAS 
number 
Supplier LOT Additional 
information 
Poloxamer 407 9003-11-6 BASF SE 
(Germany) 
WPMI563B Kindly 
donated 
Myristyltrimethylammoniu
mbromide  
(Tetradecyltrimethylamm
onium bromide) 
1119-97-7 Sigma 
Aldrich 
Chemie 
GmbH 
(Steinheim
, Germany) 
SLBG3708V 99 % 
Sodium dodecyl  sulfate 151-21-3 Sigma 
Aldrich 
Chemie 
GmbH 
(Steinheim
, Germany) 
several  
Double-distilled water - produced 
in house 
with Finn 
Aqua 75, 
San-Asalo 
Sohlberg 
Corp., 
Finland 
-  
 
9.2.2 Surface area measurements 
Table 24 lists the supplier and quality information about the gases used. 
Table 24: Information on gases used in BET measurements. 
Gas Quality Supplier 
Helium 5.0 Linde Gas, Germany 
Nitrogen 5.0 Linde Gas, Germany 
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9.2.3 Buffer in dissolution studies 
Boric acid buffer pH 9.4 
A 0.2 M boric acid + 0.2 M KCl solution as well as a 0.2 M NaOH solution were prepared 
in demineralised water. 
802.5 mL of NaOH solution and 1250 mL of boric acid/KCl solution were transferred to 
a 5000 mL volumetric flask and filled up with demineralised water to 5 L. 
Phosphate buffer pH 8 
0.2 M KH2PO4 solution as well as 0.2 M NaOH solution in demineralised water were 
prepared. 
1250 mL of KH2PO4 solution and 1152.5 mL 0.2 M NaOH were transferred to a 
5000 mL volumetric flask and filled up with demineralised water to 5 L. 
Acetic acid buffer pH 4 
A solution of 50 % (m/V) NaOH in demineralised water was prepared. 50 mL of this 
solution were added to 143 mL acetic acid and filled up to 5000 mL with demineralised 
water. 
9.2.3.1 Ionic strength of buffers 
Following dissociation reactions in buffered solutions were assumed for the calculation 
of ionic strength: 
Phosphate buffer:  
KH2PO4+ NaOH  HPO42- + H2O + H++ Na+ 
Boric acid buffer: 
4 B(OH)3 + 4 KCl + 6 NaOH  2 B4O72− + 2 HB4O7- + 5 H2O + 6 Na+ + 4 Cl- +6 OH-+ 
6 K+ 
Ionic strength was calculated as ½ sum of (concentration of salt in mol × number of 
ions × charge of ion2) 
So that the ionic strength was calculated for phosphate buffer with ½ × (0.05 M × 1 × 
2² + 0.05 M × 1 × 1² + 0.05 M × 1 ×1²)=0.15 M/L and boric acid buffer with ½ × (0.05 
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M × 2 × 2² + 0.05 M × 2 ×1² + 0.032 M × 6 × 1² + 0.05 M × 4 × 1² + 0.032 M × 6 × 
1² + 0.05 M × 4 × 1²]= 0.64 M/ L. 
9.2.4 Cell culture 
Caco-2 cells were acquired from the European collection of cell cultures, Salisbury, 
Great Britain. RAW 264.7 were purchased form ATCC® with a passage number of 8. 
DMSO was acquired from Sigma Aldrich Chemie GmbH (Germany). Trypsin/EDTA 
solution 0.25 %/0.02 %, penicillin/streptomycin solution (10.000 U/mL/10.000 µg/mL 
and non-essential amino acids (100x) were ordered from Biochrom GmbH (Germany). 
Hanks’ Salt solution (HBSS), Phosphate buffered saline (PBS) and Dublecco’s MEM 
(DMEM) were ordered from Biochrom GmbH (Germany) with following composition 
(Table 25): 
Table 25: Composition of buffers and cell culture medium. 
Substance Dulbecco’s 
Phosphate buffered 
saline (PBS) (mg/L) 
Hanks’ Salt 
solution (HBSS) 
(mg/L) 
Dublecco’s 
MEM (DMEM) 
(mg/L) 
NaCl 8000 8000 6400 
KCl 200 400 400 
Na2HPO4 1150 48 124 
KH2PO4 200 60 - 
MgCl2*6H20 100 - - 
MgSO4*7H2O - 200 200 
CaCl2 100 140 200 
glucose - 1000 4500 
NaHCO3 - 350 3700 
Fe(NO3)3*9H2O - - 0.1 
Phenol red - - 15 
 
DMEM with 3.7 g/L NaHCO3, 4.5 g/L D-Glucose and stable) containing additionally the 
substances listed in Table 26. 
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Table 26: Composition of DMEM as received from the supplier. 
Substance Concentration in mg/L 
L-cystine 48 
L-glutamine 580 
L-histidine-HCl*H20 42 
L-isoleucine 106 
L-leucine 106 
L-methionine 30 
L-lysine-HCl 146 
L-arginine-HCl 84 
L-phenylalanine 66 
L-threonine 95 
L-tryptophan 16 
L-tyrosine 72 
L-valine 94 
Glycine 30 
L-serine 42 
Choline chloride 4 
Folic acid 4 
Myo-inositole 7.2 
nicotinamide 4 
D-Ca-pantothenate 4 
Pyridoxine-HCl 4 
Riboflavin 0.05 
Thiamine-HCl 4 
 
9.2.4.1 Materials for toxicity tests 
SDS was used as listed in chapter 9.2.1. MTT (Thiazolyl Blue Tetrazolium Bromide) 
supplied from Sigma Aldrich Chemie GmbH (Germany) with a purity of >97.5 %. 
Dimethyl formamid ordered as N, N-Dimethylformamid pro analysi from Merck GmbH 
(Germany) 
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9.2.4.2 Materials for transport studies 
Transport buffer consisting of the substances displayed in Table 27. The pH was 
adjusted with sodium hydroxide before filling up 1 L with double-distilled water. 
Table 27: Composition of transport buffer used in transport studies. 
Substances Concentration/Volume 
Hydroxyethyl- piperazineethane-sulfonic acid (HEPES) 2380 in mg/L 
Glucose 4500 in mg/L 
HBSS 500 mL 
 
Atenolol with a purity of ≤ 98 % and Lucifer yellow CH dilithium salt were purchased 
from Sigma Aldrich Chemie GmbH (Germany). 
9.3 Methods 
9.3.1 HPLC 
Table 28, Table 29 and Table 30 display information about the utilised HPLC methods. 
Table 28: HPLC method for CUR. 
HPLC system 
Waters HPLC system (Waters Materials and 
Methods Corporation, Milford, USA) 
Software 
Empower® Pro 2 software (Waters Corporation, 
Milford, USA 
Column 
LiChroCart® 125-4, LiChrospher® 100 RP18-5 
(Merck KGaA, Germany) with precolumn 
Mobile phase 
Acetonitrile to citric acid (Carl Roth GmbH+ Co. KG, 
Germany) (1 % m/v to pH 3 with NaOH) in a ratio of 
60:40 
Injection volume 100 µL 
Flow rate 1 mL/min 
Retention time 3 minutes 
Detection wavelength 425 nm 
Temperature Room temperature 
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Table 29: HPLC method for GLI. 
HPLC system 
Agilent 1100 Series LC with diode array detector 
(Agilent Technologies Inc., United States of America) 
Software HPChemstation (Agilent Technologies Inc.) 
Column 
LiChroCart® 125-4, LiChrospher® 100 RP18-5 (Merck 
KGaA, Germany) with precolumn 
Mobile phase 
A: 50 % of 20 mL triethylamine adjusted to pH 3 + 50 
mL acetonitrile ad 1000 mL with double-distilled water 
B: 50 % of 20 mL mobile phase A + 65 mL double-
distilled water + 915 mL acetonitrile 
Injection volume 10 µL 
Flow rate 1 mL/min 
Retention time 6 minutes 
Detection wavelength 230 nm 
Temperature 35 °C 
 
Table 30: HPLC method for atenolol. 
HPLC system 
Agilent 1100 Series LC with diode array detector 
(Agilent Technologies Inc., United States of America) 
Software HPChemstation (Agilent Technologies Inc.) 
Column 
LiChroCart® 125-4, LiChrospher® 100 RP18-5 
(Merck KGaA, Germany) with precolumn 
Mobile phase 
Potassium dihydrogen phosphate buffer (0.067 M 
adjusted to pH 3) with 0.2 % triethylamine to 
acetonitrile in a ratio of 90:10 
Injection volume 100 µL 
Flow rate 0.8 mL/min 
Retention time 4 minutes 
Detection wavelength 225 nm 
Temperature 21 °C 
 
Phosphate buffer was production with 9.1188 g KH2PO4, solubilised in approximately 
950 mL double-distilled water. 2 mL of triethylamine were added and the pH was 
adjusted to 3.0 with orthophosphoric acid 85 %. 
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Acetonitrile and triethylamine were purchased from Sigma-Aldrich Chemie GmbH 
(Germany) while KH2PO4 and citric acid were ordered from Carl Roth GmbH+ Co. KG 
(Germany) 
9.3.2 Fluorimetry 
LY content was analysed with the following parameters (Table 31). 
Table 31: Set-up of fluometric measurements. 
Excitation wavelength 480 nm 
Emission wavelength 520 - 550 nm 
Width of slit Excitation 10 nm 
Width of slit Emission 15 nm 
 
9.4 Additions to results 
9.4.1 Particle sizes and conductivity of zeta-potential measurements 
In Table 32 and Table 33, additional information to the suspensions, that were 
investigated with zeta-potential measurements, are shown. 
Table 32: Z-average and conductivity of CUR suspensions. 
Stabiliser Concentration 
in % 
Z-average 
in nm 
Conductivity 
in mS/cm 
PS80 50 170 0.0268 
SDS 1 609 0.01 
TTAB 1 153 0.00217 
PS80 + SDS 50 + 1 152 0.00574 
PS80 + TTAB 50 + 1 161 0.00206 
 
Table 33: Z-average and conductivity of GLI suspensions. 
Stabiliser Concentration 
in % 
Z-average 
in nm 
Conductivity 
in mS/cm 
PS80 5 272 0.0109 
SDS 1 1135 0.00598 
TTAB 1 1643 0.0113 
PS80 + SDS 5 + 1 261 0.00756 
PS80 + TTAB 5 + 1 2519 0.0132 
Appendix 
 
192 
 
9.4.2 Particle size distributions 
Figure 84 displays particle size distributions of CUR and GLI. 
 
 
Figure 84: Particle size distributions acquired from laser diffraction measurements for CUR (top) 
and GLI (bottom). 
9.4.3 Solid state of nanosuspensions 
Additions to DSC measurements are listed in Table 34. 
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Table 34: Onset and Peak temperatures of GLI and CUR nanosuspensions. 
Freeze dried suspension Onset in °C Peak in °C 
GLI 500 nm  
10 % HPMC 
165.51 171.90 
GLI 500 nm 
2.5 % HPMC + 2.5 % PS80 
161.59 170.50 
GLI 300 nm 
10 % HPMC 
161.29 168.13 
GLI 300 nm 
2.5 % HPMC + 2.5 % PS80 
162.48 168.10 
CUR 500 nm 
25 % HPMC 
163.23 171.10 
CUR 500 nm 
12.5 % HPMC + 12.5 % PS80 
161.20 170.35 
CUR 300 nm 
10 % HPMC 
161.82 173.53 
CUR 300 nm 
12.5 % HPMC + 12.5 % PS80 
164.72 172.03 
 
9.4.4 Isothermal titration calorimetry 
Figure 85 and Figure 86 hold information about the heat change in ITC experiments 
for the titration of water into CUR and GLI drug suspensions. 
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Figure 85: Control experiment of CUR. Titration of milli q water in a CUR suspension. 
 
Figure 86: Control experiment for GLI. Titration of milli q water in a GLI suspension. 
9.4.5 Quantification of particle uptake in cells with Imaris 
An exemplary image of one data set with two channels (membrane and nanocrystals) 
is shown in Figure 87. 
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Figure 87: Image of RAW 264.7 cells (green) and nanocrystals (red) after application of the dot 
and surface wizard of Imaris demo software. The nanocrystals are marked with grey dots. 
9.4.6 Calculation of dose per macrophage 
A 300 nm nanocrystal which is a perfect sphere has a volume of 
4
3
∗ 𝜋 ∗ 0.150 µ𝑚3 =
0.015 µ𝑚3. The density of GLI was measured with a helium pycnometer (Pycnomatic 
ATC, Porotec GmbH, Germany) at 1.66 g/mL. So, the mass of one particle is 
1.4 x 10-14 mL * 1.66 g/mL = 2.324 x 10-5 ng.  
CUR had a measured density (with the helium pycnometer Pycnomatic ATC, Porotec 
GmbH, Germany) of 1.89 g/mL so that the resulting mass of one particle is 
2.646 x 10-5 ng. 
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